AMENDMENT/MODIFICATION NO. 3. EFFECTIVE DATE 4. REQUISITION/PURCHASE REQ. NO.	ACT ID CODE	PAGE OF PAGE
18-May-2012	V	1 2
A ADMINSTRAD BY (If other than items 6) DOMANTHEM AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) Part	5. PROJEC	CT NO.(Ifapplicable)
IMAGENCY AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) WINTSHALD ALL 2807-2801 WAND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) WAND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) WAND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) WAND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) WAND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) WAND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) WAND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) WAND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) WAND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) WAND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) WAND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) WAND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) WAND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) WAND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) WAND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) WAND ADDRESS OF COUNTY (No., Street, County, State and Zip Code) WAND ADDRESS OF COUNTY (No., Street, County, State and Zip Code) WAND ADDRESS OF COUNTY (No., Street, County, State and Zip Code) WAND ADDRESS OF COUNTY (No., Street, County, State and Zip Code) WAND ADDRESS OF COUNTY (No., Street, County, State and Zip Code) WAND ADDRESS OF COUNTY (No., Street, County, State and Zip Code) WAND ADDRESS OF COUNTY (No., Street, County, State and Zip Code) WAND ADDRESS OF COUNTY (No., Street, County, State and Zip Code) WAND ADDRESS OF COUNTY (No., Street, County, State and Zip Code) WAND ADDRESS OF COUNTY (No., Street, County, State and Zip Code) WAND ADDRESS OF COUNTY (No., Street, County, State and Zip Code) WAND ADDRESS OF COUNTY (No., Street, County, State and Zip Code) WAND ADDRESS OF COUNTY (No., Street, County, State and Zip Code) WAND ADDRESS OF COUNTY (No., Street		
SOLIVELES TO MENDER ADMINISTRATIVE CODE. SOLIVELES TO MENDMENTS OF SOLICITATIONS 10B. DATED 10B. DATED	CODE S22	205A
SELONGER MA ORSTO-4600 P. D. A. S. 360-460 P. D. S. 360-460 P.	DMENT OF S	SOLICITATION NO
DE 05716 FACILITY CODE X 30Jan-1998 10. DATS 30Jan-1998 11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS 10. Embove numbered solicitation is amended as see the file is letten 14. The boar and date appeid to the two letters or a semaded by one of the billowing method (a) By completing items 8 and 15, and returning copies of the amendment; (b) By acknowledging receipt of this amendment prior to the boar and date appeid to it to solicitation or as amended by one of the billowing method (a) By completing items 8 and 15, and returning copies of the amendment; (b) By acknowledging receipt of this amendment or (c) By separate letter or telegramwhich includes a strikeneous to the solicitation and amendment matures. FALURE OF YOUR ACKNOWLEDGMEI RECEIVED A THIS FALURE OF YOUR ACKNOWLEDGMEI RECEIVED A THIS FALURE OF YOUR ACKNOWLEDGMEI RECEIVED A THIS FALURE OF YOUR ACKNOWLEDGMEI RECEIVED A THIRD FALURE DESIGNATED FOR THE RECEIVED FOR THIS HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFIRE THE SECRET OF OFFIRE PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFIRE THE SECRET OF OFFIRE PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFIRE THE CONTRACT OFFIRE PRIOR THE ACCOUNT OF	O (SEE ITEM	11)
DE 05716 FACILITY CODE X 30-Jan-1996 11. THIS ITEM ONLY A APPLIES TO AMENDMENTS OF SOLICITATIONS The above numbered selicitation is arounded as set 6 orth in Item 14. The boar and date specified for receipt of Office and the selicitation of the selection of t	OF CONTRA 8-C-0001	ACT/ORDER NO.
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS The above numbered solicitation is amended as set both in Item 14. The hour and date specified for receipt of Offer is extended. Other must exhanowledge receipt of this amendemat prior to the hour and date specified for receipt of Offer (a) By completing treat and 15. and returning copies of the amendment, 15. By acknowledging receipt of this amendemat one one opp of the or (a) By separate letter or telegrams which includes a reference to the solicitation and amendment numbers. PAILURE OF YOUR ACKNOWLEDGMEN RECEIVED ATTHE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER Ifby virtue of this amendment you desire to change an offer already submitted, such change any be sended by telegramon provided each telegramon letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified. ACCOUNTING AND APPROPRIATION DATA (If required) 13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACT SORDERS. IT MODIFIES THE CONTRACT ORDER NO. AS DESCRIBED IN 17EM 14. A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify mathority) THE CHANGES SET FORTH IN ITEM 14 ARE CONTRACT ORDER NO. IN ITEM 10A. B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (state of the capture of the properties on date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B). C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: D. OTHER (Specify type of modification and authority) IMPORTANT: Contractor	D (SEE ITEN	M 13)
The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Office and Color of this amendment prior to the hour and date specified for receipt of Office and amended by one of the fallowing methods (c) By completing items 8 and 15, and returning copies of the amendment; (b) By solicious or as amended by one of the fallowing methods (c) By completing items 8 and 15, and returning copies of the amendment; (b) By solicious or as a mended by one of the fallowing methods (c) By solicious or and amendment numbers. PAILURE OF YOUR ACKNOWLEDGMEN RECEIVED ATTHE PLACE DESIGNATED FOR THE RECEIPT OF OFERS PRIOR TO THE HOUR AND DATE SPECIFED MAY RESULT IN RESECTION OF YOUR OF THE RECEIPT OF OFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN RESECTION OF YOUR OF THE VERY RESULT IN RESECTION OF YOUR OF THE AMENDMENT OF THE HOUR AND DATE SPECIFIED MAY RESULT IN PROVIDED AND APPROPRIATION DATA (If required) 13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACT SORDERS. IT MODIFIES THE CONTRACT ORDER NO. AS DESCRIBED IN ITEM 14. A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE CONTRACT ORDER NO. IN ITEM 10A. B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (six office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B). C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: D. OTHER (Specify type of modification and authority) MPORTANT: Contractor is not, is required to sign this document and return copies to the issue described by the provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as herefore changed, remains unchanged and in fall force in the provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as herefore changed, remains unchanged and in fall force in the provided herein, all terms and conditions of the document referenced in Item 9A or 10A)8 [*]	
Other must scienowledge receipt of this amendment prior to the bour and date specified in the solicitation or as aremded by one of the following methods (a) By completing Items 8 and 15, and enturning		
(a) By completing from 3 and 13, and returning copies of the armodremit; (b) By seaknowledging receipt of this armodremit on each copy of the copy of	is not ext	dended.
IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14. A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE CONTRACT ORDER NO. IN ITEM 10A. B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (SIX office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B). C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: D. OTHER (Specify type of modification and authority) MPORTANT: Contractor is not, is required to sign this document and return copies to the issuence of the results.) DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract swhere feasible.) Modification Control Number: Description of the modification is correct the CN in Modification P00251, ACRNMX, from CN: GFEBS001015913300001 to FEBS001015913300030. All other terms and conditions remain the same and no additional funding has been provided. Description of the modification is correct the CN in Modification P00251, ACRNMX, from CN: GFEBS001015913300001 to FEBS001015913300030. All other terms and conditions remain the same and no additional funding has been provided. Description of the modification is correct the CN in Modification P00251, ACRNMX, from CN: GFEBS001015913300001 to FEBS001015913300030. All other terms and conditions remain the same and no additional funding has been provided. Description of the modification is correct the CN in Modification P00251, ACRNMX, from CN: GFEBS001015913300001 to FEBS001015913300001 to FEBS00101591330001 to FEBS		
A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE CONTRACT ORDER NO. IN ITEM 10A. B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (suc office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B). C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: D. OTHER (Specify type of modification and authority) MPORTANT: Contractor X is not, is required to sign this document and return copies to the issuence feasible.) MODIFICATION (Organized by UCF section headings, including solicitation/contract swhere feasible.) Modification Control Number: Me purpose of this modification is correct the CN in Modification P00251, ACRN MX, from CN: GFEBS001015913300001 b FEBS001015913300030. All other terms and conditions remain the same and no additional funding has been provided. Modification Control Number: Modification P00251, ACRN MX, from CN: GFEBS001015913300001 b FEBS001015913300030. All other terms and conditions remain the same and no additional funding has been provided. MAME AND TITLE OF SIGNER (Type or print)		
B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (sw. office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B). C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: D. OTHER (Specify type of modification and authority) MPORTANT: Contractor X is not, is required to sign this document and return copies to the issuence for the cashible.) MODIFICATION (Organized by UCF section headings, including solicitation/contract swhere feasible.) Modification Control Number: Be purpose of this modification is correct the CN in Modification P00251, ACRN MX, from CN: GFEBS001015913300001 b FEBS001015913300030. All other terms and conditions remain the same and no additional funding has been provided.	E MADE IN 1	TUG
office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B). C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: D. OTHER (Specify type of modification and authority) MPORTANT: Contractor X is not, is required to sign this document and return copies to the issuent purple of the interest of the issuent and return copies to the issuent purple of the modification POPA AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract such the remaining purple of this modification is correct the CN in Modification POO251, ACRNMX, from CN: GFEBS001015913300001 to FEBS001015913300030. All other terms and conditions remain the same and no additional funding has been provided. The provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as hereto five changed, remains unchanged and in fall force in the provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as hereto five changed, remains unchanged and in fall force in the provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as hereto five changed, remains unchanged and in fall force in the provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as hereto five changed, remains unchanged and in fall force in the provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as hereto five changed, remains unchanged and in fall force in the provided herein. A NAME AND TITLE OF SIGNER (Type or print)	E MADE IN	THE
MPORTANT: Contractor X is not, is required to sign this document and return copies to the issued the section of the issued the issued the section of the issued the section of the issued the issued the section of the issued the i	uch as changes	in paying
MPORTANT: Contractor X is not, is required to sign this document and return copies to the issued by UCF section headings, including solicitation/contract subtraction Control Number: The purpose of this modification is correct the CN in Modification P00251, ACRN MX, from CN: GFEBS001015913300001 to FEBS001015913300030. All other terms and conditions remain the same and no additional funding has been provided. The purpose of this modification is correct the CN in Modification P00251, ACRN MX, from CN: GFEBS001015913300001 to FEBS001015913300030. All other terms and conditions remain the same and no additional funding has been provided. The purpose of this modification is correct the CN in Modification P00251, ACRN MX, from CN: GFEBS001015913300001 to FEBS001015913300030. All other terms and conditions remain the same and no additional funding has been provided. The purpose of this modification is correct the CN in Modification P00251, ACRN MX, from CN: GFEBS001015913300001 to FEBS001015913300030. All other terms and conditions remain the same and no additional funding has been provided. The purpose of this modification is correct the CN in Modification P00251, ACRN MX, from CN: GFEBS001015913300001 to FEBS001015913300030. All other terms and conditions remain the same and no additional funding has been provided.		
DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract solicitation Control Number: the purpose of this modification is correct the CN in Modification P00251, ACRN MK, from CN: GFEBS001015913300001 to FEBS001015913300030. All other terms and conditions remain the same and no additional funding has been provided. The provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofter changed, remains unchanged and in full force to the provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofter changed, remains unchanged and in full force to the provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofter changed, remains unchanged and in full force to the provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofter changed, remains unchanged and in full force to the provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofter changed, remains unchanged and in full force to the provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofter changed, remains unchanged and in full force to the provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofter changed, remains unchanged and in full force to the provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofter changed, remains unchanged and in full force to the provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofter changed, remains unchanged and in full force to the provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofter changed, remains unchanged and in full force to the provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofter changed herein, all terms are the		
where feasible.) Modification Control Number: e purpose of this modification is correct the CN in Modification P00251, ACRN MX, from CN: GFEBS001015913300001 to FEBS001015913300030. All other terms and conditions remain the same and no additional funding has been provided. pt as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofire changed, remains unchanged and in full force in the CN ITEM AND TITLE OF SIGNER (Type or print) 16A, NAME AND TITLE OF SIGNER (Type or print)	uing office.	
Modification Control Number: the purpose of this modification is correct the CN in Modification P00251, ACRN MX, from CN: GFEBS001015913300001 to FFEBS001015913300030. All other terms and conditions remain the same and no additional funding has been provided. The provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as hereto fire changed, remains unchanged and in full fires and the conditions of the document referenced in Item 9A or 10A, as hereto fire changed, remains unchanged and in full fires and the conditions of the document referenced in Item 9A or 10A, as hereto fire changed, remains unchanged and in full fires and the conditions of the document referenced in Item 9A or 10A, as hereto fire changed, remains unchanged and in full fires and the conditions of the document referenced in Item 9A or 10A, as hereto fire changed, remains unchanged and in full fires and the conditions of the document referenced in Item 9A or 10A, as hereto fire changed, remains unchanged and in full fires and the conditions of the document referenced in Item 9A or 10A, as hereto fire changed, remains unchanged and in full fires and the conditions of the document referenced in Item 9A or 10A, as hereto fire changed, remains unchanged and in full fires and the conditions of the document referenced in Item 9A or 10A, as hereto fire changed, remains unchanged and in full fires and the conditions of the document referenced in Item 9A or 10A, as hereto fire changed, remains unchanged and in full fires and the conditions of the document referenced in Item 9A or 10A, as hereto fire changed, remains unchanged and in full firest and the conditions of the document referenced in Item 9A or 10A, as hereto fires the changed and the full firest and the conditions of the document referenced in Item 9A or 10A, as hereto firest and the conditions of the document referenced in Item 9A or 10A, as hereto firest and the conditions of the document referenced in Item 9A or 10A, as hereto firest and the conditions of t	subject matter	•
A. NAME AND TITLE OF SIGNER (Type or print) 16A. NAME AND TITLE OF CONTRACTING OF	to CIN:	(b)(6)
A. NAME AND TITLE OF SIGNER (Type or print) 16A. NAME AND TITLE OF CONTRACTING OF		
	and offict.	
B. CONTRACTOR/OFFEROR 15C, DATE SIGNED 16B. UNITED STATES OF AMERICA	FFICER (Type	e or print) (b)(6
	10	6C. DATE SIGNED (b)(6
(Signature of person authorized to sign) (Signature of Contracting Officer)		-,
PROVED BY OIRM 11-84	STANDARD F Prescribed by (FAR (48 CFR)	

(End of Summary of Changes)

AMENDMENT OF SOLICIT	ATION/MODIF	ICATION OF CONTRACT		V	1 12
AMENDMENT/MODIFICATION NO. PO0254	3. EFFECTIVE DATE	4. REQUISITION/PURCHASE REQ. NO.		5. PROJECT	NO.(Ifapplicable)
USASMDC/ARSTRAT SMDC-RDC PO BOX 1500 HUNTSVILLE AL 35807-3801	18-May-2012 W9113M	7. ADMINISTERED BY (Ifother than item 6) DCMA RAYTHEON 50 APPLE HILL DRIVE M/S TZFR2 TEWKSBURY MA 01876		CODE S220	5A
8. NAME AND ADDRESS OF CONTRACTOR RAYTHEON COMPANY 350 LOWELL ST. ANDOVER MA 01810-4400	(No., Street, County,	State and Zip Code)	9B. DATEI X 10A. MOD. DASG60-9 10B. DATE	OF CONTRAC 8-C-0001 ED (SEE ITEM	T/ORDER NO.
CODE 05716	THIS ITEM ONLY	DE PPLIES TO AMENDMENTS OF SOLIC	X 30-Jan-199	98	
The above numbered solicitation is amended as set for Offer must acknowledge receipt of this amendment pr (a) By completing Items 8 and 15, and returning or (c) By separate letter or telegram which includes a RECEIVED ATTHE PLACE DESIGNATED FOR TREJECTION OF YOUR OFFER. If by virtue of this a provided each telegram or letter makes reference to the	copies of the amendment copies of the amendment reference to the solicitation THE RECEIPT OF OFFERS amendment you desire to cha	ified in the solicitation or as amended by one of thit; (b) By acknowledging receipt of this amendment and amendment numbers. FAILURE OF YOUR APRIOR TO THE HOUR AND DATE SPECIFIED nge an offer already submitted, such change may be	nt on each copy oft CKNOWLEDGMI MAY RESULT IN e made by telegram	ne offer submitted; ENTTO BE	ded.
12. ACCOUNTING AND APPROPRIATION D See Schedule	OATA (If required)				
The state of the s	EM APPLIES ONLY T	O MODIFICATIONS OF CONTRACTS	ORDERS.		
	TO COMPANY AND	CT/ORDER NO. AS DESCRIBED IN ITE		E MADE IN T	TIP
A. THIS CHANGE ORDER IS ISSUED PURS CONTRACT ORDER NO. IN ITEM 10A		unionty) The Changes set FORTH	IN II EM 14 AF	E MADE IN 1	ile.
B. THE ABOVE NUMBERED CONTRACT/ office, appropriation date, etc.) SET FOR	TH IN ITEM 14, PUR	SUANT TO THE AUTHORITY OF FAI		uch as changes is	n paying
C. THIS SUPPLEMENT AL AGREEMENT I	S ENTERED INTO PU	JRSUANT TO AUTHORITY OF:			
D. OTHER (Specify type of modification and UNILATERAL: FAR 52.243-2, Changes, and		tation of Funds	4		
3. IMPORTANT: Contractor X is not,	is required to sig	n this document and return	copies to the is	suing office.	
DESCRIPTION OF AMENDMENT/MODII where feasible.) Modification Control Number: To issue a change order for additional JLENS outlined in CCAM-CAB-B letters, JLENS-2012 required training is as follows: Genie Man-L students; and Maintainer Course Training, U	Limited User Testing (2-012 and JLENS-2012 ift Training, Utah Test	(b)(6) (LUT) training due to replacement of so 2-018, dated March 30, 2012 and April 2	diers conductin 26, 2012, respe	g the LUT as	k 6
except as provided herein, all terms and conditions of the	do numerat software 4 in to	9A or 10A no heratofine about 1	and and in City	and affirm	
A. NAME AND TITLE OF SIGNER (Type o	The state of the s	77 OF TOA, as hereto are changed, remains unionar	ged and in in in inco	e and eaect.	(b)(6)
5B. CONTRACTOR/OFFEROR	15C. DATE SIGNE	0			DATE SIGNED
	- DATE STORES				-May-2012
(Signature of person authorized to sign)					

002503


Prescribed by GSA FAR (48 CFR) 53.243

SUMMARY OF CHANGES

1. SECTION A - SOLICITATION/CONTRACT FORM

The total cost of this contract was increased by \$724,879.00 from \$1,920,203,430.00 to \$1,920,928,309.00.

2. SECTION B - SUPPLIES OR SERVICES AND PRICES



* As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017AA, identified, accounted for, invoiced, analyzed, or reported separately from SubCLIN 0017, including EVMS. All scope remains under SubCLIN 0017AA with associated incentive events and flat zones.

SUBCLIN 003002 is added as follows:

ITEM NO SUP 003002

SUPPLIES/SERVICES

QUANTITY

UNIT UNIT PRICE

AMOUNT

GFEBS Funding for SubCLIN 0017AA

CPIF

FOB: Destination

ACRN MX

\$719,132.00

CIN: GFEBS001017438300030

B-17. INCENTIVE FEE FOR SUBCLIN 0017AA/CLIN 0018 (SEE H-19):

In accordance with FAR 52.216-7, entitled "Allowable Cost and Payments", and FAR 52.216-10, entitled "Incentive Fee", the total amount for reimbursement of cost and fee for performance under SubCLIN 0017AA/CLIN 0018 are set forth below:

Target Cost



(b)(4)

DASG60-98-C-0001 P00254 Page 3 of 12

Target Fee (b)(4)

Incentive Arrangement: Maximum Fee:
Minimum Fee:
(b)(4)

(Share Ratio: Government/Contractor)

Underrun: Underrun: (b)(4) which the total allowable cost is less than the target cost until maximum fee is attained.

Overrun: Overrun: (b)(4) fee is attained.

FAR 52.216-10, INCENTIVE, paragraph (e)(1), is stated as follows:

(e) Fee Payable.

(1) The fee payable under this contract shall be the target fee increased by the state of the total allowable cost is less than the target cost or decreased by the state of the total allowable cost exceeds the target cost. In no event shall the fee be greater than the contract shall be the target fee increased by the state of the total allowable cost exceeds the target cost. In no event shall the fee be greater than the contract shall be the target fee increased by the state of the total allowable cost exceeds the target cost. In no event shall the fee be greater than the contract shall be the target fee increased by the state of the target cost. (b)(4)

B-18. TARGET COST, TARGET FEE, MINIMUM INCENTIVE FEE, MAXIMUM INCENTIVE FEE, AND INCENTIVE ARRANGEMENT FOR SUBCLIN 0017AA/CLIN 0018:

SUBCLIN 0017AA – (Two SDD JLENS Systems)

a. Target cost:

(b)(4)

b. Target fee:

(b)(4)

(b)(4)

(b)(4)

(b)(4)

d. Maximum incentive fee:

(b)(4)

\$1,683,179,862

3. SECTION G - CONTRACT ADMINISTRATION DATA

e. Total target cost and target fee:

Accounting and Appropriation

Summary for the Payment Office

As a result of this modification, the total funded amount for this document was increased by \$719,132.00 from \$1,876,986,879.63 to \$1,877,706,011.63.

SUBCLIN 003002 (GFEBS funding for SubCLIN 0017AA):

Funding on SUBCLIN 003002 is initiated as follows:

ACRN: MX

CIN: GFEBS001017438300030

Acctng Data: 02120122013204000001171722550030003242A.0000013.1.1 6100.9000021001 Increase: \$719,132.00 Total: \$719,132.00 Cost Code: A5XFJ Target Cost, Target Fee, and total for the above increase of \$719,132 is distributed as follows and includes an increase in target cost os f cost and f facilities capital cost of money) and an increase in target fee of **Target Cost** (b)(4)Target Fee Total \$719,132 IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows: SUBCLIN 0017AA: **CUMULATIVE** THIS PRIOR MODIFICATION TOTAL* (1) Amount Required for Full Funding, Including Fee: \$1,682,454,983 \$724,879 \$ 1,683,179,862 (2) Amount Allotted Under the LOF Clause for Payment of Costs: الحالطا (3) Amount Separately Obligated for Payment of Fee: (b)(4 (4) Total Amount Allotted and Obligated: \$1,643,784,189.27 \$719,132 \$1,644,503,321.27 (5) Net Amount Required for Full Funding 38,670,793.73 \$ 5,747 38,676,540.73 * These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17AH) 4. SECTION H - SPECIAL CONTRACT REQUIREMENTS is revised as follows: Paragraph H-19, INCENTIVE FEE STRUCTURE AND PAYMENT FOR CLIN 0017, SYSTEM <u>DEVELOPMENT AND DEMONSTRATION (SDD)</u>, subparagraph c., is revised as follows: a. General. SubCLIN 0017AA, System Development and Demonstration (SDD), is a cost-plus-incentive-fee (CPIF) Line Item with cost and schedule incentives as described below. Paragraph H-19(b) applies only to the Cost Incentive and Paragraph H-19(c) applies only to the Schedule Incentive. The contract price amount of \$1,683,179,862 includes a (P/A) target cost of hich includes of cost an of facilities capital cost of money) and a target incentive fee o which i of target cost less facilities capital cost of money. (b)(4) b. Cost Incentive. (1) The target fee payable under SubCLIN 0017AA is the target cost less facilities capital cost of money an amount equal to

(2) The maximum fee payable under SubCLIN 0017AA is facilities capital cost of money and amount equal to	(P)(A) (P)(A)
(3) The minimum fee payable under SubCLIN 0017AA is substituted for the target cost less facilities capital cost of money an amount equal to	(b)(4)
(4) Fee will be adjusted for actual cost that is less than or more than the target cost stated above using a share ratio of Government / Contractor for actual costs less than the target cost, and a ratio of Government / Contractor for actual costs greater than the target cost range applied according to Paragraph H-19(c)(1).	<i>(</i> અ <i>(</i> 4)
(5) Nothing stated in this clause shall take precedence over the clause 52.216-10 - Incentive Fee contained in this contract.	
c. Schedule and Performance Incentive.	
(1) A maximum "flat zone" will be established at the target cost value of the conduct of milestones below. The "flat zone" over which the contractor will earn target fee is for eligible costs from	ЬX
Some to Some once the program milestones set forth below are conducted. (Note: As of the effective date of Modification P00253, only of the maximum attended to zone" has been acknowledged as earned.)	(P)(r
(a) System of the maximum benefit of the "flat zone", earned by the conduct of the SDD System Functional Review NLT 2nd Quarter, Fiscal Year 2007. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive of	(E)Y4
Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract. Reference letter,	(p)(r) (p)(r)
(b) the maximum benefit of the "flat zone", earned by the conduct of SDD Orbit Critical Design review NLT 2nd Quarter, Fiscal Year 2009. (It is hereby acknowledged by the government that Raytheon	(P)(P)
completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive of determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the	. (૧)પ્લ
contract. Reference letter,	(p)(b)
(c) 6 of the maximum benefit of the "flat zone", earned by the conduct of the Developmental Test 1 (DT-1) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 11/1/11. (It is hereby acknowledged by the government	(b)(y)
that Raytheon completed the requirement for this flat zone and earned a "Flat Zone" schedule incentive of Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract.)	ריאא
(d) from the first of the maximum benefit of the "flat zone", earned by the conduct of the Electromagnetic Environmental Effects (E3) Testing in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 11/1/11.	(b)(4) (b)(b)
(e) of the maximum benefit of the "flat zone", earned by the conduct of the Integrated Fire Control Event in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 11/1/11.	(b)(4) ^{₺)} ᠘'
(f) of the maximum benefit of the "flat zone", earned by the conduct of the Functional Configuration Audit (FCA) #1 in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 11/1/11.	(b)(4) b)(c

- (3) For Earned Value and cost reporting purposes, the target cost value of \$1,463,647,573 will be used.
 - d. Changes issued under FAR 52.243-2, Changes Cost Reimbursement

In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the performance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLIN 0017 are added and exercised, the incentive fee for cost and schedule/performance applicable to the Option will be incorporated in accordance with the incentive fee structure of this provision.

5. The following is an update to Modification P00252 showing a summary of funding by ACRN through Modification P00254:

<u>ACRN</u>	<u>FUNDING</u>
AA	440,100.00
AB	2,298,235.00
AC	17,832,987.00
AD	0.00
AE	7,500,000.00
AF	3,300,000.00
AG	17,192,400.00
AH	700,000.00
AJ	200,000.00
AK	85,000.00
AL	45,000.00
AM	17,045,000.00
AN	5,800.00
AP	20,779,000.00
AQ	105,000.00
AR	35,000.00
AS	0.00
AT	6,984,678.52
AU	7,970,000.00
AV	0.00
AW	100,000.00
AX	3,396,000.00
AY	550,000.00
AZ	19,412,000.00
BA	24,527,878.00
BB	146,000.00
BC	72,000.00
BD	85,000.00
BE	100,000.00
BF	100,000.00
BG	1,975,321.00
ВН	38,018,908.00
BJ	7,896,673.34
BK	260,000.00
BL	0.00

BM	125,000.00
BN	103,000.00
BP	10,199,288.50
BU	350,000.00
BV	9,000.00
BW	84,896,852.00
BX	1,146,000.00
BY	3,880,000.00
BZ	190,000.00
KL	118,250.00
KM	192,793,000.00
KN	0.00
KQ	92,811.00
KR	0.00
KS	0.00
KT	386,377,998.00
KU	2,203,183.00
KV	65,000.00
KW	20,000.00
KX	60,000.00
KY	25,000.00
KZ	25,000.00
LA	13,508.00
LB	12,500.00
LC	
LD	200,000.00 7,943,648.00
LE	1,173,850.00
LF	10,000.00
LG	62,000.00
LH	400,000.00
LJ	7,476.00
LK	\$281,575,897.00
LL	\$173,798.00
LM	\$1,410,376.00
LN	\$630,061.00
LP	\$83,200.00
LQ	\$235,566.00
LR	\$125,000.00
LS	\$6,069,616.00
LT	\$530,377.00
LU	\$9,100,000.00
LV	\$1,957,265.00
LW	\$255,567.00
LX	\$68,000.00
LY	\$264,807,424.52
LZ	\$1,751,384.00
MA	\$2,982,442.00
MB	\$375,000.00
MC	\$2,283,481.00
MD	\$8,573.00


ME	\$0.00
MF	\$270,514,880.00
MG	\$6,262,095.00
MH	\$213,390.00
MJ	\$858,495.00
MK	\$56,076.00
ML	\$116,044.00
MM	\$1,618,600.00
MN	\$2,573,000.00
MP	\$250,000.00
MQ	\$691,421.00
MR	\$0.00
MS .	\$700,000.00
MT	\$16,289,524.00
MU	\$7,864,499.00
MV	\$39,921,199.75
MW	\$10,000,000.00
MX	\$53,693,415.00

6. The following is an update to Modification P00252 showing a summary of funding by CLIN by ACRN through Modification P00254:

CLIN	<u>ACRN</u>	FUNDING AMT	CLIN TOTAL
CLIN 0001	AA	440,100.00	
CLIN 0001	AD	0.00	
		•	440,100.00
CLIN 0003	AB	2,298,235.00	
CLIN 0003	AC	17,832,987.00	
CLIN 0003	AD	0.00	
CLIN 0003	ΑE	7,500,000.00	
CLIN 0003	AF	3,300,000.00	
CLIN 0003	AG	17,192,400.00	
CLIN 0003	AH	700,000.00	
CLIN 0003	AM	17,045,000.00	
CLIN 0003	AN	5,800.00	
CLIN 0003	AP	20,779,000.00	
CLIN 0003	AS	0.00	
CLIN 0003	AT	6,984,678.52	
CLIN 0003	AW	100,000.00	
CLIN 0003	ΑY	550,000.00	
			94,288,100.52
CLIN 0005	BA	24,527,878.00	
CLIN 0005	BB	146,000.00	
CLIN 0005	BC	72,000.00	
CLIN 0005	BD	85,000.00	

CLIN 0005	BE	100,000.00	
CLIN 0005	BF	100,000.00	
CLIN 0005	BG	1,975,321.00	
CLIN 0005	ВН	38,018,908.00	
CLIN 0005	BL	0.00	
CLIN 0005	BZ	0.00	
CLIN 0003	DL	0.00	CE 025 107 00
		-	65,025,107.00
CLIN 0007AA	BP	10,199,288.50	
			10,199,288.50
		\(\frac{1}{2}\)	
CLIN 0009AA	AQ	45,106.00	
CLIN 0009AA	AV	0.00	
CLIN 0009AA	BK	256,545.00	
CLIN 0009AA	BM	125,000.00	
CLIN 0009AA	BN	21,315.00	
CLIN 0003AA	DIN	21,515.00	147.066.00
		en e	447,966.00
CLIN 0009AB	AJ	200,000.00	
CLIN 0009AB	AK	85,000.00	
CLIN 0009AB	AL	45,000.00	
CLIN 0009AB	AQ	59,894.00	
CLIN 0009AB	AR	35,000.00	
CLIN 0009AB	BK	3,455.00	
CLIN 0009AB	BN	81,685.00	
CLIN 0009AB	BU	350,000.00	
CLIN 0009AB	BV	9,000.00	
		, <u> </u>	869,034.00
			003,000,000
CLIN 0013	ATT	7,970,000.00	
	AU		
CLIN 0013	AX	3,396,000.00	
CLIN 0013	AY	0.00	
CLIN 0013	AZ	19,412,000.00	
CLIN 0013	BJ	7,896,673.34	
		******	38,674,673.34
CLIN 0017	BW	0.00	
CLIN 0017	KM	0.00	
			0.00
		-	
CT IN 00174 A	DV	2 000 000 00	
CLIN 0017AA	BY	3,880,000.00	
CLIN 0017AA	BX	1,146,000.00	
CLIN 0017AA	BW	84,896,852.00	
CLIN 0017AA	BZ	0.00	
CLIN 0017AA	KM	192,793,000.00	
CLIN 0017AA	KN	0.00	
CLIN 0017AA	KQ	66,151.00	

CLIN 0017AA	KS	0.00
CLIN 0017AA	KT	386,204,200.00
CLIN 0017AA	KU	2,203,183.00
CLIN 0017AA CLIN 0017AA	KY	0.00 200,000.00
CLIN 0017AA CLIN 0017AA	LC LD	7,943,648.00
CLIN 0017AA	LE	0.00
CLIN 0017AA	LH	400,000.00
CLIN 0017AA	LJ	7,476.00
CLIN 0017AA	LK	281,575,897.00
CLIN 0017AA	LQ	235,566.00
CLIN 0017AA	LS	6,069,616.00
CLIN 0017AA	LT	530,377.00
CLIN 0017AA	LU	\$9,100,000.00
CLIN 0017AA	LV	\$1,957,265.00
CLIN 0017AA	LW	\$255,567.00
CLIN 0017AA	LX	\$68,000.00
CLIN 0017AA	LY	\$264,807,424.52
CLIN 0017AA	MB	\$375,000.00
CLIN 0017AA	MC	\$2,283,481.00
CLIN 0017AA	MD	\$8,573.00
CLIN 0017AA	ME	\$0.00
CLIN 0017AA	MF	\$270,514,880.00
CLIN 0017AA	MH	\$213,390.00
CLIN 0017AA	MJ	\$858,495.00
CLIN 0017AA	MK	\$56,076.00
CLIN 0017AA	ML	\$116,044.00
CLIN 0017AA	MM	\$1,618,600.00
CLIN 0017AA	MN	\$2,573,000.00
CLIN 0017AA	MP	\$250,000.00
CLIN 0017AA	MQ	\$691,421.00
CLIN 0017AA	MR	\$0.00
CLIN 0017AA	MS	\$700,000.00
CLIN 0017AA	MT	\$16,289,524.00
CLIN 0017AA	MV	\$39,921,199.75
CLIN 0017AA	MW	\$10,000,000.00
CLIN 0017AA	MX	\$53,693,415.00
		1,644,503,321.27
CLIN 0017AB	KL	118,250.00
CLIN OUI /AD	R.L.	118,250.00
		110,230.00



CLIN 0017AC	BZ	190,000.00	
		-	190,000.00
CLIN 0017AD	KN	0.00	
CLIN 0017AD	KS	0.00	
		***************************************	0.00
CLIN 0017AE	LL	173,798.00	
		,	173,798.00
CLIN 0017AH	KT	173,798.00	
			173,798.00
CLIN 0020AA	KN	0.00	
CLIN 0020AA	KQ	26,660.00	
			26,660.00
CLIN 0021AA	KW	0.00	
			0.00
CLIN 0021AB	KV	0.00	
CLIN 0021AB	LB	0.00	
CLIN 0021AB	KX	0.00	
CLIN 0021AB	KY	0.00	
			0.00
CLIN 0021AC	KZ	0.00	
CLIN 0021AC	LA	0.00	
		tion at an	0.00
CLIN 0022	KW	0.00	
		***************************************	0.00
CLIN 0023	KX	60,000.00	
CLIN 0023	KY	25,000.00	
CLIN 0023	KV	65,000.00	
CLIN 0023	LB	12,500.00	
CLIN 0023	LF	10,000.00	
CLIN 0023	LR	\$125,000.00	
		Chance	297,500.00
CLIN 0024	LA	13,508.00	
CLIN 0024	LG	62,000.00	
CLIN 0024	KZ	25,000.00	
CLIN 0024	KW	20,000.00	

CLIN 0024	LP	83,200.00	
		distribution of the state of th	203,708.00
CLIN 0025	LE	1,173,850.00	
CLIN 0025	LM	1,080,404.00	
CLIN 0025	MA	0.00	
			2,254,254.00
CLIN 0026	LN	630,061.00	
			630,061.00
CLIN 0027	LZ	1,751,384.00	
			1,751,384.00
CLIN 0028	LM	329,972.00	
CLIN 0028	MA	2,982,442.00	
CLIN 0028	MG	6,262,095.00	
CLIN 0028	MU	\$7,864,499	
			17,439,008.00
CLIN 003001*	MX	\$52,974,283.00	
CLIN003002*	MX	\$719,132.00	

^{*} CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. For pruposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017AA and should not be counted twice with regards of the total contract funding obligated.

(End of Summary of Changes)

A RATIONAL DISCOURAGE ACTOR	ATTONIAGONE	TO A TROOK OF CONTROL A CON		I. CONTRACT	ID CODE	PAGE OF	PAGES
AMENDMENT OF SOLICIT	ATION/MODIF	ICATION OF CONTRACT		V		1 1	10
AMENDMENT/MODIFICATION NO	3. EFFECTIVE DATE	4. REQUISITION/PURCHASE REQ. NO.			5 PROJECTN	NO (Ifapplica	ble)
00255	24-May-2012						
SSUED BY CODE	W9113M	7. ADMINISTERED BY (Ifother than item 6)		COI	DE S2205	A	
SASMDC/ARSTRAT		DCMA RAYTHEON					
MDC-RDC		50 APPLE HILL DRIVE M/S T2FR2					
O BOX 1500 UNTSVILLE AL 35807-3801		TEWKSBURY MA 01876					
011704111111111111111111111111111111111		}					
NAME AND ADDRESS OF CONTRACTOR	(No Street County 5	State and Zin Code)	9A	. AMENDM	ENT OF SOL	ICITATIO	N NO.
RAYTHEON COMPANY	(110., carout, county,	Late and Sap Cook)					
350 LOWELL ST. ANDOVER MA 01810-4400			9B.	. DATED (S	EE ITEM 11)	
			X 104	A. MOD. OF \ SG60-98- C	CONTRACT	I/ORDER I	NO.
		ļ			SEE ITEM 1		
DE 05716	FACILITY COD	ne -		-Jan-1998	(000 11 0111 1	,	
		PPLIES TO AMENDMENTS OF SOLIC	CITATI	ONS			
The above numbered solicitation is amended as set for				dended.	is not exten	ded.	
			لــا	· L		. =	
Offer must acknowledge receipt of this amendment pri- (a) By completing Items 8 and 15, and returning	=	thed in the solicitation or as amended by one oftr it; (b) By acknowledging receipt ofthis amendmen		-	er submitted:		
or (c) By separate letter or telegram which includes a r							
RECEIVED AT THE PLACE DESIGNATED FOR T							
REJECTION OF YOUR OFFER. If by virtue of this a provided each telegram or letter makes reference to the					tter,		
ACCOUNTING AND APPROPRIATION D		maxi, and is received prior to the opening nost a					
See Schedule	ATA (IT required)						
	EM ADDITES ON WA	CO MODIFICATIONS OF CONTRACTS	WODDE.	DC			····
		TO MODIFICATIONS OF CONTRACTS CT/ORDER NO. AS DESCRIBED IN ITE		.K.S.			
A. THIS CHANGE ORDER IS ISSUED PURS CONTRACT ORDER NO. IN ITEM 10A.		uthority) THE CHANGES SET FORTH	IN ITE	M 14 ARE N	MADE IN TH	ΙE	
B. THE ABOVE NUMBERED CONTRACT/0	ORDER IS MODIFIED	TO REFLECT THE ADMINISTRATIV	Æ CHA	NGES (such	as changes in	paving	
office, appropriation date, etc.) SET FOR						7-7-6	
C. THIS SUPPLEMENTAL AGREEMENT IS	S ENTERED INTO PU	IRSUANT TO AUTHORITY OF:					
D. OTHER (Specify type of modification and UNILATERAL: FAR 52.232-22, "Limitation of			· · · · ·				
MPORTANT: Contractor X is not,		n this document and return	conies	to the issuin	r office		
	<u> </u>	***************************************				-	
DESCRIPTION OF AMENDMENT/MODIF where feasible.)	TCATION (Organized	by OCF section neadings, including solici	itation/	contract subj	ect marter		L \
Modification Control Number:						(1	b)(6)
increase incremental funding in the amoun	t or \$5,747.						
pt as provided herein, all terms and conditions of the d							· > = ·
. NAME AND TITLE OF SIGNER (Type or	r print)	16A. NAME AND TITLE OF COL	NTRAC	TING OFFI	CER (Type o	r print) (b)(6)
			۹_				
CONTRA OTOD OFFICE	Iso Dame do				1,75	DATE	(A)ED
3. CONTRACTOR/OFFEROR	15C. DATE SIGNEI	16B			116C	DATE SI	/6\/6\
	_	ВУ			24	-May-2012	
(Signature of person authorized to sign)		(Signature of Contracting Off	ficer)			•	
CEPTION TO SF 30	1	10-105-04		STA	NDARD FO	RM 30 (Re	v. 10-83)

EXCEPTION TO SF 30 APPROVED BY OIRM 11-84

002515

STANDARD FORM 30 (Rev. 10-83) Prescribed by GSA FAR (48 CFR) 53.243

SUMMARY OF CHANGES

1. SECTION B - SUPPLIES OR SERVICES AND PRICES

CLIN 0030

The total cost of this line item has increased by \$5,747.00 from \$53,693,415.00 to \$53,699,162.00. *

* As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017AA, identified, accounted for, invoiced, analyzed, or reported separately from SubCLIN 0017, including EVMS. All scope remains under SubCLIN 0017AA with associated incentive events and flat zones.

SUBCLIN 003003 is added as follows:

ITEM NO SUPPLIES/SERVICES

QUANTITY

UNIT

UNIT PRICE

AMOUNT

003003

GFEBS Funding for SubCLIN 0017

CPIE

FOB: Destination

ACRN MX

MX

CIN: GFEBS001017438400030

\$5,747.00

2. SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation

Summary for the Payment Office

As a result of this modification, the total funded amount for this document was increased by \$5,747.00 from \$1,877,706,011.63 to \$1,877,711,758.63.

SUBCLIN 003003:

Funding on SUBCLIN 003003 is initiated as follows:

ACRN: MX

CIN: GFEBS001017438400030

Acctng Data: 02120122013204000001171722550030003242A.0000013.1.1

6100.9000021001

Increase: \$5,747.00

Total: \$5,747.00

Cost Code: A5XFJ

Target Cost, Target Fee, and total for the above increase of the listributed as follows and includes an increase in target cost os \$403.

Target Cost
Target Cost
Target Fee
Total
\$5,747

IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows:

SUE	SCLIN 0017AA :	<u>PRIOR</u>	THIS MODIFICATION	CUMULATIVE TOTAL*
(1)	Amount Required for Full Funding, Including Fee:	\$1,683,179,862	\$ 0	\$ 1,683,179,862 (b)(4)
(2)	Amount Allotted Under the LOF Clause			(b)(4)
	for Payment of Costs:			
(3)	Amount Separately Obligated for			_
	Payment of Fee:			\$1.644.500.068.27 (b)(4)
(4)	Total Amount Allotted and Obligated:	\$1,644,503,321.27	\$5,747	\$1,644,509,068.27 (D)(4)
(5)	Net Amount Required for Full Funding	\$ 38,676,540.73	(\$5,747)	\$ 38,670,793.73

^{*} These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17AH)

3. The following is an update to Modification P00254 showing a summary of funding by ACRN through Modification P00255:

AA 440,100.00 AB 2,298,235.00 AC 17,832,987.00 AD 0.00 AE 7,500,000.00 AF 3,300,000.00 AG 17,192,400.00 AH 700,000.00 AJ 200,000.00 AK 85,000.00 AL 45,000.00 AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00 AR 35,000.00	<u>ACRN</u>	<u>FUNDING</u>
AC 17,832,987.00 AD 0.00 AE 7,500,000.00 AF 3,300,000.00 AG 17,192,400.00 AH 700,000.00 AJ 200,000.00 AK 85,000.00 AL 45,000.00 AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00	AA	440,100.00
AD 0.00 AE 7,500,000.00 AF 3,300,000.00 AG 17,192,400.00 AH 700,000.00 AJ 200,000.00 AK 85,000.00 AL 45,000.00 AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00	AB	2,298,235.00
AE 7,500,000.00 AF 3,300,000.00 AG 17,192,400.00 AH 700,000.00 AJ 200,000.00 AK 85,000.00 AL 45,000.00 AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00	AC	17,832,987.00
AF 3,300,000.00 AG 17,192,400.00 AH 700,000.00 AJ 200,000.00 AK 85,000.00 AL 45,000.00 AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00	AD	0.00
AG 17,192,400.00 AH 700,000.00 AJ 200,000.00 AK 85,000.00 AL 45,000.00 AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00	AE	7,500,000.00
AH 700,000.00 AJ 200,000.00 AK 85,000.00 AL 45,000.00 AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00	AF	3,300,000.00
AJ 200,000.00 AK 85,000.00 AL 45,000.00 AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00	AG	17,192,400.00
AK 85,000.00 AL 45,000.00 AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00	AH	700,000.00
AL 45,000.00 AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00	AJ	200,000.00
AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00	AK	85,000.00
AN 5,800.00 AP 20,779,000.00 AQ 105,000.00	AL	45,000.00
AP 20,779,000.00 AQ 105,000.00	AM	17,045,000.00
AQ 105,000.00	AN	5,800.00
	AP	20,779,000.00
AR 35,000.00	AQ	105,000.00
	AR	35,000.00
AS 0.00	AS	0.00

AT	6,984,678.52
AU	7,970,000.00
AV	0.00
AW	100,000.00
AX	3,396,000.00
AY	550,000.00
AZ	19,412,000.00
BA	24,527,878.00
ВВ	146,000.00
BC	72,000.00
BD	85,000.00
BE	100,000.00
BF	100,000.00
BG	1,975,321.00
BH	38,018,908.00
BJ	7,896,673.34
BK	260,000.00
BL	0.00
BM	125,000.00
BN	103,000.00
BP	10,199,288.50
BU	350,000.00
II.	
BV	9,000.00
BW	84,896,852.00
BX	1,146,000.00
BY	3,880,000.00
BZ	190,000.00
KL	118,250.00
KM	192,793,000.00
KN	0.00
KQ	92,811.00
KR	0.00
KS	0.00
KT	386,377,998.00
KU	2,203,183.00
KV	65,000.00
KW	20,000.00
KX	60,000.00
KY	25,000.00
KZ	25,000.00
LA	13,508.00
LB	12,500.00
LC	200,000.00
LD	7,943,648.00
LE	1,173,850.00
LF	10,000.00
LG	62,000.00
LH	400,000.00
LJ	7,476.00
LK	\$281,575,897.00
	• -•

LL	\$173,798.00
LM	\$1,410,376.00
LN	\$630,061.00
LP	\$83,200.00
LQ	\$235,566.00
LR	\$125,000.00
LS	\$6,069,616.00
LT	\$530,377.00
LU	\$9,100,000.00
LV	\$1,957,265.00
LW	\$255,567.00
LX	\$68,000.00
LY	\$264,807,424.52
LZ	\$1,751,384.00
MA	\$2,982,442.00
MB	\$375,000.00
MC	\$2,283,481.00
MD	\$8,573.00
ME	\$0.00
MF	\$270,514,880.00
MG	\$6,262,095.00
MH	\$213,390.00
MJ	\$858,495.00
MK	\$56,076.00
ML	\$116,044.00
MM	\$1,618,600.00
MN	\$2,573,000.00
MP	\$250,000.00
MQ	\$691,421.00
MR	\$0.00
MS	\$700,000.00
MT	\$16,289,524.00
MU	\$7,864,499.00
MV	\$39,921,199.75
MW	\$10,000,000.00
MX	\$53,699,162.00

4. The following is an update to Modification P00254 showing a summary of funding by CLIN by ACRN through Modification P00255:

<u>CLIN</u>	ACRN	FUNDING AMT	CLIN TOTAL
CLIN 0001	AA	440,100.00	
CLIN 0001	AD	0.00	
			440,100.00
GT D 1 0 0 0 0	4.70	2 400 444 00	
CLIN 0003	AB	2,298,235.00	
CLIN 0003	AC	17,832,987.00	
CLIN 0003	AD	0.00	

CLIN 0003	ΑE	7,500,000.00	
CLIN 0003	AF	3,300,000.00	
CLIN 0003	AG	17,192,400.00	
CLIN 0003	AH	700,000.00	
CLIN 0003	AM	17,045,000.00	
CLIN 0003	AN	5,800.00	
CLIN 0003	AP	20,779,000.00	
CLIN 0003	AS	0.00	
CLIN 0003	AT	6,984,678.52	
CLIN 0003	AW	100,000.00	
CLIN 0003	AY	550,000.00	
			94,288,100.52
		,	
CLIN 0005	BA	24,527,878.00	
CLIN 0005	BB	146,000.00	
CLIN 0005	BC	72,000.00	
CLIN 0005	BD	85,000.00	
CLIN 0005	BE	100,000.00	
CLIN 0005	BF	100,000.00	
CLIN 0005	BG	1,975,321.00	
CLIN 0005	вн	38,018,908.00	
CLIN 0005	BL	0.00	
CLIN 0005	BZ	0.00	
		-	65,025,107.00
CLIN 0007AA	ВР	10,199,288.50	
			10,199,288.50
CLIN 0009AA	AQ	45,106.00	
CLIN 0009AA	AV	0.00	
CLIN 0009AA	BK	256,545.00	
CLIN 0009AA	BM	125,000.00	
CLIN 0009AA	BN	21,315.00	
			447,966.00
CLIN 0009AB	AJ	200,000.00	
CLIN 0009AB	AK	85,000.00	
CLIN 0009AB	AL	45,000.00	
CLIN 0009AB	AQ	59,894.00	
CLIN 0009AB	AR	35,000.00	
CLIN 0009AB	BK	3,455.00	
CLIN 0009AB	BN	81,685.00	
CLIN 0009AB	BU	350,000.00	
CLIN 0009AB	BV	9,000.00	
		-	869,034.00
CLIN 0013	AU	7,970,000.00	

CLIN 0013	AX	3,396,000.00
CLIN 0013	AY	0.00
CLIN 0013	ΑZ	19,412,000.00
CLIN 0013	ВЈ	7,896,673.34
		38,674,673.34
CLIN 0017	BW	0.00
CLIN 0017	KM	0.00
		0.00
CLIN 0017AA	BY	3,880,000.00
CLIN 0017AA	BX	1,146,000.00
CLIN 0017AA	BW	84,896,852.00
CLIN 0017AA	BZ	0.00
CLIN 0017AA	KM	192,793,000.00
CLIN 0017AA	KN	0.00
CLIN 0017AA	KQ	66,151.00
CLIN 0017AA	KS	0.00
CLIN 0017AA	KT	386,204,200.00
CLIN 0017AA	KU	2,203,183.00
CLIN 0017AA	KY	0.00
CLIN 0017AA	LC	200,000.00
CLIN 0017AA	LD	7,943,648.00
CLIN 0017AA	LE	0.00
CLIN 0017AA	LH	400,000.00
CLIN 0017AA	LJ	7,476.00
CLIN 0017AA	LK	281,575,897.00
CLIN 0017AA	LQ	235,566.00
CLIN 0017AA	LS	6,069,616.00
CLIN 0017AA	LT	530,377.00
CLIN 0017AA	LU	\$9,100,000.00
CLIN 0017AA	LV	\$1,957,265.00
CLIN 0017AA	LW	\$255,567.00
CLIN 0017AA	LX	\$68,000.00
CLIN 0017AA	LY	\$264,807,424.52
CLIN 0017AA	MB	\$375,000.00
CLIN 0017AA	MC	\$2,283,481.00
CLIN 0017AA	MD	\$8,573.00
CLIN 0017AA	ME	\$0.00
CLIN 0017AA	MF	\$270,514,880.00
CLIN 0017AA	MH	\$213,390.00
CLIN 0017AA	MJ	\$858,495.00
CLIN 0017AA	MK	\$56,076.00
CLIN 0017AA	ML	\$116,044.00
CLIN 0017AA	MM	\$1,618,600.00

	\$2,573,000.00	MN	CLIN 0017AA
	\$250,000.00	MP	CLIN 0017AA
	\$691,421.00	MQ	CLIN 0017AA
	\$0.00	MR	CLIN 0017AA
	\$700,000.00	MS	CLIN 0017AA
	\$16,289,524.00	MT	CLIN 0017AA
	\$39,921,199.75	MV	CLIN 0017AA
	\$10,000,000.00	MW	CLIN 0017AA
	\$53,699,162.00	MX	CLIN 0017AA
1,644,509,068.27	, , , , , , , , , , , , , , , , , , ,		
	=		
	_		
	118,250.00	KL	CLIN 0017AB
118,250.00	-		
	190,000.00	BZ	CLIN 0017AC
190,000.00	-		
	0.00	KN	CLIN 0017AD
	0.00 _	KS	CLIN 0017AD
0.00	-		
	173,798.00	LL	CLIN 0017AE
173,798.00			
	173,798.00 _	KT	CLIN 0017AH
173,798.00	===		
	0.00	KN	CLIN 0020AA
	26,660.00	KQ	CLIN 0020AA
26,660.00	=		
	0.00 _	KW	CLIN 0021AA
0.00	_		
	0.00	KV	CLIN 0021AB
	0.00	LB	CLIN 0021AB
	0.00	KX	CLIN 0021AB
0.00	0.00 _	KY	CLIN 0021AB
0.00	==		
	0.00	KZ	CLIN 0021AC
	0.00	LA	CLIN 0021AC

		-	0.00
		2==	
CLIN 0022	KW	0.00	
		-	0.00
CLIN 0023	KX	60,000.00	
CLIN 0023	KY	25,000.00	
CLIN 0023	KV	65,000.00	
CLIN 0023	LB	12,500.00	
CLIN 0023	LF	10,000.00	
CLIN 0023	LR	\$125,000.00	
		_	297,500.00
CLIN 0024	LA	13,508.00	
CLIN 0024	LG	62,000.00	
CLIN 0024	KZ	25,000.00	
CLIN 0024	KW	20,000.00	
CLIN 0024	LP	83,200.00	
			203,708.00
CLIN 0025	LE	1,173,850.00	
CLIN 0025	LM	1,080,404.00	
			
CLIN 0025	MA	0.00	2 254 254 00
			2,254,254.00
CLIN 0026	LN	630,061.00	
			630,061.00
CLIN 0027	LZ	1,751,384.00	
		_	1,751,384.00
CLIN 0028	LM	329,972.00	
CLIN 0028	MA	2,982,442.00	
CLIN 0028	MG	6,262,095.00	
CLIN 0028	MU	\$7,864,499	
		-	17,439,008.00
CLIN 003001*	MX	\$52,974,283.00 —	
CLIN003002*	MX	\$719,132.00	
CLIN 000303*	MX	\$5,747.00	
CTTI 000303	MIV	33,/4/.00	

DASG60-98-C-0001 P00255 Page 10 of 10

* CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. For pruposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017AA and should not be counted twice with regards to the total contract funding obligated.

(End of Summary of Changes)

AMENDMENT OF SOLICITA	ATION/MODIF	ICATION OF CONTRACT	, CONTRACT	ID CODE	PAGE OF PA	AGES 10
MENDMENT/MODIFICATION NO.	3 EFFECTIVE DATE	4 REQUISITION/PURCHASE REQ, NO.		5. PROJECT N	VO.(Ifapplicable)	
00256	19-Jun-2012				_	
ISSUED BY CODE UBASMDC/ARSTRAT BOOL RDC PO BOX 1800 HUNTSVILLE AL 36807-3801	W9113M	7. ADMINISTERED BY (Ifother than item6) OCMA RAYTHEON SUAPPLE HILL DRIVE M/S TZFR2 TEVKSBURY MA 01676	со	DE [\$2205	<u> </u>	
NAME AND ADDRESS OF CONTRACT OR RAYTHEON COMPANY 350 LOWELL ST. ANDOVER MA 01810-4400	(No., Street, County, S	I Rate and Zip Code)	9A. AMENDM 9B. DATED (S			NO.
			X 10A MOD OF DASG60-98-0	CONTRACT	CORDER NO) <u>.</u>
			10B. DATED	(SEE ITEM I	3)	
DDE 05716	FACILITY COL	DE	X 30-Jen-1998			
11.	THIS ITEM ONLY A	PPLIES TO AMENDMENTS OF SOLI	CITATIONS			
The above numbered solicitation is amended as set fort	h in Item 14. The hour and	date specified for receipt of Offer	is extended,	is not extend	ded.	
RECEIVED ATTHE PLACE DESIGNATED FOR THE REJECTION OF YOUR OFFER. If by virtue of this as provided each telegramor letter makes reference to the ACCOUNTING AND APPROPRIATION D.	rendment you desire to the solicitation and this arrand	nge an offic already submitted, such change may	be made by tologramor le	éter,		
See Schedule						
		O MODIFICATIONS OF CONTRACT TORDER NO. AS DESCRIBED IN IT				
A. THIS CHANGE ORDER IS ISSUED PURS CONTRACT ORDER NO, IN ITEM 10A.	JANT TO: (Specify a	uthority) THE CHANGES SET FORTH	IN ITEM 14 ARE N	MADE IN TH	B	
B. THE ABOVE NUMBERED CONTRACT/C office, appropriation date, etc.) SET FORT				as changes in	paying	
C. THIS SUPPLEMENTAL AGREEMENT IS	SENTERED INTO PU	RSUANT TO AUTHORITY OF:				
D. OTHER (Specify type of modification and UNILATERAL: FAR 52.232-22, "Limitation of						
IMPORTANT: Contractor X is not,	is required to sig	n this document and return	copies to the issuin	g office.		
DESCRIPTION OF AMENDMENT/MODIF, where feasible.) Modification Control Number: To provide incremental funding in the amount of the provide incremental funding in the provide i		by UCF section headings, including solid	citation/contract subj	ect matter	(b))(b
sept as provided horsin, all terms and conditions of the d. A. NAME AND TITLE OF STONER (Type or B. CONTRACTOR/OFFEROR		16A. NAME AND TITLE OF CO		CER (Type o	print) DATE SIGN	(<i>ما</i> (
(Signature of agency and agined to give		B			-Jun-2012	
(Signature of person authorized to sign) (CEPTION TO SF 30		(Signature of Contracting Of		NDA PD POT	2M 20 (Paul	10-921
PROVED BY OIRM 11-84		0-105-04 102525	Pres	scribed by GSA R (48 CFR) 53		(0-63)

SUMMARY OF CHANGES

1. SECTION B - SUPPLIES OR SERVICES AND PRICES

CLIN 0030

The total cost of this line item has increased by \$16,000,000.00 from \$53,699,162.00 to \$69,699,162.00.*

* As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017AA, identified, accounted for, invoiced, analyzed, or reported separately from SubCLIN 0017, including EVMS. All scope remains under SubCLIN 0017AA with associated incentive events and flat zones.

UNIT

SUBCLIN 003004 is added as follows:

SUPPLIES/SERVICES

ITEM NO 003004

GFEBS Funding for SubCLIN 0017AA

QUANTITY

CPIF

FOB: Destination

ACRN MX

CIN: GFEBS001019081700030

UNIT PRICE AMOUNT

\$16,000,000.00

2. SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation

Summary for the Payment Office

As a result of this modification, the total funded amount for this document was increased by \$16,000,000.00 from \$1,877,711,758.63 to \$1,893,711,758.63.

SUBCLIN 003004:

Funding on SUBCLIN 003004 is initiated as follows:


ACRN: MX

CIN: GFEBS001019081700030

Acctng Data: 02120122013204000001171722550030003242A.0000013.1.1 6100.9000021001

Increase: \$16,000,000.00

Total: \$16,000,000.00



Cost Code: A5XFJ

Target Cost, To increase in targ increase in targ		(FXI)
Target Cost Target Fee Total	\$16,000,000	(P)(A (P)(A

IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows:

SUE	BCLIN 0017AA:	<u>PRIOR</u>	THIS MODIFICATION	CUMULATIVE TOTAL*
(1)	Amount Required for Full Funding,			
	Including Fee:	\$1,683,179,862	\$ 0	\$ 1,683,179,862
(2)	Amount Allotted Under the LOF Clause			_
	for Payment of Costs:			y y dy
(3)	Amount Separately Obligated for			(b)(4)
	Payment of Fee:	\$		\$ (b)(4)
(4)	Total Amount Allotted and Obligated:	\$1,644,509,068.27	\$16,000,000	\$1,660,509,068.27 (D)(4)
(5)	Net Amount Required for Full Funding	\$ 38,670,793.73	(\$16,000,000)	\$ 22,670,793.73

^{*} These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17AH)

3. The following is an update to Modification P00255 showing a summary of funding by ACRN through Modification P00256:

<u>ACRN</u>	FUNDING	
AA		440,100.00
AB		2,298,235.00
AC		17,832,987.00
AD		0.00
AE		7,500,000.00
AF		3,300,000.00
AG		17,192,400.00
AH		700,000.00
AJ		200,000.00
AK		85,000.00
AL		45,000.00
AM		17,045,000.00
AN		5,800.00
AP		20,779,000.00
AQ		105,000.00

AR	35,000.00
AS	0.00
AT	6,984,678.52
AU	7,970,000.00
AV	0.00
AW	100,000.00
AX	3,396,000.00
AY	÷ 550,000.00
AZ	19,412,000.00
BA	24,527,878.00
BB	146,000.00
BC	72,000.00
BD	85,000.00
BE	100,000.00
BF	100,000.00
BG	1,975,321.00
BH	38,018,908.00
BJ	7,896,673.34
BK	260,000.00
BL	0.00
BM	125,000.00
BN	103,000.00
BP	10,199,288.50
BU	350,000.00
BV	9,000.00
BW	84,896,852.00
BX	1,146,000.00
BY	3,880,000.00
BZ	190,000.00
KL	118,250.00
KM	192,793,000.00
KN	0.00
KQ	92,811.00
KR	0.00
KS	0.00
KT	386,377,998.00
KU	2,203,183.00
KV	65,000.00
KW	20,000.00
KX	60,000.00
KY	25,000.00
KZ	25,000.00
LA	13,508.00
LB	12,500.00
LC	200,000.00
LD	7,943,648.00
LE	1,173,850.00
LF	10,000.00
LG	62,000.00
LH	400,000.00
Lil	400,000.00

LJ	7,476.00
LK	\$281,575,897.00
LL	\$173,798.00
LM	\$1,410,376.00
LN	\$6 30,061.00
LP	\$83,200.00
LQ	\$235,566.00
LR	\$125,000.00
LS	\$6,069,616.00
LT	\$530,377.00
LU	\$9,100,000.00
LV	\$1,957,265.00
LW	\$255,567.00
LX	\$68,000.00
LY	\$264,807,424.52
LZ	\$1,751,384.00
MA	\$2,982,442.00
MB	\$375,000.00
MC	\$2,283,481.00
MD	\$8,573.00
ME	\$0.00
MF	\$270,514,880.00
MG	\$6,262,095.00
MH	\$213,390.00
MJ	\$858,495.00
MK	\$56,076.00
ML	\$116,044.00
MM	\$1,618,600.00
MN	\$2,573,000.00
MP	\$250,000.00
MQ	\$691,421.00
MR	\$0.00
MS	\$700,000.00
MT	\$16,289,524.00
MU	\$7,864,499.00
MV	\$39,921,199.75
MW	\$10,000,000.00
MX	\$69,699,162.00

4. The following is an update to Modification P00255 showing a summary of funding by CLIN by ACRN through Modification P00256:

CLIN	ACRN	FUNDING AMT	CLIN TOTAL
CLIN 0001 CLIN 0001	AA AD	440,100.00 0.00	
			440,100.00
CLIN 0003	AB	2,298,235.00	

CLIN 0003	AC	17,832,987.00	
CLIN 0003	AD	0.00	
CLIN 0003	AE	7,500,000.00	
CLIN 0003	AF	3,300,000.00	
CLIN 0003	AG	17,192,400.00	
CLIN 0003	AH	700,000.00	
CLIN 0003	AM	17,045,000.00	
CLIN 0003	AN	5,800.00	
CLIN 0003	AP	20,779,000.00	
CLIN 0003	AS	0.00	
CLIN 0003	AT	6,984,678.52	
CLIN 0003	AW	100,000.00	
CLIN 0003	AY	550,000.00	
CLIII 0003	,	220,000.00	94,288,100.52
		-	74,200,100.32
CLIN 0005	ВА	24,527,878.00	
CLIN 0005	BB	146,000.00	
CLIN 0005	BC	72,000.00	
CLIN 0005	BD	85,000.00	
CLIN 0005	BE	100,000.00	
CLIN 0005	BF	100,000.00	
CLIN 0005	BG	1,975,321.00	
CLIN 0005	BH	38,018,908.00	
CLIN 0005	BL	0.00	
CLIN 0005	BZ	0.00	
CLIN 0003	DZ	0.00	(5.025.107.00
			65,025,107.00
CLIN 0007AA	ВР	10,199,288.50	
			10,199,288.50
CLIN 0009AA	AQ	45,106.00	
CLIN 0009AA	AV	0.00	
CLIN 0009AA	BK	256,545.00	
CLIN 0009AA	BM	125,000.00	
CLIN 0009AA	BN	21,315.00	
02111 0003111	2		447,966.00
CLIN 0009AB	AJ	200,000.00	
CLIN 0009AB	AK	85,000.00	
CLIN 0009AB	AL	45,000.00	
CLIN 0009AB	AQ	59,894.00	
CLIN 0009AB	AR	35,000.00	
CLIN 0009AB	BK	3,455.00	
CLIN 0009AB	BN	81,685.00	
CLIN 0009AB	BU	350,000.00	
CLIN 0009AB	BV	9,000.00	
		-	869,034.00
		-	

CLIN 0013	AU	7,970,000.00
CLIN 0013	AX	3,396,000.00
CLIN 0013	AY	0.00
CLIN 0013	ΑZ	19,412,000.00
CLIN 0013	BJ	7,896,673.34
		38,674,673.34
CLIN 0017	BW	0.00
CLIN 0017	KM	0.00
02211 0017	22.2	0.00
CLIN 0017AA	BY	3,880,000.00
CLIN 0017AA	BX	1,146,000.00
CLIN 0017AA	BW	84,896,852.00
CLIN 0017AA	BZ	0.00
CLIN 0017AA	KM	192,793,000.00
CLIN 0017AA	KN	0.00
CLIN 0017AA	KQ	66,151.00
CLIN 0017AA	KS	0.00
CLIN 0017AA	KT	386,204,200.00
CLIN 0017AA	KU	2,203,183.00
CLIN 0017AA	KY	0.00
CLIN 0017AA	LC	200,000.00
CLIN 0017AA	LD	7,943,648.00
CLIN 0017AA	LE	0.00
CLIN 0017AA	LH	400,000.00
CLIN 0017AA	LJ	7,476.00
CLIN 0017AA	LK	281,575,897.00
CLIN 0017AA	LQ	235,566.00
CLIN 0017AA	LS	6,069,616.00
CLIN 0017AA	L T	530,377.00
CLIN 0017AA	LU	\$9,100,000.00
CLIN 0017AA	LV	\$1,957,265.00
CLIN 0017AA	LW	\$255,567.00
CLIN 0017AA	LX	\$68,000.00
CLIN 0017AA	LY	\$264,807,424.52
CLIN 0017AA	MB	\$375,000.00
CLIN 0017AA	MC	\$2,283,481.00
CLIN 0017AA	MD	\$8,573.00
CLIN 0017AA	ME	\$0.00
CLIN 0017AA	MF	\$270,514,880.00
CLIN 0017AA	MH	\$213,390.00
CLIN 0017AA	MJ	\$858,495.00
CLIN 0017AA	MK	\$56,076.00



CLIN 0017AA	ML	\$116,044.00	
CLIN 0017AA	MM	\$1,618,600.00	
CLIN 0017AA	MN	\$2,573,000.00	
CLIN 0017AA	MP	\$250,000.00	
CLIN 0017AA	MQ	\$691,421.00	
CLIN 0017AA	MR	\$0.00	
CLIN 0017AA	MS	\$700,000.00	
CLIN 0017AA	MT	\$16,289,524.00	
CLIN 0017AA	MV	\$39,921,199.75	
CLIN 0017AA	MW	\$10,000,000.00	
CLIN 0017AA	MX	\$69,699,162.00	
		±	1,660,509,068.27
		=	
CLIN 0017AB	KL	118,250.00	
		-	118,250.00
G1 D1 004 - 1 G		100.000.00	
CLIN 0017AC	BZ	190,000.00	100 000 00
		-	190,000.00
CLIN 0017AD	KN	0.00	
CLIN 0017AD	KS	0.00	
		- -	0.00
		.=	
CLIN 0017AE	LL	173,798.00	172 709 00
			173,798.00
CLIN 0017AH	KT	173,798.00	
		_	173,798.00
		_	
CLIN 0020AA	KN	0.00	
CLIN 0020AA	KQ	26,660.00	26.660.00
		-	26,660.00
CLIN 0021AA	KW	0.00	
		-	0.00
		-	
CLIN 0021AB	KV	0.00	
CLIN 0021AB	LB	0.00	
CLIN 0021AB CLIN 0021AB	KX KY	0.00 0.00	
CLIN UUZIAD	K I	0.00 _	0.00
			0.00

CLIN 0021AC	KZ	0.00	
CLIN 0021AC	LA	0.00	
		\$20000	0.00
CLIN 0022	KW	0.00	
			0.00
Ct Di 0000	1737	CO 000 00	
CLIN 0023	KX KY	60,000.00	
CLIN 0023 CLIN 0023	KV	25,000.00 65,000.00	
CLIN 0023 CLIN 0023	LB	12,500.00	
CLIN 0023 CLIN 0023	LF	10,000.00	
CLIN 0023	LR	\$125,000.00	
0211 0023	DA C	Ψ123,000.00	297,500.00
CI DI 0004	T. A.	12 509 00	
CLIN 0024 CLIN 0024	LA	13,508.00	
CLIN 0024 CLIN 0024	LG KZ	62,000.00 25,000.00	
CLIN 0024 CLIN 0024	KW	20,000.00	
CLIN 0024 CLIN 0024	LP	83,200.00	
CLIN 0024	LF	83,200.00	202 502 00
			203,708.00
CLIN 0025	LE	1,173,850.00	
CLIN 0025	LM	1,080,404.00	
CLIN 0025	MA	0.00	
			2,254,254.00
CLIN 0026	LN	630,061.00	
			630,061.00
CLIN 0027	LZ	1,751,384.00	
			1,751,384.00
CLIN 0028	LM	329,972.00	
CLIN 0028	MA	2,982,442.00	
CLIN 0028	MG	6,262,095.00	
CLIN 0028	MU	\$7,864,499	
CLIN 0028	MO	\$1,004,433	17,439,008.00
CLIN 003001*	MX	\$52,974,283.00	
CLIN003002*	MX	\$719,132.00	
CLIN 000303*	MX	\$5,747.00	
CLIN 000304*	MX	\$16,000,000.00	
			69,699,162.00

* CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. For pruposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017AA and should not be counted twice with regards to the total contract funding obligated.

(End of Summary of Changes)

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT			1.CONTRACT	ID CODE	PAGEOF PA	GES	
·			٧		1 1	15	
AMENDMENT MODIFICATION NO.	3. EFFECTIVE DATE	4. REQUINTION/PURCHASE REQ. NO.		5. PROJECT	NO.((fapplicable)	,	
)00251	116 AUG 12						
SEUED BY CODE	W9113M	7, ADMINISTERED BY (Ifother than Items)	CO	DB 82206	A		
CARATRAT		OCMA RAYTHEON 50 APPLE HILL DRIVE					
NATIC-PIDG ID BCX 1830		I NOS TEFRE				ļ	
LUNTOVILLE AL 3000T-3001							
MANAGE AND A DOUBLE OF COLUMN A COLUMN	Ol- Ares Court		I 9A. AMENDM	ENT OF ON	TOTATION!		
NAME AND ADDRESS OF CONTRACTOR RAYTHEON COMPANY	(No., Street, County,	state and Zip Code)	7A. AMENUM	ENI UF BUI	HCI I NI IUN I	NO.	
380 LOWELL ST. ANDOVER MA 01810-400		Г	98. DATED (S	E ITEM I)		
		<u> </u>					
		· .	C DASCESS SEC	-0001 KAC	PORDER NO.	'	
			10B. DATED	SEE ITEM	3)		
DE 05718	FACILITY COL)E	30-Jen-1995				
11	. This item only a	PPLIES TO AMENDMENTS OF SOLIC	TATIONS				
The above numbered solicitation is exended as set for	th in Itum 14. The hour and	date specified for receipt of Other	is entended,	is not exten	ded.		
Offic asset acknowledge receipt of this assessment pri	•	•	•	_		- 1	
(a) By completing from 8 and 15, and returning ar (c) By seasons inter-orthogonawwhich includes a		or; (b) By asknowledging receipt of this musedown				- 1	
RECEIVED ATTHE PLACE DESIGNATED FOR T				IO BE			
REJECTION OF YOUR OFFER, Hey virtue of his				ier,			
provided such telegramor letter makes reduces to th		immi, and is mostred prior to the opening hourses	dete specified.				
ACCOUNTING AND APPROPRIATION D	ATA (If required)						
See Schedule							
		TO MODIFICATIONS OF CONTRACTS TOORDER NO. AS DESCRIBED IN ITE					
A. THIS CHANGE ORDER IS ISSUED PURS				ADE IN TH	re		
CONTRACT ORDER NO. IN ITEM 10A		Manay) in Charge of Port in 1	411 EM 14 VVE 9	MPS IN IN			
B. THE ABOVE NUMBERED CONTRACT/ office, appropriation date, etc.) SET FOR	th in Item 14, pur	SUANT TO THE AUTHORITY OF FAR	CHANGES (such 43.103(B).	es changes in	paying		
C. THIS SUPPLEMENTAL AGREEMENT I FAR 52.232-22, Linkellon of Funds and FA	R 43.103(a)(3), Mutual		-				
D. OTHER (Specify type of modification and	l authority)						
IMPORTANT: Contractor is not,	is required to sig	n this document and return1	opies to the issuing	office.			
DESCRIPTION OF AMENDMENT/MODIF	TCATION (Organized	by UCF section headings, including solicity	ntion/contract subi	ot metter			
where feasible.)				,		(by)	
Modification Control Number:	ad 846 000 000; to am	ing Seating IJ 40 AVCENTIVE CUE COM I			A.	lφ μ	
is provide incremental funding in the amount 1017, SYSTEM DEVELOPMENT AND DEMON	STRATION (SOO) to m	nd decidit 17-18, NVCCVIIVE FEE 3 INV. ndify the flat anot incentive criticle to def	ar nee performen	ce orleda fo	DAU DAU		
he integrated Fire Control (IFC) event to the	Functional Configuration	on Audit (FCA) #1 event and to add addit	lonal flat apot ince	ntive criteria	to		
ncrease the flat spot incentive apportunity in	the future; and to rev	iee Section J to include the revised flat a	pot incentive crite				
evision to Contract Data Requirements List (CORL) B004. All other	r terms and conditions remain unchanged	i.				
						- 1	
						Ì	
pt as provided hereis, all terms and conditions of the d	a cumust pullamond in Item!	A or IOA, as hereto fire changed, remains unchange	her sort HG al her b	ellet.			
NAME		ISA NAME AND THE				(by	
THE RESERVE OF THE RESERVE OF THE PARTY OF T	Luca Barraga	LES INITED STATES		1122	DATE AND	الحسرا	
	ISC. DATE SIGNED	The state of the s		16C.	DATE SIGNE	ַ ער יייע	
	8/16/2012			FI	ا میں م	2 [b)	
person person full horized to sign)	1-1-1-	(Superior of Contracting Office	<u> </u>		()		
CEPTION TO SP 30 ' PROVED BY OIRM 11-84	. 3	0-105-04			tM 30 (Rev. 10	D- 8 3)	
1 444 R. P. MOLENE : 4.41	•			eribed by GS/ .(48 CFR) 53		•	
	A .	~~~~	E-MIN	ALE PRINCES			

SUMMARY OF CHANGES

1. SECTION B - SUPPLIES OR SERVICES AND PRICES

CLIN 0030

The total cost of this line item has increased by \$16,000,000.00 from \$69,699,162.00 to \$85,699,162.00.*

* As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017AA, identified, accounted for, invoiced, analyzed, or reported separately from SubCLIN 0017, including EVMS. All scope remains under SubCLIN 0017AA with associated incentive events and flat zones.

SUBCLIN 003005 is added as follows:

ITEM NO 003005

SUPPLIES/SERVICES

OUANTITY

UNIT UNIT PRICE

AMOUNT

GFEBS Funding for SubCLIN 0017AA

CPIF

FOB: Destination

ACRN MX

\$16,000,000.00

CIN: GFEBS001015913300030

2. SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation

Summary for the Payment Office

As a result of this modification, the total funded amount for this document was increased by \$16,000,000.00 from \$1,893,711,758.63 to \$1,909,711,758.63.

SUBCLIN 003005:

Funding on SUBCLIN 003005 is initiated as follows:

ACRN: MX

CIN: GFEBS001015913300030

Accting Data: 02120122013204000001171722550030003242A.0000013.1.1 6100.9000021001

Increase: \$16,000,000.00

Total: \$16,000,000.00

Cost Code: A5XFJ

Target Cost, Target Fee, and total for the increase in target cost of increase in target fee of		s distributed as follows an Dfacilities capital cost of		(b)(d)
Target Cost Target Fee Total \$16,000,000				(ઇ ૪૫)
IMPLEMENTATION OF AND EXPLA			N OF FUNDS	
SUBCLIN 0017AA:	<u>PRIOR</u>	THIS MODIFICATION	CUMULATI TOTAL*	
 Amount Required for Full Funding Including Fee: Amount Allotted Under the LOF for Payment of Costs: 	\$1,683,179,8	62 \$ 0	\$ 1,683,179,86	52 (b)(4)
 (3) Amount Separately Obligated for Payment of Fee: (4) Total Amount Allotted and Oblig (5) Net Amount Required for Full Full 	gated: \$1,660,509,06		\$1,676,509,066 \$ 6,670,793	
* These figures take into consideration the SubCLIN 17AH)	, ,	(* , , , ,	, ,	
3. SECTION H – SPECIAL CONTRACT Paragraph H-19, INCENTIVE FEE STEDEVELOPMENT AND DEMONSTRACE. c. Schedule and Performance Incer	RUCTURE AND PAYMENT FOR ATION (SDD), subparagraph c., is	R CLIN 0017, SYSTEM		
(1) A maximum "flat zone conduct of milestones below. The "flat zone	e" will be established at the estima zone" over which the contractor we the program milestones set forth	rill earn target fee is for elibelow are conducted. (No	igible costs from	(b)(4) (b)(4)
Functional Review NLT 2nd Quarter, Finantheon completed the requirement for	r this flat zone and earned the "Fla incentive fee payment utilizing th	nowledged by the government Zone" schedule incentive	nent that e of	(b)(4) (b)(b) (b)(b)
(b) Section (b) Section (b) Section (c) Se	zone and earned the "Flat Zone" so	edged by the government chedule incentive of	that Raytheon Final	(P)(P) (P)(P) (P)(P)

contract. Reference letter, dated 12 January 2009, from		(D)(P)
(c) The second of the maximum benefit of the "flat zone", earned by the conduct of the Development Test 1 (DT-1) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. (It is hereby acknowledged by the government of the Development of the Developm		(મ)ત્મ)
that Raytheon completed the requirement for this flat zone and earned a "Flat Zone" schedule incentive of specific or the available Final determination of incentive fee payment utilizing "Flat Zone" amount will be made at the conclusion of the contract.)	the	(b) (4)
(d) for the maximum benefit of the "flat zone", earned by the conduct of the Electromagn Environmental Effects (E3) Testing in accordance with the criteria set forth in Section J attachment entitled Flat Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12.		(PXA)
(e) of the maximum benefit of the "flat zone", earned by the conduct of the Integrated I Control Event in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned a "Flat Zone" schedule.		(PXH)
incentive of payment or a subject of the available subject. Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract.) *NOTE: The		(৮)પ્રય)
notential has been decreased from . To to to movement of the incentive f	(b) (i)8	(5)(4) (3)(A) &Title 10 Sec (a)(b)
(f) * of the maximum benefit of the "flat zone", earned by the conduct of the Functional Configuration Audit (FCA) #1 in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. *Note: The potential has be increased from State of the State	e (i)&Title) (b)(4) 0
mercased from 5 meetings of the 5	(b)(3)(A)	(ቀ)ረሳ
(g) of the maximum benefit of the "flat zone", earned by the conduct of Developmental Test 2 (DT-2) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. *	(i)&Title	(b)(4),
(h) 6 of the maximum benefit of the "flat zone", earned by the conduct of the Early I Test (previously defined as Limited User Test) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. *	Jser	(b)(4)
(i) of the maximum benefit of the "flat zone", earned by the conduct of the Final Functional Configuration Audit (FCA) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. *		(b)(4)
* These additional incentives are added to the contract contingent upon agreement to a pending contract ceiling increase. Should the parties not be able to reach agreement on such increase, the Government reserves the right to rescind the incentives.		
(3) For Earned Value and cost reporting purposes, the estimated cost value of which will be used.		(4)(d)
d. Changes issued under FAR 52.243-2, Changes - Cost Reimbursement		

In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the performance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLIN 0017 are added and exercised, the incentive fee for cost and schedule/performance applicable to

the Option will be incorporated in accordance with the incentive fee structure of this provision.

4. SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS

The following has been revised:

TITLE	DATE	# OF PAGES	
Contract Security Classification Specification (DD Form 254), Revision 13 (Added per Modification P00235)	14 Apr 11	13	
JLENS Software Source Code Specifically Negotiated License License Number JLENS-SWLA-01 (Added per Modification P00166)	, 04 Sep 08	8	
CLIN 0017: JLENS System Development and Demonstration (SDD) Program Statement of Work (Revised by Incorporating CSDR Plans dated 20 Febr 2007 in Appendix C per Modification P00136)	30 Nov 06 - Revised 20 Feb 07	37	
JLENS System Development and Demonstration (SDD) Program Statement of Work (Added per Modification P00187)	Revised 06 Apr 09	38	
JLENS System Development and Demonstration (SDD) Program Statement of Work, Revision 2 (Added per Modification P00207)	Revised 09 Mar 10	36	
JLENS System Development and Demonstration (SDD) Program Statement of Work, Revision 3 (Added per Modification P00239)	Revised 01 Sep 11	36	
JLENS System Development and Demonstration (SDD) Program Statement of Work (Added per Modification P00240)	Revised 26 Sep 11	36	
	March 08	1 ,	(b)(3)(A)(i)&Title 10 Sec 130 (a)(b)
Contract Data Requirements List (DD Form 1423) Exhibit A with Distribution List & Data Item Nos. B001 through B062	01 Dec 06	63	
(Replace Data Item Nos. B026 and B027, only Per Modification P00136)	Revised 05 Apr 07		
(Replace Data Item Nos. B048 and B049, only Per Modification P00143 & to add statement in	Revised 24 Oct 07		
Section A of Modification P00143) (Replace Data Item No. B033 only, per Modification P00161)	Revised 11 Jul 08	1	
Contract Data Requirements List (DD Form 1423) Exhibit A, Data Item Nos. B001 and B014 (Added per Modification P00187)	Revised 07 May 09	2	

Contract Data Requirements List (DD Form 1423) Exhibit A, Data Item Nos. B002 through B062 (less B014)	Revised 20 Mar 09	60
(Added per Modification P00187)		
Contract Data Requirements List (DD Form 1423)	Revised 30 Aug 11	2
Exhibit A, Data Item Nos. B001 and B014		
(Added per Modification P00239)		
Contract Data Requirements List (DD Form 1423)	Revised 31 Jul 12	1
Exhibit A, Data Item Nos. B004		
(Added per Modification P00257)		19


*Added statement below to address weekends/Holidays: (In Mod P00143)

24 October 07

*Per a mutual agreement between Raytheon and JLENS Product Office all Contract Data Requirements List (CDRL's) (DD Form 1423) are due on the next business day after the required due date if the due date falls on Saturday, Sunday or a Government Holiday. In addition, for any CDRL with a requirement to resubmit within 10 days or less after receipt of comments, where Raytheon receives the comments on a Friday, the timeframe for resubmittal will begin on the next business day. Statement added in Mod P00143 on 24 Oct. 2007.

GFE/GFP/GFS List for SDD	28 Nov 06	2
Replaced with Rev. B List	15 Oct 07	6
**Add items below	Revised 22 Oct 07	
For record-keeping purposes		
(Per Mod P00143)		
Replaced with Revision C List	09 Mar 09	12
(Per Modification P00183)		
Replaced with Revision D List	23 Feb 10	11
(Per Modification P00207)		

**Per the DCMA and Raytheon is authorized rent free use on a non-interference use of the equipment listed below for utilization on JLENS Fire Control Radar Prime Contract DASG60-98-C- (b)(4) 0001 for the period from 19 April 2007 through 30 September 2011.



Hereby added in Mod P00148 for tracking purposes: Originated in Basic Contract: Government Furnished Equipment - Spiral 1

Government Furnished Equipment - Spiral 1 (Spiral 1 Equipment Transferred to Government 20 Jun 03 1 List 25 Mar 07* 34 pages Contract DASG60-00-C-0091 DD Form 1149 (attached) (b)(6)

(Revised 21 Nov 07)* 34 pages

Ship to address:

(0)(0)

(b)(4)

(b)(4)		
*NOTE: Items 1-1060 transferred to Contract DASG60-0 1061 – 1116 GFE items retained on Contract DASG60-98-		
JLENS Performance Specification, MIS-PRF-55628, Revision A (Added by reference per Modification P00168)	27 Jun 08	136
Annex A to the JLENS Performance Specification, MIS-PRF-55628, Revision A (Added by reference per Modification P00168)	27 Jun 08	10
JLENS SDD DD250 Plan (Added per Modification P00207)	11 Dec 09	5
Engineering Change Proposal (ECP) MI-N3893, Revision 2, CDRL B039-005b	15 Nov 10	15
Engineering Change Proposal (ECP) MI-N3894, CDRL B039-006	18 Aug 10	16
Engineering Change Proposal (ECP) MI-N3895, CDRL B039-007	28 Sep 10	50
Engineering Change Proposal (ECP) JL1359 (Added per Modification P00240)	20 Jun 11	7
Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c) (Added per Modification P00242)	01 Nov 11	4
Revised Flat Zone Performance Criteria for JLENS SD Contract, Section H-19(c) (Added per Modification P00257)	D 10 Aug 12	7
Test Spares List (Added per Modification P00247)	Undated	8
CLINs 0023 and 0024 JLENS Simulation Support SOW dated 28 January 2008 Simulation Support Tasks (b)(3)(A)	28 January 2008	2
(Added per Mod P00160) <u>CLIN 0025</u>	Σ	

002541

14 Sep 09


3

JLENS Integrated Fire Control Demonstration Program

Statement of Work, Revision 5 (Added per Modification P00211)		
JLENS Integrated Fire Control Demonstration Program Program and Technical Clarification Description, incorporated herein by reference (Added per Modification P00211)	30 Mar 10	26
Contract Data Requirements List (DD Form 1423) Exhibit B, Data Items Nos. B001 through B004, with Data Item Descriptions (Added per Modification P00165)	16 Oct 07	19
Contract Data Requirements List (DD Form 1423), CLIN 0028, Exhibit B, Data Item Nos. B001 through B006 (Added per Modification P00211)	16 Jun 10	6
<u>CLIN 0027</u>		
JLENS System Integration Lab (SIL) Equipment List (Added per Modification P00196)	Undated	6
Revision to System Integration Lab (SIL) Equipment List (Added per Modification P00217)	02 Aug 10	6

5. The following is an update to Modification P00256 showing a summary of funding by ACRN through Modification P00257:

<u>ACRN</u>	FUNDING	
AA		440,100.00
AB		2,298,235.00
AC		17,832,987.00
AD		0.00
AE		7,500,000.00
AF		3,300,000.00
AG		17,192,400.00
AH		700,000.00
AJ		200,000.00
AK		85,000.00
AL		45,000.00
AM		17,045,000.00
AN		5,800.00
AP		20,779,000.00
AQ		105,000.00
AR		35,000.00
AS		0.00
AT		6,984,678.52
AU		7,970,000.00



AV	0.00
AW	100,000.00
AX	3,396,000.00
AY	550,000.00
AZ	19,412,000.00
BA	24,527,878.00
BB	146,000.00
BC	72,000.00
BD	85,000.00
BE	100,000.00
BF	100,000.00
BG	1,975,321.00
BH	38,018,908.00
BJ	7,896,673.34
BK	260,000.00
BL	0.00
BM	125,000.00
BN	103,000.00
BP	10,199,288.50
BU	350,000.00
BV	9,000.00
BW	84,896,852.00
BX	1,146,000.00
BY	3,880,000.00
BZ	190,000.00
KL	118,250.00
KM	192,793,000.00
KN	0.00
KQ	92,811.00
KR	0.00
KS	0.00
KT	386,377,998.00
KU	2,203,183.00
KV	65,000.00
K₩	20,000.00
KX	60,000.00
KY	25,000.00
KZ	25,000.00
LA	13,508.00
LB	12,500.00
LC	200,000.00
LD	7,943,648.00
LE	1,173,850.00
LF	10,000.00
LG	62,000.00
LH	400,000.00
LJ	7,476.00
LK	\$281,575,897.00
LL	\$173,798.00
LM	\$1,410,376.00
A-447A	Ψ1,-710,570.00

LN	\$630,061.00
LP	\$83,200.00
LQ	\$235,566.00
LR	\$125,000.00
LS	\$6,069,616.00
LT	\$530,377.00
LU	\$9,100,000.00
LV	\$1,957,265.00
LW	\$255,567.00
LX	\$68,000.00
LY	\$264,807,424.52
LZ	\$1,751,384.00
MA	\$2,982,442.00
MB	\$375,000.00
MC	\$2,283,481.00
MD	\$8,573.00
ME	\$0.00
MF	\$270,514,880.00
MG	\$6,262,095.00
MH	\$213,390.00
MJ	\$858,495.00
MK	\$56,076.00
ML	\$116,044.00
MM	\$1,618,600.00
MN	\$2,573,000.00
MP	\$250,000.00
MQ	\$691,421.00
MR	\$0.00
MS	\$700,000.00
MT	\$16,289,524.00
MU	\$7,864,499.00
MV	\$39,921,199.75
MW	\$10,000,000.00
MX	\$85,699,162.00

6. The following is an update to Modification P00256 showing a summary of funding by CLIN by ACRN through Modification P00257:

<u>CLIN</u>	<u>ACRN</u>	FUNDING AMT	CLIN TOTAL
CLIN 0001 CLIN 0001	AA AD	440,100.00 0.00	
			440,100.00
CLIN 0003	AB	2,298,235.00	
CLIN 0003	AC	17,832,987.00	
CLIN 0003	AD	0.00	
CLIN 0003	AE	7,500,000.00	
CLIN 0003	AF	3,300,000.00	

CLIN 0003 CLIN 0003	4.0		
CLIN 0003	AG	17,192,400.00	
	AH	700,000.00	
CLIN 0003	AM	17,045,000.00	
CLIN 0003	AN	5,800.00	
CLIN 0003	AP	20,779,000.00	
CLIN 0003	AS	0.00	
CLIN 0003	AT	6,984,678.52	
CLIN 0003	AW	100,000.00	
CLIN 0003	AY	550,000.00	
CLIN 0003	AI	330,000.00	94,288,100.52
			74,200,100.72
OI DI 0005	70.4	24 527 978 00	
CLIN 0005	BA	24,527,878.00	
CLIN 0005	BB	146,000.00	
CLIN 0005	BC	72,000.00	
CLIN 0005	BD	85,000.00	
CLIN 0005	BE	100,000.00	
CLIN 0005	BF	100,000.00	
CLIN 0005	BG	1,975,321.00	
CLIN 0005	BH	38,018,908.00	
CLIN 0005	BL	0.00	
CLIN 0005	BZ	0.00	
			65,025,107.00
		to many ye	
CLIN 0007AA	BP	10,199,288.50	
02111 000 1111		10,122,100.00	
•		_	10,199,288.50
			10,177,200.00
CI TN 0000 A A	40	45 106 00	
CLIN 0009AA	AQ	45,106.00	
CLIN 0009AA	AV	0.00	
CLIN 0009AA	BK	256,545.00	
		107 000 00	
CLIN 0009AA	BM	125,000.00	
CLIN 0009AA CLIN 0009AA	BM BN	125,000.00 21,315.00	
		· ·	447,966.00
		21,315.00	447,966.00
		· ·	447,966.00
CLIN 0009AA	BN	21,315.00	447,966.00
CLIN 0009AA CLIN 0009AB	BN AJ	21,315.00	447,966.00
CLIN 0009AA CLIN 0009AB CLIN 0009AB	BN AJ AK	21,315.00 == 200,000.00 85,000.00	447,966.00
CLIN 0009AB CLIN 0009AB CLIN 0009AB CLIN 0009AB	BN AJ AK AL	21,315.00 200,000.00 85,000.00 45,000.00	447,966.00
CLIN 0009AB CLIN 0009AB CLIN 0009AB CLIN 0009AB CLIN 0009AB	BN AJ AK AL AQ	21,315.00	447,966.00
CLIN 0009AB CLIN 0009AB CLIN 0009AB CLIN 0009AB CLIN 0009AB CLIN 0009AB	BN AJ AK AL AQ AR	21,315.00	447,966.00
CLIN 0009AB	AJ AK AL AQ AR BK	21,315.00	447,966.00
CLIN 0009AB	AJ AK AL AQ AR BK BN	200,000.00 85,000.00 45,000.00 59,894.00 35,000.00 3,455.00	447,966.00
CLIN 0009AB	AJ AK AL AQ AR BK BN BU	21,315.00	
CLIN 0009AB	AJ AK AL AQ AR BK BN BU	21,315.00	447,966.00 869,034.00
CLIN 0009AA CLIN 0009AB	AJ AK AL AQ AR BK BN BU BV	21,315.00	
CLIN 0009AA CLIN 0009AB	AJ AK AL AQ AR BK BN BU BV	21,315.00	
CLIN 0009AA CLIN 0009AB	AJ AK AL AQ AR BK BN BU BV	21,315.00	


CLIN 0013	AZ	19,412,000.00	
CLIN 0013	ВЈ	7,896,673.34	
		38,674,673.34	4
_			
CLIN 0017	BW	0.00	
CLIN 0017	KM	0.00	
		0.00)
CLIN 0017AA	BY	3,880,000.00	
CLIN 0017AA	BX	1,146,000.00	
CLIN 0017AA	\mathbf{BW}	84,896,852.00	
CLIN 0017AA	BZ	0.00	
CLIN 0017AA	KM	192,793,000.00	
CLIN 0017AA	KN	0.00	
CLIN 0017AA	KQ	66,151.00	
CLIN 0017AA	KS	0.00	
CLIN 0017AA	KT	386,204,200.00	
CLIN 0017AA	KU	2,203,183.00	
CLIN 0017AA	KY	0.00	
CLIN 0017AA	LC	200,000.00	
CLIN 0017AA	LD	7,943,648.00	
CLIN 0017AA	LE	0.00	
CLIN 0017AA CLIN 0017AA	LH LJ	400,000.00	
CLIN 0017AA CLIN 0017AA	LJ LK	7,476.00	
CLIN 0017AA		281,575,897.00 235,566.00	
	LQ	6,069,616.00	
CLIN 0017AA	LS		
CLIN 0017AA	LT	530,377.00	
CLIN 0017AA	LU	\$9,100,000.00 \$1,057,265,00	
CLIN 0017AA	LV	\$1,957,265.00	-
CLIN 0017AA	LW	\$255,567.00	
CLIN 0017AA	LX	\$68,000.00	=
CLIN 0017AA	LY	\$264,807,424.52	
CLIN 0017AA	MB	\$375,000.00	_
CLIN 0017AA	MC	\$2,283,481.00	
CLIN 0017AA	MD	\$8,573.00	
CLIN 0017AA	ME	\$0.00	
CLIN 0017AA	MF	\$270,514,880.00	_
CLIN 0017AA	MH	\$213,390.00	_
CLIN 0017AA	MJ	\$858,495.00	
CLIN 0017AA	MK	\$56,076.00	-
CLIN 0017AA	ML	\$116,044.00	
CLIN 0017AA	MM	\$1,618,600.00	
CLIN 0017AA	MN	\$2,573,000.00	-
CLIN 0017AA	MP	\$250,000.00	
			

	\$691,421.00	MQ	CLIN 0017AA
	\$0.00	MR	CLIN 0017AA
	\$700,000.00	MS	CLIN 0017AA
	\$16,289,524.00	MT	CLIN 0017AA
	\$39,921,199.75	MV	CLIN 0017AA
	\$10,000,000.00	MW	CLIN 0017AA
	\$85,699,162.00	MX	CLIN 0017AA
1,676,509,068.27	=		
	=		
<u> </u>	201		
	118,250.00	KL	CLIN 0017AB
118,250.00			
	190,000.00 _	BZ	CLIN 0017AC
190,000.00	=		
	0.00	KN	CLIN 0017AD
	0.00	KS KS	CLIN 0017AD
0.00		110	,
			
	173,798.00	LL	CLIN 0017AE
173,798.00			
	172 709 00	VT	CLINI 0017 A H
173,798.00	173,798.00 _	KT	CLIN 0017AH
173,790.00	-		
	0.00	KN	CLIN 0020AA
	26,660.00 _	KQ	CLIN 0020AA
26,660.00	<u></u>		
	0.00	KW	CLIN 0021AA
0.00	_		
	0.00	KV	CLIN 0021AB
	0.00	LB	CLIN 0021AB CLIN 0021AB
	0.00 0.00	KX KY	CLIN 0021AB
0.00		K1	CEII (002 II II)
0.00	-		
	0.00	KZ	CLIN 0021AC
	0.00	LA	CLIN 0021AC
0.00			

CLIN 0022	KW	0.00	
			0.00
CLIN 0023	KX	60,000.00	
CLIN 0023	KY	25,000.00	
CLIN 0023	KV	65,000.00	
CLIN 0023	LB	12,500.00	
CLIN 0023	LF	10,000.00	
CLIN 0023	LR	\$125,000.00	
		· · · · · ·	297,500.00
		-	
CLIN 0024	LA	13,508.00	
CLIN 0024	LG	62,000.00	
CLIN 0024	KZ	25,000.00	
CLIN 0024	KW	20,000.00	
CLIN 0024	LP	83,200.00	
		•	203,708.00
			203,700.00
CLIN 0025	LE	1,173,850.00	
CLIN 0025	LM	1,080,404.00	
	2	1,000,101100	
CLIN 0025	MA	0.00	
		-	2,254,254.00
CLIN 0026	LN	630,061.00	
		-	630,061.00

CLIN 0027	LZ	1,751,384.00	
		· · · —	1,751,384.00
CLIN 0028	LM	329,972.00	
CLIN 0028	MA	2,982,442.00	
CLIN 0028	MG	6,262,095.00	
CLIN 0028	MU	\$7,864,499	
CLIN 0020	MO	\$7,004,427	17 420 000 00
			17,439,008.00
CT INT 002001*	MY	esa 074 202 00	
CLIN 003001*	MX	\$52,974,283.00	
CLIN003002*	MX	\$719,132.00	
CLIN 000303*	MX	\$5,747.00	
CLIN 000304*	MX	\$16,000,000.00	
			85,699,162.00

^{*} CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. For pruposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017AA and should not be counted twice with regards to the total contract funding obligated.



(End of Summary of Changes)

CONTRACT DATA REQUIREMENTS LIST Form Approved OMB No. 0704-0188										
Public reporting surfer to	y you underdane of externation :		e bestage VVO h	ors per respector, entitling the long t	name white		يست راد	n golleri	7 144	1
suppositions for reducing to	Per buston to Department of Di	Harry Was	Partie House	ins per respector, calcing the test is a diest converse regarding that been pr bevery, Carlottelle for intermedia and respect (1704-170) which is applied to be the calcing the calcing applied to the calcing the calcing	Openhous and Report	H 1215 Johnson Do	ren er inn vern Ny		1201	
A CONTRACT LIN	nd term to the Government House	Corrector	Officer for Cont	and the latest an allegan of						
18		A		C CATEGORY	er X					
L				1						•
D SYSTEMITEM				ACT/PRINO.	FCONTRAC					
	LENS SDD		DASG	60-98-C-0001	Raytheor					
1 DATA (TEM NO	2 TIPLE OF DATA			Dam	3 SUBTITLE					17 PRICE GROUP
B004	Contract f			CEPORT PREPENCE	6 MEQUINING O			·		
4 AUTHORITY (Date	Acquisition Document No.	' [A MECONIMING O	PFICE		•		IS BETHALLS TOTAL PRICE
	GMT-81466A	10 FRE		W para 2.6.1	SFAE-M	SLS-CMI	DS-B	MD		INSERT
7 DD 250 REQ	9 DIST STATEMENT	14 I	DISTRIBUTION				IN			
LT								COPE	•	SECT. B
B APP CODE		11 AR C		DATE OF SUBBROUENT	a ADDRESSEE		-	F		GEC 1. D
.000	F	~~	1	NEWISSION	a wowcoose		Draft			
N\A		N	/A :	SEE BLOCK 16				Itag	ğ	
14. REMARKE:	·				SPALMELSC	MOSPE CM	0	1		
	r F. Fuither dissemil						1	1 1	1	
	8ystema Project Offi al, Al. 35698-5000, 2			ADS-PE-CNI.			1	1		
	ii, Al. 33000-3000, 2 Itial submission shal			e after the close of			l	1 1		
	unting month after S						1	1		
				eller the close of each			Ι.			
	h through the period						`			
	re required and shall						1	1 1		
	t is compatible with t forecast periods. Th						1	1 1		
				verterly, semi-annual.			1			
or annually to cor	mpletion. To maintai			the CPR shall report			1	1 1		
via the WBS stru							l			
W66 1 - level 2, W68 2 - level 2.	WBS 5 - level 2 WBS 6 - level 4		MB\$ 9 — Le MBS A — Le				1	1 1		
WBS 3 - level 2.	WBS 7 - level :		160 A - U	141 3			1	1 1	1	
WBS 4 - level 2,	WBS 8 - level 3						l	1 1		
	ting shall be accomp						ļ	1 1	ı	
	ell include "Best Car			a minimum, verlance			1))	1	
	e provided for currer							1 1	1	
				ve cost and achedule			l	1 1		
	+/-10% and greater						1	i i	1	
	lell also provide vers -5% and greater the							1 1	.	
				ber of vertenous to be				i i		
	menth shall not exc					i		i i	ı	
	an 15 reportable vari								1	
				gory, based on dollar					1	
	e WBS's, that expec cost (3); cumulative							lí	1	
complete (3), as a	applicable. The varia		heis shell i	nclude a detailed					- 1	
explanation of the	problem, corrective	action, p	program impore	pact, and expected				1		
	ule verience nametiv		identify sign	nificent missed					1	
	npact to major miles!		-	News. II ENG						
	delivery of this data to Management OP								- 1	
	ed in portal or rapes					1		l i	1	
signed electronics										
			_		LL TOTAL		0	1	0	
G PHEPA			A.E.							
			2.74	OF THE						F .

(b)(b)

DD Form 1423-1, 1 Jun 90

T SPOT INCENTIVE CRITERIA FOR JLENS SDD (TRACT, SECTION H-19(C), DATED 10 AUG 1

Total Flat Spot Opportunity for Event	event	Critoria	Firt Spot Allotment (Opportunity)	Refdence *	Remarks	Incentive Fee Amount Awarded by JPG	Yotel Flat Spot for Minjor Event	Americal / Recommended	
\$5.500,000	Floring Wa								(6)(4
									(b)X
									(b)(4)
Q									(ک)(ط)
702552									
٥									(16)(4)
									(h)(4)
									(B)(Y)

T SPOT INCENTIVE CRITERIA FOR JLENS SDD (RACT, SECTION H-19(C), DATED 10 AUG 12

Total Plat Spot Opportunity for Event	Event	Criteria	First Spot Allotracyt (Opportunity)	Evidence	Reconflis	Incentive Fee Amount Assurded by JPO	Total Plat Spot for Major Breat	Americal / Recommended	
									(b)
									<u>رط)</u> (ط)
									(b
									(d)
									رق
									<u>(</u>
									"
									<u>(L</u>
									()
									ط)

T SPOT INCENTIVE CRITERIA FOR JLENS SDD (*** TRACT, SECTION H-19(C), DATED 10 AUG 1.**

	Total Flat Spot Opportunity for Event	EVENT	Criteria	Plat Spot Allotment (Opportunity)	Exidence	Remerks	Amount Amount Amountal by SPO	Total Flat Spot for Major Ereat	Averded / Recommended	
	\$16,000,000	Dunicomental								CAXY
										نا(ط)
									(b)	(þ)Y:
									(b)(4)	
0										(4)(4)
C02554										
4										436.
										(b) (4
									•	
								•		

TSPOT INCENTIVE CRITERIA FOR JLENS SDD (TRACT, SECTION H-19(C), DATED 10 AUG 1:

Total First Spot Opportunity for Event	cvent	· Criterie	First Spot Allutment (Opportunity)	Politica		Resperts	Incontive Fee Amount Awarded by JPO	Total Flat Spot for Major Sveat	Americal / Recommended	
										(A)
										(bl4)
										(4)Xd
									((b)(4)
										C. 3 ,
										0. %
									,	(b)(4)

T SPOT INCENTIVE CRITERIA FOR JLENS SDD (TRACT, SECTION H-19(C), DATED 10 AUG 1

Total Flat Spot Opportunity for Event	treet.	Critieria	First Spot Allotment (Opportunity)	Evidence	•	Remarks	Incentive Fee Amount Awarded by JPO	Total Flat Spot for Major Event	Awarded / Recommended	
									. .	(b)(4)
							1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			(6X49)
										டுபடி
										(b) (4)
										(b)14)
										(b)(4)
										(4)

332k

T SPOT INCENTIVE CRITERIA FOR JLENS SDD (TRACT, SECTION H-19(C), DATED 10 AUG 1:

Opportunity for Event	a-416	Create	Allotment (Opportunity)		Amount Amount Amended by 3PO	Major Buent	Recommended	
ts om em I	Classificant Manual							(4) (4)
								(b)(4)

AMENDMENT OF SOLICI	TATIONBAODIES	CATION OF CONTRACT	1.	CONTRACT	ID CODE	PAGE OF	PAGES
AMENDMENT OF SOLICI	TYTYON/MYONILI	CATION OF CONTRACT		٧		1	13
MENDMENT/MODIFICATION NO.		4. REQUISITION/PURCHASE REQ. NO.			5.PROJECT	NO (Ifapplica	ble)
100258	124 AUGIA						
SUED BY CODE	W9113M	7. ADMINISTERED BY (If other than item 6) DCMA RAYTHEON		CO	DE \$2205	iA	
SASMOC/ARSTRAT MOC-ROC		SO APPLE HILL DRIVE					ļ
O BOX 1600		MAS TREFRE TENNISBURY MA 01876					i
UNTSVILLE AL 36607-3601							
NAME AND ADDRESS OF CONTRACTO	R (No., Street, County, St	ate and Zip Code)	9A.	AMENDM	ENT OF SOI	LICITATIO	ON NO.
RAYTHBON COMPANY	,						
MNDOVER MA 01810-4400			9B.	DATED (S	EE ITEM ! I)	1
			x 10A	, MOD. OF	CONTRAC 0001	T/ORDER 1	NO.
			\rightarrow				
DC 40740	<u> </u>			. DATED (Jan-1998	(SEE ITEM	13)	1
DE 05716	L THIS ITEM ONLY AP	PLIES TO AMENDMENTS OF SOLIC	100				+
The above numbered solicitation is assended as set if				ended.	is not exten	nded	
Offer must acknowledge receipt of this amendment p		•	ш	L			1
(a) By completing Items 8 and 15, and ectuming	copies of the amendment;	(b) By acknowledging receipt of this amendme	ent on each	copy of the of			1
or (c) By separate letter or telegram which includes RECEIVED ATTRE PLACE DESIGNATED FOR					TO BE		Į
REJECTION OF YOUR OFFER. Ifby virtue of this	s amendment you desire to chang	ge an offic already submitted, such change may b	be made by	telegramor le	uer.]
provided each telegramor letter makes reference to t	he solicitation and this anunds	ent, and is received prior to the opening hour s	nd date sp	eci Sed.			
ACCOUNTING AND APPROPRIATION	DATA (If required)						-
See Schedule		LANDING MOVED OF COLUMN	00000				
) MODIFICATIONS OF CONTRACT! F/ORDER NO. AS DESCRIBED IN ITI		CZ.			1
A. THIS CHANGE ORDER IS ISSUED PUR CONTRACT ORDER NO. IN ITEM 10/		hority) THE CHANGES SET PORTH	in Itea	4 14 ARE N	AADE IN TI	łE	
B. THE ABOVE NUMBERED CONTRACT					as changes in	paying	
office, appropriation date, etc.) SET FO			R 43.103	(B).			
FAR 43.103(a)(3), Mutual Agreement and							
D. OTHER (Specify type of modification as							
MPORTANT: Contractor is not.	[V] is asserted to sim	this document and return 1	conies s	o the issuin	o office		
	٠						
DESCRIPTION OF AMENDMENT/MODI where feasible.)	IFICATION (Organized b	y UCF section headings, including solic	it at ion/c	ontract subj		Gur Strett	ļ
Modification Control Number:							ļ
ne purpose of this modification is to increatiate of Developmental Test 2 (DT-2) and to			un resul	ting from th	e delayed st	art	
ate of Developmental lest 2 (D1-2) and to	provide incremental rund	EN FIRE EMOURE OF \$30,200,045.		•			- 1
It other terms and conditions remain unche	nged.						
							1
and an annual dead beautiful add comment and are added to the	. do			. E.O 4			- 1
pt as provided herein, all terms and conditions of the	ocument referenced in Item9.A	16A. NAME AND TITLE OF CO.				r oriet)	
be	ut print)	IVA. NAME AND LL			Alus (Dinit)	
		T					
	ISC. DATE SIGNED	TO STATES OF AMERICA	NCA		1160	DATE 20	
	_ 8/24/2012	B.				10	us 1
orizarto sign)		(Signature of Contracting Of	icer)		10	Tung	100
CEPTILLETOSF30	30	-105-04		STA	NDARD FO	RM 30 (Re	v. 10-83)

STANDARD FORM 30 (Rev. 10-83) Prescribed by GSA FAR (48 CFR) 53.243


SECTION SF 30 BLOCK 14 CONTINUATION PAGE

SUMMARY OF CHANGES

1. SECTION A - SOLICITATION/CONTRACT FORM

The total cost of this contract was increased by \$34,309,700.00 from \$1,920,928,309.00 to \$1,955,238,009.00.

2. SECTION B - SUPPLIES OR SERVICES AND PRICES



The Target Cost is consisting of the cost and second facilities	
capital cost of money.	
The Target Fee is	
Total Target Cost plus Fee is	

Pursuant to FAR 16.405-1, the target cost and target fee will be finally determined and adjusted after contract performance.


The table below provides a summary of the target cost, target fee, and total:

CLIN	MOD	TARGET COST	FCCM	TARGET FEE	TOTAL
17AA	Pre-P00251				\$1,594,280,516.00
17AA	P00251				\$1,594,280,516.00
17AA	P00254				\$1,595,005,395.00
17 AA	P00258				\$1,595,005,395.00

CLIN 0030

The total cost of this line item has increased by \$38,000,000.00 from \$85,699,162.00 to \$123,699,162.00.

SUBCLIN 003006 is added as follows:



ITEM NO 003006

SUPPLIES/SERVICES

QUANTITY

UNIT

UNIT PRICE

AMOUNT

GFEBS funding for SubCLIN 0017AA

CPIF

FOB: Destination

ACRN MX

\$38,000,000.00

CIN: GFEBS001019081700030

* As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017AA, identified, accounted for, analyzed, or reported separately from SubCLIN0017, including EVMS. All scope remains under SubCLIN 0017AA with associated incentive events and flat zones.

B-17. INCENTIVE FEE FOR SUBCLIN 0017AA/CLIN 0018 (SEE H-19):

In accordance with FAR 52.216-10, entitled "Incentive Fee", the total amount originally negotiated, adjusted in accordance with paragraph d. of this clause, for target cost and target fee for performance under SubCLIN 0017AA/CLIN 0018 are set forth below:

Target Cost


Target Fee



Incentive Arrangement: Maximum Fee:

Minimum Fee:

(Share Ratio: Government/Contractor)



for the amount by which the total allowable cost is less than the estimated cost until Underrun: maximum fee is attained.

or the amount by which the total allowable cost exceeds the estimated cost until Overrun: minimum fee is attained.

(P)(A)

FAR 52.216-10, INCENTIVE, paragraph (e)(1), is stated as follows:

(e) Fee Payable.

(1) The fee payable under this contract shall be the target fee increased by the ents for every dollar that the total allowable cost is less than the estimated cost or decreased by ents for every dollar that the total allowable cost exceeds the estimated cost. In no event shall the fee be greater than a control (Maximum fee) or less than percent (Minimum fee) of the estimated cost.

B-18. ESTIMATED COST, ESTIMATED INCENTIVE FEE, MINIMUM INCENTIVE FEE, MAXIMUM INCENTIVE FEE, AND INCENTIVE ARRANGEMENT FOR SUBCLIN 0017AA/CLIN 0018:

SUBCLIN 0017AA - (Two SDD JLENS Systems)

a. Estimated cost:

(b)(4)

b. Estimated fee:
(b)(4)

c. Minimum incentive fee:
(b)(4)

(b)(4)

e. Total estimated cost and estimated fee: \$1,717,489,562

3. SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation

Summary for the Payment Office

As a result of this modification, the total funded amount for this document was increased by \$38,266,043.00 from \$1,909,711,758.63 to \$1,947,977,801.63.

SUBCLIN 0017AA:

MF: 21 1 2040 5L 5L68 P172419E555L 255Y 4M1J730000 S01021 4M1J730000/14MJLE/4M5 was increased by \$266,043.00 from \$270,514,880.00 to \$270,780,923.00

Estimated Cost, Estimated Fee, and Estimated total for the above increase of the state of distributed as follows and includes an increase in estimated cost of \$400.00 (b)(4) and an increase in estimated fee of \$400.00 (c)

SUBCLIN 003006 (GFEBS Funding for SubCLIN 0017AA): Funding on SUBCLIN 003006 is initiated as follows:

ACRN: MX

CIN: GFEBS001019081700030

Accting Data: 02120122013204000001171722550030003242A.0000013.1.1 ' 6100.9000021001

Increase: \$38,000,000.00

Total: \$38,000,000.00

Cost Code: A5XFJ

Estimated Cost, Estimated Fee, and Estimated total for the above increase of \$38,000,000 is distributed as follows and includes an increase in estimated cost of cost and cost of money) and an increase in estimated fee

Estimated
Cost
Estimated Fee
Total
\$38,000,000

IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS

(LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows:

SUBCLIN 0017AA:	<u>PRIOR</u>	THIS MODIFICATION	CUMULATIVE TOTAL*	
 Amount Required for Full Funding, Including Fee: Amount Allotted Under the LOF Clause for Payment of Costs: 	\$1,683,179,862	\$34,309,700	\$ 1,717,489,562	(৮)
(3) Amount Separately Obligated for Payment of Fee:				UDJH.
(4) Total Amount Allotted and Obligated:	\$1,676,509,068.27	\$38,266,043	\$1,714,775,111.27	ω ξ η.
(5) Net Amount Required for Full Funding	\$ 6,670,793.73	(\$ 3,956,343)	\$ 2,714,450.73	
* These figures take into consideration the negotiated total SubCLIN 17AH)	al value of SubCLIN 001	7AA (This does not i	nclude	
4. SECTION H - SPECIAL CONTRACT REQUIREM	IENTS is revised as follo	ows:		
Paragraph H-19, <u>INCENTIVE FEE STRUCTURE ANI</u> <u>DEVELOPMENT AND DEMONSTRATION (SDD)</u> , s			lows:	
a. General.				
SubCLIN 0017AA, System Development and Demonstration with cost and schedule incentives as described below. For Paragraph H-19(c) applies only to the Schedule Incentive includes a target cost of (which includes cost of money) and a target incentive fee of of money.	Paragraph H-19(b) applied. The target contract paragraph costs.	es only to the Cost In	centive and 5,005,395 facilities capital	(b)(4) (b)(4)
b. Cost Incentive.				
(1) The target fee payable under SubCLIN 0017AA is money an amount equal to	f the estimated of	cost less facilities cap	ital cost of	(b) (4)
(2) The maximum fee payable under SubCLIN 0017AA money mount equal to	A is some of the estimate	ed cost less facilities	capital cost of	(4) (4)
(3) The minimum fee payable under SubCLIN 0017A2 money an amount equal to	A of the estimated	d cost less facilities ca	apital cost of	(b)(4) (b)(4)
	or more than the estimat	ed cost stated above	usino a share	
(4) Fee will be adjusted for actual cost that is less than a ratio of the covernment Contractor for actual costs greater to H-19(c)(1):	osts less than the estimat	ted cost, and a ratio o	f	(P)(A)
ratio of Contractor for actual contractor for actual contractor for actual contractor for actual costs greater the	osts less than the estimat han the estimated cost ra	ted cost, and a ratio o	f	

(1) A maximum flat zone" will be established at the estimated cost value of conduct of milestones below. The "flat zone" over which the contractor will earn target fee is for eligible costs from

once the program milestones set forth below are conducted. (Note: As of the effective date of Modification P00257, only find the maximum find the maximum find the program acknowledged as earned.)	(P)(A) (P)(A)
(a) of the maximum benefit of the "flat zone", earned by the conduct of the SDD System Functional Review NLT 2nd Quarter, Fiscal Year 2007. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and carned the "Flat Zone" schedule incentive of	(১১૫५)
Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract. Reference letter, dated 5 March 2007 from	(p)(4)
	(P)(P)
(but the conduct of SDD Orbit Critical Design review NLT 2nd Quarter, Fiscal Year 2009. (It is hereby acknowledged by the government that Raytheon	(P) (A)
completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive of \$1 final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the	(b)(4)
contract. Reference letter, dated 12 January 2009, from	(P)(P)
(c) of the maximum benefit of the "flat zone", earned by the conduct of the Developmental Test 1 (DT-1) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. (It is hereby acknowledged by the government	(b)(49)
that Raytheon completed the requirement for this flat zone and earned a "Flat Zone" schedule incentive of Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract.)	b)(4
(d) Section of the maximum benefit of the "flat zone", earned by the conduct of the Electromagnetic Environmental Effects (E3) Testing in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12.	(bXY)
(e) of the maximum benefit of the "flat zone", earned by the conduct of the Integrated Fire Control Event in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned a "Flat Zone" schedule incentive of	હ <mark>્</mark> યાપ)
of the available .* Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract.) *NOTE: The potential has been decreased	(b)(4)
from \$ to movement of the \$ ncentive for '	(4)(4)
(f) *** *** *** *** *** *** *** *** *** *	(b)(4)
increased from to the to movement of the to mentive for (b)(3)(A) (i)&Title 10 Sec 130	رهارطا
(g) for the maximum benefit of the "flat zone", earned by the conduct of Developmental (a)(b) Test 2 (DT-2) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. *	(b)L4)
(h) 6 of the maximum benefit of the "flat zone", earned by the conduct of the Early User Test (previously defined as Limited User Test) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12.*	७ ૪૮૫)

(i) of the maximum benefit of the "flat zone", earned by the conduct of the Final Functional Configuration Audit (FCA) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12.*

(b)X4)

(b)(f)

(3) For Earned Value and cost reporting purposes, the estimated cost value of

vill be used.

d. Changes issued under FAR 52.243-2, Changes - Cost Reimbursement

In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the performance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLIN 0017 are added and exercised, the incentive fee for cost and schedule/performance applicable to the Option will be incorporated in accordance with the incentive fee structure of this provision.

5. The following is an update to Modification P00257 showing a summary of funding by ACRN through Modification P00258:

<u>ACRN</u>	FUNDING
AA	440,100.00
AB	2,298,235.00
AC	17,832,987.00
AD	0.00
AE	7,500,000.00
AF	3,300,000.00
AG	17,192,400.00
AH	700,000.00
AJ	200,000.00
AK	85,000.00
AL	45,000.00
AM	17,045,000.00
AN	5,800.00
AP	20,779,000.00
AQ	105,000.00
AR	35,000.00
AS	0.00
AT	6,984,678.52
AU	7,970,000.00
AV	0.00
AW	100,000.00
AX	3,396,000.00
AY	550,000.00
ΑZ	19,412,000.00
BA	24,527,878.00
BB	146,000.00
BC	72,000.00
BD	85,000.00
BE	100,000.00
BF	100,000.00
BG	1,975,321.00

BH	38,018,908.00
BJ	7,896,673.34
BK	260,000.00
BL	0.00
BM	125,000.00
BN	103,000.00
ВР	10,199,288.50
BU	350,000.00
BV	9,000.00
BW	84,896,852.00
BX	1,146,000.00
BY	3,880,000.00
BZ	190,000.00
KL	118,250.00
KM	192,793,000.00
KN	0.00
KQ	92,811.00
KR	0.00
KS	0.00
KT	386,377,998.00
KU	2,203,183.00
KV	65,000.00
KW	20,000.00
KX	60,000.00
KY	25,000.00
KZ	25,000.00
LA	13,508.00
LB	12,500.00
LC	200,000.00
LD	7,943,648.00
LE	1,173,850.00
LF	10,000.00
LG	62,000.00
LH	400,000.00
LJ	7,476.00
LK	\$281,575,897.00
LL	\$173,798.00
LM	\$1,410,376.00
LN	\$630,061.00
LP	\$83,200.00
LQ	\$235,566.00
LR	\$125,000.00
LS	\$6,069,616.00
LT	\$530,377.00
LU	\$9,100,000.00
LV	\$1,957,265.00
LW	\$255,567.00
LX	\$68,000.00
LY	\$264,807,424.52
LZ	\$1,751,384.00
DE .	φ1,731,304.00

MA	\$2,982,442.00
MB	\$375,000.00
MC	\$2,283,481.00
MD	\$8,573.00
ME	\$0.00
MF	\$270,780,923.00
MG	\$6,262,095.00
MH	\$213,390.00
MJ	\$858,495.00
MK	\$56,076.00
ML	\$116,044 .00
MM	\$1,618,600.00
MN	\$2,573,000.00
MP	\$250,000.00
MQ	\$691,421.00
MR	\$0.00
MS	\$700,000.00
MT	\$16,289,524.00
MU	\$7,864,499.00
MV	\$39,921,199.75
MW	\$10,000,000.00
MX	\$123, 699,162.00

6. The following is an update to Modification P00257 showing a summary of funding by CLIN by ACRN through Modification P00258:

CLIN	ACRN	FUNDING AMT	CLIN TOTAL
CLIN 0001	AA	440,100.00	
CLIN 0001	AD	0.00	
			440,100.00
CLIN 0003	AB	2,298,235.00	
CLIN 0003	AC	17,832,987.00	
CLIN 0003	AD	0.00	
CLIN 0003	AE	7,500,000.00	
CLIN 0003	AF	3,300,000.00	
CLIN 0003	AG	17,192,400.00	
CLIN 0003	AH	700,000.00	
CLIN 0003	AM	17,045,000.00	
CLIN 0003	AN	5,800.00	
CLIN 0003	AP	20,779,000.00	
CLIN 0003	AS	0.00	
CLIN 0003	AT	6,984,678.52	
CLIN 0003	AW	100,000.00	
CLIN 0003	AY	550,000.00	
			94,288,100.52

CLIN 0005	BA	24,527,878.00	
CLIN 0005	BB	146,000.00	
CLIN 0005	BC	72,000.00	
CLIN 0005	BD	85,000.00	
CLIN 0005	BE	100,000.00	
		•	
CLIN 0005	BF	100,000.00	
CLIN 0005	BG	1,975,321.00	
CLIN 0005	ВН	38,018,908.00	
CLIN 0005	BL	0.00	
CLIN 0005	BZ	0.00	
			65,025,107.00
CLIN 0007AA	ВР	10,199,288.50	
		_	10,199,288.50
		-	10,199,200.50
CLIN 0009AA	AQ	45,106.00	
CLIN 0009AA	AV	0.00	
CLIN 0009AA	BK	256,545.00	
CLIN 0009AA	BM	125,000.00	
CLIN 0009AA	BN	21,315.00	
			447,966.00
CLIN 0009AB	AJ	200,000.00	
CLIN 0009AB	AK	85,000.00	
CLIN 0009AB	AL	45,000.00	
CLIN 0009AB	AQ	59,894.00	
CLIN 0009AB	AR	35,000.00	
		•	
CLIN 0009AB	BK	3,455.00	
CLIN 0009AB	BN	81,685.00	
CLIN 0009AB	BU	350,000.00	
CLIN 0009AB	BV	9,000.00	····
		_	869,034.00
CLIN 0013	AU	7,970,000.00	
CLIN 0013	AX	3,396,000.00	
CLIN 0013	AY	0.00	
CLIN 0013	AZ	19,412,000.00	
CLIN 0013	ВЈ	7,896,673.34	
02211 0012		.,05 0,012.01	38,674,673.34
		-	JU,U/J,U/J.J4
CLIN 0017	BW	0.00	
CLIN 0017	KM	0.00	
			0.00
CLIN 0017AA	BY	3,880,000.00	
CLIN 0017AA	· BX	1,146,000.00	
CLIN 0017AA	BW	84,896,852.00	
CLIN UUI /AA	D AA	04,070,032.00	

CLIN 0017AA	BZ	. 0.00	
CLIN 0017AA	KM	192,793,000.00	
CLIN 0017AA	KN	0.00	
CLIN 0017AA	KQ	66,151.00	
CLIN 0017AA	KS	0.00	
CLIN 0017AA CLIN 0017AA	KT KU	386,204,200.00 2,203,183.00	
CLIN 0017AA	KY	0.00	
CLIN 0017AA	LC	200,000.00	
CLIN 0017AA	LD	7,943,648.00	
CLIN 0017AA	LE	0.00	
CLIN 0017AA	LH	400,000.00	
CLIN 0017AA	LJ	7,476.00	
CLIN 0017AA	LK	281,575,897.00	
CLIN 0017AA	LQ	235,566.00	
CLIN 0017AA	LS	6,069,616.00	
CLIN 0017AA	LT	530,377.00	
CLIN 0017AA	LU	\$9,100,000.00	
CLIN 0017AA	LV	\$1,957,265.00	
CLIN 0017AA	LW	\$255,567.00	
CLIN 0017AA	LX	\$68,000.00	
CLIN 0017AA	LY	\$264,807,424.52	
CLIN 0017AA	MB	\$375,000.00	
CLIN 0017AA	MC	\$2,283,481.00	
CLIN 0017AA	MD	\$8,573.00	
CLIN 0017AA	ME	\$0.00	
CLIN 0017AA	MF	\$270,780,923.00	
CLIN 0017AA	MH	\$213,390.00	
CLIN 0017AA	MJ	\$858,495.00	
CLIN 0017AA	MK	\$56,076.00	
CLIN 0017AA	ML	\$116,044.00	
CLIN 0017AA	MM	\$1,618,600.00	
CLIN 0017AA	MN	\$2,573,000.00	
CLIN 0017AA	MP	\$250,000.00	
CLIN 0017AA	MQ	\$691,421.00	
CLIN 0017AA	MR	\$0.00	
CLIN 0017AA	MS	\$700,000.00	
CLIN 0017AA	MT	\$16,289,524.00	
CLIN 0017AA	MV	\$39,921,199.75	
CLIN 0017AA	MW	\$10,000,000.00	
CLIN 0017AA	MX	\$123,699,162.00	
			1,714,775,111.27
		•	

CLIN 0017AB	KL	119 250 00	
CLIN OUT /AB	KL	118,250.00	118,250.00
CLIN 0017AC	BZ	190,000.00	
ODIN OUT THE	DL		190,000.00
CLIN 0017AD	KN	0.00	
CLIN 0017AD	KS	0.00	
			0.00
CLIN 0017AE	LL	173,798.00	
			173,798.00
CLIN 0017AH	KT	173,798.00	
		N. COLONIA	173,798.00
CLIN 0020AA	KN	0.00	
CLIN 0020AA	KQ	26,660.00	
		-	26,660.00
CLIN 0021AA	ĸw	0.00	
			0.00
CLIN 0021AB	KV	0.00	
CLIN 0021AB	LB	0.00	
CLIN 0021AB	KX	0.00	
CLIN 0021AB	KY	0.00	0.00
			0.00
CLIN 0021AC	KZ	0.00	
CLIN 0021AC	LA	0.00	
		-	0.00
CLIN 0022	KW	0.00	
			0.00
CLIN 0023	KX	60,000.00	
CLIN 0023	KY	25,000.00	
CLIN 0023	KV	65,000.00	
CLIN 0023	LB	12,500.00	
CLIN 0023 CLIN 0023	LF LR	10,000.00 \$125,000.00	
CLIN 0023	LK	φ123,000.00	297,500.00
			271,300.00

CLIN 0024	LA	13,508.00	
CLIN 0024	LG	62,000.00	
CLIN 0024	KZ	25,000.00	
CLIN 0024	KW	20,000.00	
CLIN 0024	LP	83,200.00	
		-	203,708.00
CLIN 0025	LE	1,173,850.00	
CLIN 0025	LM	1,080,404.00	
CLIN 0025	MA	0.00	
		-	2,254,254.00
CLIN 0026	LN	630,061.00	
			630,061.00
CLIN 0027	LZ	1,751,384.00	. •
			1,751,384.00
CLIN 0028	LM	329,972.00	
CLIN 0028	MA	2,982,442.00	
CLIN 0028	MG	6,262,095.00	
CLIN 0028	MU	\$7,864,499	
		-	17,439,008.00
CLIN 003001*	MX	\$52,974,283.00	
CLIN003002*	MX	\$719,132.00	
CLIN 000303*	MX	\$5,747.00	
CLIN 000304*	MX	\$16,000,000.00	
CLIN 000305*	MX	\$16,000,000.00	
CLIN 003006*	MX	\$38,000,000.00	
			123,699,162.00

^{*} CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. For pruposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017AA and should not be counted twice with regards to the total contract funding obligated.

(End of Summary of Changes)

	OFM MY ON 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1	CATION OF CONTRA	1. CONTRACT	ID CODE	PAGE OF PAGES
AMENDMENT OF SOLI	CITATION/MODIF	ICATION OF CONTRACT	V	•	1 20
AMENDMENT MODIFICATION NO.	3. EFFECTIVE DATE	4. REQUISITION/PURCHASE REQ. NO.		5. PROJECT	NO ((fapplicable)
P00259	lon sep 12	Ì			j
	DE W9113M	7. ADMINISTERED BY (Ifother than item6)	cor	DE \$2205	iA
USASMIDCIARSTRAT		DOMA RAYTHEON 80 APPLE HILL DRIVE			
SMDC-ROC PO BOX 1800		M/S T2FR2 TEVKSBURY MA 01876			
HUNTEVILLE AL 35807-3601		TENTOGOTT WAS DOWN			
			104 4145 (5)4	EVE OF ON	ICT LEVOLVIO
. NAME AND ADDRESS OF CONTRAC RAYTHEON COMPANY	TOR (No., Street, County, S	late and Zip Code)	YA. AMENUMI	ENI UT SUI	LICITATION NO.
350 LOWELL ST. ANDOVER MA 01510-400		į	9B. DATED (S	EE ITEM II)
		1	X DASG80-98-C	CONTRAC 0001	T/ORDER NO.
			10B. DATED (
ODE 05716	FACILITY COD	E	X 30-Jan-1998		
	11. THIS ITEM ONLY A	PPLIES TO AMENDMENTS OF SOLIC	ZYATIONS		
The above numbered solicitation is amended as	set forth in Item 14. The hour and d	late specified for receipt of Offer	is extended,	is not exten	ded.
	•	fied in the solicitation or as arrended by one of the	_	Lt -1	·
(a) By completing Items 8 and 15, and returning or (c) By separate letter or telegram which inch	·	t; (b) By acknowledging receipt of this amend me ad amendment numbers. FAILURE OF YOUR A	• • •		
		RIOR TO THE HOUR AND DATE SPECIFIED			
		ige an official ready submitted, such change may b ment, and is received prior to the opening hour a		ler,	ļ
2. ACCOUNTING AND APPROPRIATE					
See Schedule					1
13. TH	ISTEM APPLIES ONLY T	O MODIFICATIONS OF CONTRACTS	ORDERS.		
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		T/ORDER NO. AS DESCRIBED IN ITE			
A. THIS CHANGE ORDER IS ISSUED CONTRACT ORDER NO. IN ITEM		thority) THE CHANGES SET FORTH	IN ITEM 14 ARE M	IADE IN TH	ie į
B. THE ABOVE NUMBERED CONTR. office, appropriation date, etc.) SET		TO REFLECT THE ADMINISTRATIVUANT TO THE AUTHORITY OF FAI		u changes in	paying
C. THIS SUPPLEMENT AL AGREEME					
FAR 43.013(a)(3), Mutual Agreement of D. OTHER (Specify type of modification	— — المنظمة البريدية المنظمة ا	on of Hunds"			
b. Of rank appears type of mountain	ii mid manionity)				]
IMPORTANT: Contractor is no	ot, X is required to sign	this document and return 1	copies to the issuing	office.	
DESCRIPTION OF AMENDMENTAM	ODIFICATION (Organized)	w UCF section headings, including solici	tation/contract subje	ct matter	
where feasible.)		,			k
Modification Control Number: See Confinuation Page					(6)
SOS CONTRICIONANT I ANG					
•					
					}
cept as provided herein, all terms and conditions	of the document referenced in Item 9/	A or IOA, as hereto fore changed, romains unchan	ged and in full force and e	effect.	
A NAME AND TITLE OF SIGNER (T)		16A. NAME AND TITLE OF COM		DP-47	(b)
					1
	ISC. DATE SIGNED			1125	White steems
	L L			JIOC.	DATE SIGNED
	9/7/2012			7 .	dep 12
XCEPTION 10-2-30	<u>''                                   </u>	(Signature or Contracting Offi	· · · · · · · · · · · · · · · · · · ·	VIDA DD TO	N 30 (Part 10 22)
PPROVED BY OIRM 11-84	30	)-105 <b>-</b> 04 .		NDARO FOR	RM 30 (Rev. 10-83)

FAR (48 CFR) 53.243

## SECTION SF 30 BLOCK 14 CONTINUATION PAGE

The	purpose	of this	modification	is:
-----	---------	---------	--------------	-----

1. Settlement of the proposal submitted by the contractor in response to Change Order Modification P00236 for JLENS 14 Day Endurance Test. The target cost, target fee, and total contract value will be adjusted as follows to account for the difference in the change order value and the final negotiated amount: target cost decreased by arget fee decreased by and total contract value decreased by \$640,600.		(D)(4)
2. Settlement of the proposal submitted by the contractor in response to Change Order Modification P00239 to delete paragraph 3.12.4, System Capability Reviews, from the System Development and Demonstration (SDD) Program Statement of Work, SW-JLENS-SDD-2006. The target cost, target fee, and total contract value will be adjusted as follows to account for the difference in the change order value and the final negotiated amount for costs incurred: target cost increased by target fee increased by \$660,095.	(b)(4)	PXC
3. Settlement of the proposal submitted by the contractor in response to Change Order Modification P00246 for JLENS  The target cost,	(b)(3)(A (i)&Titl Sec 130	le 10
target fee, and total contract value will be adjusted as follows to account for the difference in the change order value and the final negotiated amount: target cost decreased by target fee decreased by and total contract value decreased by \$199,804.		(b)X4
4. Settlement of the proposal submitted by the contractor in response to Change Order Modification P00247 for JLENS System Development and Demonstration (SDD) Spares. The target cost, target fee, and total contract value will be adjusted as follows to account for the difference in the change order value and the final negotiated amount: target cost decreased by target fee decreased by \$600,733.	(	(b)H)
5. Settlement of the proposal submitted by the contractor in response to Directorate B, Contract Operations Division 2, letter JLENS-2012-001, dated January 19, 2012, subject: Contract DASG60-98-C-0001, "Joint Land Attack Cruise Missile Defense Elevated Netted Sensor (JLENS)," for de-scope of four functionalities from MIS-PRF-55628, Revision B, dated 18 August 2009. The target cost, target fee, and total contract value will be adjusted as follows to account for the final negotiated amount: target cost decreased by and total contract value decreased by \$931,707.		(b)(4)
6. Settlement of the proposal submitted by the contractor in response to Directorate B, Contract Operations Division 2, letter JLENS-2011-036, dated July 1, 2011, requesting an update to Contract Data Requirements List (CDRL) B017, Integrated Support Plan, Sub-Plan entitled Deployment Transition Plan. The target cost, target fee, and total contract value will be adjusted as follows to account for the final negotiated amount: target cost increased by \$\frac{1}{2}\text{Target fee increased by \$\frac{1}{2}\text{Target fee increased by \$\frac{1}{2}\text{Target fee} and total contract value increased by \$2,091,048.		(H)

7. To provide incremental funding in the amount of \$1,096,196.

## **SUMMARY OF CHANGES**

1. SECTION A - SOLICITATION/CONTRACT FORM

The total cost of this contract was increased by \$378,299.00 from \$1,955,238,009.00 to \$1,955,616,308.00.

### 2. SECTION B - SUPPLIES OR SERVICES AND PRICES

### SUBCLIN 0017AA

The target fee has increased by the from the target fee has increased by the form the target fee has increased by the form the factor of the f

The total target cost plus fee of this line item has increased by \$378,299.00 from \$1,595,005,395.00 to \$1,595,383,694.00.

This includes an increase in target cost of consisting of a consisting of a consisting of a consisting of a cost and cost and cost of money, and an increase in target fee of cost and cost of money, and an increase in target fee of cost and cost of money.

The target cost and target fee set forth above and in the table below reflects the negotiated Section B values prior to any adjustments made resulting from estimated cost overruns and share ratio impacts to the fee. Any differences between the Estimated Cost values provided below and the Target Cost values provided above and shown on the table below are as a result of estimated cost overruns. Any differences between the Estimated Fee values provided below and the Target Fee values provided above and shown on the table below are a result of reductions based on current share ratio impacts to the Target Fee and do not include any allocation for yet to be earned incentives as set forth in Section H-19. As of the date of this modification, the estimated cost and estimated fee are as follows:

The Estimated Cost is consisting of \$ consisting of \$ in cost and cost of money.

The Estimated Fee is

Total Estimated Cost plus Fee is \$1,717,867,861.

Pursuant to FAR 16.405-1, the target cost and target fee will be finally determined and adjusted after contract performance.

The table below provides a summary of the target cost, target fee, and total:

CLIN	MOD	TARGET COST	FQCM	TARGET FEE	TOTAL
17 <b>AA</b>	Pre-P00251		2000		\$1,594,280,516.00
17 <b>AA</b>	P00251				\$1,594,280,516.00
17AA	P00254				\$1,595,005,395.00
17AA	P00258				\$1,595,005,395.00
17 <b>AA</b>	P00259				1,595,383,694.00

002573

(A)(d)

ŕ

(b)(4 (b)(4

(VXÝ

(b) L4

(W)C

(b)L4

6)L4

.6)L4

(b)(4)

**CLIN 0030** 

The total cost of this line item has increased by \$1,096,196.00 from \$123,699,162.00 to \$124,795,358.00.

SUBCLIN 003007 is added as follows:

ITEM NO 003007

SUPPLIES/SERVICES

OUANTITY

UNIT

**UNIT PRICE** 

**AMOUNT** 

GFEBS Funding for SubCLIN 0017AA

**CPIF** 

FOB: Destination

**ACRN MX** 

CIN: GFEBS001021201300030

\$1,096,196.00

* As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017AA, identified, accounted for, analyzed, or reported separately from SubCLIN0017, including EVMS. All scope remains under SubCLIN 0017AA with associated incentive events and flat zones.

### B-17. INCENTIVE FEE FOR SUBCLIN 0017AA/CLIN 0018 (SEE H-19):

In accordance with FAR 52.216-10, entitled "Incentive Fee", the total amount originally negotiated, adjusted in accordance with paragraph d. of this clause, for target cost and target fee for performance under SubCLIN 0017AA/CLIN 0018 are set forth below:

**Target Cost** 

Target Fee

Incentive Arrangement: Maximum Fee:

Minimum Fee:

(Share Ratio: Government/Contractor)

for the amount by which the total allowable cost is less than the estimated cost until Underrun: maximum fee is attained.

Overrun: for the amount by which the total allowable cost exceeds the estimated cost until minimum fee is attained.

FAR 52.216-10, INCENTIVE, paragraph (e)(1), is stated as follows:





### (e) Fee Payable.

(1) The fee payable under this contract shall be the target fee increased by the for every dollar that the total allowable cost is less than the estimated cost or decreased by the every dollar that the total allowable cost exceeds the estimated cost. In no event shall the fee be greater than (Maximum fee) or less that linimum fee) of the estimated cost.

(b)X

(p)(ı

B-18. ESTIMATED COST, ESTIMATED INCENTIVE FEE, MINIMUM INCENTIVE FEE, MAXIMUM INCENTIVE FEE, AND INCENTIVE ARRANGEMENT FOR SUBCLIN 0017AA/CLIN 0018:

## SUBCLIN 0017AA - (Two SDD JLENS Systems)

a. Estimated cost:b. Estimated fee:c. Minimum incentive fee:

(b)(4)

**b)(4** 

e. Total estimated cost and estimated fee:

d. Maximum incentive fee:

\$1,717,867,861

### 3. SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation

Summary for the Payment Office

As a result of this modification, the total funded amount for this document was increased by \$1,096,196.00 from \$1,947,977,801.63 to \$1,949,073,997.63.

SUBCLIN 003007:

Funding on SUBCLIN 003007 is initiated as follows:

ACRN: MX

CIN: GFEBS001021201300030

Acctng Data: 02120122013204000001171722550030003242A.0000013.1.1 6100.9000021001


Increase: \$1,096,196.00

Total: \$1,096,196.00

Cost Code: A5XFJ

Estimated Cost, Estimated Fee, and Estimated total for the above increase of \$1,096,196 is distributed as follows and includes an increase in estimated cost of money) and an increase in estimated fee





(P)(A)

IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows:

SUBCLIN 0017AA:		-	THIS	CUMULATIVE	
		PRIOR	MODIFICATION	TOTAL*	
(1)	Amount Required for Full Funding,				(b)(4)
	Including Fee:				
(2)	Amount Allotted Under the LOF Clause				(b)(4)
	for Payment of Costs:				(b)(c
(3)	Amount Separately Obligated for				(b)(4)
	Payment of Fee:		S		الملا
(4)	Total Amount Allotted and Obligated:	\$1,714,775,111.27	\$1,096,196	\$1,715,871,307.27	
(5)	Net Amount Required for Full Funding	\$ 2,714,450.73	(\$ 717,897)	\$ 1,996,553.73	

4. SECTION H - SPECIAL CONTRACT REQUIREMENTS is revised as follows:

Paragraph H-19, <u>INCENTIVE FEE STRUCTURE AND PAYMENT FOR CLIN 0017</u>, <u>SYSTEM DEVELOPMENT AND DEMONSTRATION (SDD)</u>, subparagraph a., b., and c., are revised as follows:

a. General.

SubCLIN 0017AA, System Development and Demonstration (SDD), is a cost-plus-incentive-fee (CPIF) Line Item with cost and schedule incentives as described below. Paragraph H-19(b) applies only to the Cost Incentive and Paragraph H-19(c) applies only to the Schedule Incentive. The target contract price amount of \$1,595,383,694 includes a target cost of which includes which includes 2 of cost and 5 facilities capital

^{*} These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17AH)

cost of money) and a target incentive fee of which is facilities capital cost of (b)(4) money. b. Cost Incentive. (b)(¢ (1) The target fee payable under SubCLIN 0017AA is of the estimated cost less facilities capital cost of an amount equal to (b)(4) (2) The maximum fee payable under SubCLIN 0017AA is of the estimated cost less facilities capital cost of an amount equal to (3) The minimum fee payable under SubCLIN 0017AA is the estimated cost less facilities capital cost of (b)(4 money an amount equal to (4) Fee will be adjusted for actual cost that is less than or more than the estimated cost stated above using a share ratio of Government Contractor for actual costs less than the estimated cost, and a ratio of (V) Contractor for actual costs greater than the estimated cost range applied according to Paragraph (b)L1 H-19(c)(1). (5) Nothing stated in this clause shall take precedence over the clause 52.216-10 - Incentive Fee contained in this c. Schedule and Performance Incentive. "flat zone" will be established at the target cost value of PAG conduct of milestones below. The "flat zone" over which the contractor will earn target fee is for eligible costs from once the program milestones set forth below are conducted. (Note: As of the (b)(4 effective date of Modification P00259, only of the maximum "flat zone" has been (YO)(.4 acknowledged as earned.) of the maximum benefit of the "flat zone", earned by the conduct of the SDD System (b)(4 Functional Review NLT 2nd Quarter, Fiscal Year 2007. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive of Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the (५)(५) conclusion of the contract. Reference letter, dated 5 March 2007 from b/(b) (h)(4) of the maximum benefit of the "flat zone", earned by the conduct of SDD Orbit Critical (PX4 Design review NLT 2nd Quarter, Fiscal Year 2009. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive of Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the 6Xd contract. Reference letter, dated 12 January 2009, from (B(b) of the maximum benefit of the "flat zone", earned by the conduct of the Developmental Test 1 (DT-1) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned a "Flat Zone" schedule incentive of or of the available Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract.)

(d) the maximum benefit of the "flat zone", earned by the conduct of the Electromagnetic Environmental Effects (E3) Testing in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12.	PXA
(e) of the maximum benefit of the "flat zone", earned by the conduct of the Integrated Fire Control Event in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned a "Flat Zone" schedule incentive of	(b <b>)</b> (4)
"Flat Zone" amount will be made at the conclusion of the contract.) *NOTE: The potential has been decreased	Osc
from the form "JLENS tracks interceptor when it enters the FCR Field-of-View (FOV)" from the IFC event to the FCA #1 event.	6)(4
(f) of the maximum benefit of the "flat zone", earned by the conduct of the Functional Configuration Audit (FCA) #1 in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. *Note: The potential has been	(b)(4)
increased from the first to movement of the first the fi	(७)(
(g) 6 of the maximum benefit of the "flat zone", earned by the conduct of Developmental Test 2 (DT-2) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. *	(P)Y.
(h) Section (h) Section (h) of the maximum benefit of the "flat zone", earned by the conduct of the Early User Test (previously defined as Limited User Test) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. *	(b)(c
(i) of the maximum benefit of the "flat zone", earned by the conduct of the Final Functional Configuration Audit (FCA) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. *	(b)(Y

- (3) For Earned Value and cost reporting purposes, the estimated cost value of \$1,464,660,290 will be used.
  - d. Changes issued under FAR 52.243-2, Changes Cost Reimbursement

In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the performance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLIN 0017 are added and exercised, the incentive fee for cost and schedule/performance applicable to the Option will be incorporated in accordance with the incentive fee structure of this provision.

5. The following is an update to Modification P00258 showing a summary of funding by ACRN through Modification P00259:

ACRN FUNDING

AA	440,100.00
AB	2,298,235.00
AC	17,832,987.00
AD	0.00
AE	7,500,000.00
AF	3,300,000.00
AG	17,192,400.00
АН	700,000.00
AJ	200,000.00
AK	85,000.00
AL	45,000.00
AM	17,045,000.00
AN	5,800.00
AP	20,779,000.00
AQ	105,000.00
AR	35,000.00
AS	0.00
AT	6,984,678.52
AU	7,970,000.00
AV	0.00
AW	100,000.00
AX	3,396,000.00
AY	550,000.00
AZ	19,412,000.00
BA	24,527,878.00
ВВ	146,000.00
ВС	72,000.00

BD	85,000.00
BE	100,000.00
BF	100,000.00
BG	1,975,321.00
вн	38,018,908.00
ВЈ	7,896,673.34
ВК	260,000.00
BL	0.00
ВМ	125,000.00
BN	103,000.00
BP	10,199,288.50
BU	350,000.00
BV	9,000.00
BW	84,896,852.00
вх	1,146,000.00
BY	3,880,000.00
BZ	190,000.00
KL	118,250.00
KM	192,793,000.00
KN	0.00
KQ	92,811.00
KR	0.00
KS	0.00
KT	386,377,998.00
KU	2,203,183.00
KV	65,000.00
KW	20,000.00

KX	60,000.00
KY	25,000.00
KZ	25,000.00
LA	13,508.00
LB	12,500.00
LC	200,000.00
LD	7,943,648.00
LE	1,173,850.00
LF	10,000.00
LG	62,000.00
LH	400,000.00
LJ	7,476.00
LK	\$281,575,897.00
LL	\$173,798.00
LM	\$1,410,376.00
LN	\$630,061.00
LP	\$83,200.00
LQ	\$235,566.00
LR	\$125,000.00
LS	\$6,069,616.00
LT	\$530,377.00
LU	\$9,100,000.00
LV	\$1,957,265.00
LW	\$255,567.00
LX	\$68,000.00
LY	\$264,807,424.52
LZ	\$1,751,384.00

MA	\$2,982,442.00
MB	\$375,000.00
мс	\$2,283,481.00
MD	\$8,573.00
ME	\$0.00
MF	\$270,780,923.00
MG	\$6,262,095.00
МН	\$213,390.00
МЈ	\$858,495.00
MK	\$56,076.00
ML	\$116,044.00
MM	\$1,618,600.00
MN	\$2,573,000.00
MP	\$250,000.00
MQ	\$691,421.00
MR	\$0.00
MS	\$700,000.00
MT	\$16,289,524.00
MU	\$7,864,499.00
MV	\$39,921,199.75
MW	\$10,000,000.00
MX	\$124,795,358.00

^{6.} The following is an update to Modification P00258 showing a summary of funding by CLIN by ACRN through Modification P00259:

CLIN	ACRN	FUNDING AMT	CLIN TOTAL
CLIN 0001	AA	440,100.00	
CLIN 0001	AD	0.00	
			440,100.00
CLIN 0003	AB	2,298,235.00	
CLIN 0003	AC	17,832,987.00	
CLIN 0003	AD	0.00	
CLIN 0003	AE	7,500,000.00	
CLIN 0003	AF	3,300,000.00	
CLIN 0003	AG	17,192,400.00	
CLIN 0003	AH	700,000.00	
CLIN 0003	AM	17,045,000.00	
CLIN 0003	AN	5,800.00	
CLIN 0003	AP	20,779,000.00	
CLIN 0003	AS	0.00	
CLIN 0003	AT	6,984,678.52	
CLIN 0003	AW	100,000.00	
CLIN 0003	AY	550,000.00	
			94,288,100.52
CLIN 0005	ВА	24,527,878.00	
CLIN 0005	ВВ	146,000.00	
CLIN 0005	вс	72,000.00	
CLIN 0005	BD	85,000.00	
CLIN 0005	BE	100,000.00	

CLIN 0005	BF	100,000.00	
CLIN 0005	BG	1,975,321.00	
CLIN 0005	ВН	38,018,908.00	
CLIN 0005	BL	0.00	
CLIN 0005	BZ	0.00	
			65,025,107.00
CLIN 0007AA	BP	10,199,288.50	
		_	10,199,288.50
CLIN 0009AA	AQ	45,106.00	
CLIN 0009AA	AV	0.00	
CLIN 0009AA	ВК	256,545.00	
CLIN 0009AA	ВМ	125,000.00	
	BN	21,315.00	
CLIN 0009AA	DAY	,	
CLIN 0009AA	DIN	_	447,966.00
CLIN 0009AA			447,966.00
CLIN 0009AA CLIN 0009AB	AJ	200,000.00	447,966.00
			447,966.00
CLIN 0009AB	AJ	200,000.00	447,966.00
CLIN 0009AB CLIN 0009AB	AJ AK	200,000.00	447,966.00
CLIN 0009AB CLIN 0009AB CLIN 0009AB	AJ AK AL	200,000.00 85,000.00 45,000.00	447,966.00
CLIN 0009AB CLIN 0009AB CLIN 0009AB CLIN 0009AB	AJ AK AL AQ	200,000.00 85,000.00 45,000.00 59,894.00	447,966.00
CLIN 0009AB CLIN 0009AB CLIN 0009AB CLIN 0009AB CLIN 0009AB	AJ AK AL AQ AR	200,000.00 85,000.00 45,000.00 59,894.00 35,000.00	447,966.00
CLIN 0009AB CLIN 0009AB CLIN 0009AB CLIN 0009AB CLIN 0009AB CLIN 0009AB	AJ AK AL AQ AR BK	200,000.00 85,000.00 45,000.00 59,894.00 35,000.00 3,455.00	447,966.00
CLIN 0009AB	AJ AK AL AQ AR BK BN	200,000.00 85,000.00 45,000.00 59,894.00 35,000.00 3,455.00 81,685.00	447,966.00

		-	869,034.00
CLIN 0013	AU	7,970,000.00	
CLIN 0013	AX	3,396,000.00	
CLIN 0013	AY	0.00	
CLIN 0013	AZ	19,412,000.00	
CLIN 0013	BJ	7,896,673.34	
		-	38,674,673.34
CLIN 0017	вw	0.00	
CLIN 0017	KM	0.00	
		-	0.00
		-	
CLIN 0017AA	BY	3,880,000.00	
CLIN 0017AA	BX	1,146,000.00	
CLIN 0017AA	$\mathbf{BW}$	84,896,852.00	
CLIN 0017AA	BZ	0.00	
CLIN 0017AA	KM	192,793,000.00	
CLIN 0017AA	KN	0.00	
CLIN 0017AA	KQ	66,151.00	
CLIN 0017AA	KS	0.00	
CLIN 0017AA	KT	386,204,200.00	
CLIN 0017AA	KU	2,203,183.00	
CLIN 0017AA	KY	0.00	
CLIN 0017AA	LC	200,000.00	
CLIN 0017AA	LD	7,943,648.00	
CLIN 0017AA	LE	0.00	

CLIN 0017AA	LH	400,000.00	
CLIN 0017AA	LJ	7,476.00	
CLIN 0017AA	LK	281,575,897.00	
CLIN 0017AA	LQ	235,566.00	
CLIN 0017AA	LS	6,069,616.00	
CLIN 0017AA	LT	530,377.00	
CLIN 0017AA	LU	\$9,100,000.00	
CLIN 0017AA	LV	\$1,957,265.00	
CLIN 0017AA	LW	\$255,567.00	
CLIN 0017AA	LX	\$68,000.00	
CLIN 0017AA	LY	\$264,807,424.52	
CLIN 0017AA	MB	\$375,000.00	
CLIN 0017AA	MC	\$2,283,481.00	
CLIN 0017AA	MD	\$8,573.00	
CLIN 0017AA	ME	\$0.00	-
CLIN 0017AA	MF	\$270,780,923.00	
CLIN 0017AA	MH	\$213,390.00	
CLIN 0017AA	MJ	\$858,495.00	
CLIN 0017AA	MK	\$56,076.00	
CLIN 0017AA	ML	\$116,044.00	
CLIN 0017AA	MM	\$1,618,600.00	
CLIN 0017AA	MN	\$2,573,000.00	
CLIN 0017AA	MP	\$250,000.00	
CLIN 0017AA	MQ	\$691,421.00	
CLIN 0017AA	MR	\$0.00	

CLIN 0017AA	MS	\$700,000.00	
CLIN 0017AA	MT	\$16,289,524.00	
CLIN 0017AA	MV	\$39,921,199.75	
CLIN 0017AA	MW	\$10,000,000.00	
CLIN 0017AA	MX	\$124,795,358.00	The state of the s
		-	1,715,871,307.27
		£	
		-	
		-	<u> </u>
CLIN 0017AB	KL	118,250.00	
		-	118,250.00
		•	
CLIN 0017AC	BZ	190,000.00	
		- -	190,000.00
		_	
CLIN 0017AD	KN	0.00	
CLIN 0017AD	KS	0.00	
		-	0.00
CLIN 0017AE	LL	173,798.00	
CEIN VOI /AE	LL	173,798.00	173,798.00
			2.2,00
CLIN 0017AH	KT	173,798.00	
		-	173,798.00
		=	The second secon
CLIN 0020AA	KN	0.00	

CLIN 0020AA	KQ	26,660.00	
			26,660.00
CLIN 0021AA	ĸw	0.00	
			0.00
CLIN 0021AB	KV	0.00	
CLIN 0021AB	LB	0.00	
CLIN 0021AB	KX	0.00	
CLIN 0021AB	KY	0.00	
			0.00
CLIN 0021AC	KZ	0.00	
CLIN 0021AC	LA	0.00	
	e .		0.00
CLIN 0022	ĸw	0.00	
			0.00
CLIN 0023	KX	60,000.00	
CLIN 0023	KY	25,000.00	
CLIN 0023	KV	65,000.00	
CLIN 0023	LB	12,500.00	
CLIN 0023	LF	10,000.00	
CLIN 0023	LR	\$125,000.00	
			297,500.00

CLIN 0024	LA	13,508.00	
CLIN 0024	LG	62,000.00	
CLIN 0024	к7.	25,000.00	
CLIN 0024	KW	20,000.00	
CLIN 0024	LP	83,200.00	
		riended	203,708.00
CLIN 0025	LE	1,173,850.00	
CLIN 0025	LM	1,080,404.00	
CLIN 0025	MA	0.00	
			2,254,254.00
CLIN 0026	LN	630,061.00	
			630,061.00
CLIN 0027	LZ	1,751,384.00	
			1,751,384.00
CLIN 0028	LM	329,972.00	· Marine
CLIN 0028	MA	2,982,442.00	
CLIN 0028	MG	6,262,095.00	
CLIN 0028	MU	\$7,864,499	
		and the second s	17,439,008.00
CLIN 003001*	MX	\$52,974,283.00	

00a 589

CLIN003002*	MX	\$719,132.00	
CLIN 000303*	MX	\$5,747.00	
CLIN 000304*	MX	\$16,000,000.00	
CLIN 000305*	MX	\$16,000,000.00	
CLIN 003006*	MX	\$38,000,000.00	
CLIN 003007*	MX	\$1,096,196.00	
			124,795,358.00

^{*} CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. For pruposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017AA and should not be counted twice with regards to the total contract funding obligated.

8. In consideration of the modification agreed to herein as complete equitable adjustment for the following proposals submitted by Raytheon, the contractor hereby releases the Government from any and all liability under the contract for further equitable adjustments attributable to such facts or circumstances giving rise to the proposals for adjustment:

JLENS System Capability Review (SCR) Proposal, submitted via Raytheon letter JLENS-SDD12-016, dated 2 March 2012.

JLENS

for the Surveillance System (SuS) Proposal, submitted via Raytheon

letter JLENS-SDD-12-008, dated 16 February 2012.

JLENS 14 Day Endurance Test Proposal, submitted via Raytheon letter JLENS-SDD-12-026, dated 16 March 2012.

JLENS Capability De-Scope Proposal, submitted via Raytheon letter JLENS-SDD-12-035, dated 9 April 2012.

JLENS Deployment Transitiion Plan Proposal, submitted via Raytheon letter JLENS-SDD-12-001, dated 23 January 2012.

JLENS System Development and Demonstration (SDD) Spares, Proposal, submitted vai Raytheon letter JLENS-SDD-12-012, dated 22 February 2012.

(b)(3)(A) (i)&Title 10Sec 130 (a) (b)

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT  V 1 22  MENDMENTMODIFICATION NO. 3. EFFECTIVE DATE 28-Sep-2012  USAMDCARSTRAT 80DC-80D PO BOX 150. DCARSACTHEON BOX 150 PO BOX 150. DCARSACTHEON B
28-Sep-2012    SSUED BY   CODE   WB113M   7. ADMINISTERED BY (If other than items)   COME   S2205A
SSUED BY  CODE  WEST13M  7. ADMINISTERED BY (Ifother than item 6)  CODE  S2205A  JARANGCARSTRAT  MIDC-RDC  SORY RDC
DOWN THE AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code)  NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code)  NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code)  PRAYTHEON COMPANY  SOLOWER MAN 19810-4400  NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code)  PRAYTHEON COMPANY  9B. DATED (SEE ITEM 11)  X INA MOD. OF CONTRACT/ORDER NO. DASGED-88-C-0001  10B. DATED (SEE ITEM 13)  30-Jan-1998  11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS  The above numbered solicitation is amended as set forth in Item 14. The hour and date specified by receipt of Offer is secteded. is not extended.  Offer must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation are amended by one of the following methods:  (a) By completing Item 8 and 15, and returning copies of the amendment (b) By acknowledging receipt of this amendment accessory of this offer submitted;  or (c) By separate latter or telegrams which includes a reference to the solicitation and amendment counters. FAILURE OF YOUR ACKNOWLEDGMENT TO BE  RECEIVED AT THIS PLACE DESIGNATED FOR THIS RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY ARSULT IN  REFECTION OF YOUR OFFER. Hy virtue of this amendments of a self-in change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and offer interesting and the opening hour and date specified.  ACCOUNTING AND APPROPRIATION DATA (If required)  See Schedule  13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACT SYORDERS.  IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.  THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14.  THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).  C. THIS SUPPLEMENTAL AGREEMENT IS E
NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code)  ANTHEON COMPANY SOLOWELS T: ANDOVER MA 01810-4400  DE 05716  IFACILITY CODE  II. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS  The above numbered solicitation is assemded as set forth in Item 14. The hour and date specified for receipt of Offer (of by completing Items 8 and 15, and returning copies of the assendment, (b) By acknowledging receipt of this assendment provided of the solicitation and assended to underlying the solicitation and assended to the solicitation and assendent numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATION FOR THE THE PLACE OF THE PLACE DESIGNATION FOR THE PLACE DESIGNATION FOR THE PLACE DESIGNA
RAYTHEON COMPANY SOLOWELL ST. ANDOVER MA 0'B10-4400    PB. DATED (SEE ITEM 11)
REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer shready submitted, such change may be made by telegramor letter, provided each telegramor letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.  ACCOUNTING AND APPROPRIATION DATA (If required)  See Schedule  13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACT SORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.  THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.  B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).  C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:  D. OTHER (Specify type of modification and authority)
provided each telegramor letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.  ACCOUNTING AND APPROPRIATION DATA (If required)  See Schedule  13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACT SORDERS.
13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.  THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.  B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).  C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:  D. OTHER (Specify type of modification and authority)
13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACT SORDERS.  IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.  THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.  B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).  C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:  D. OTHER (Specify type of modification and authority)
IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.  THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.  B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).  C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:  D. OTHER (Specify type of modification and authority)
THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.  B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).  C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:  D. OTHER (Specify type of modification and authority)
office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).  C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:  D. OTHER (Specify type of modification and authority)
C. THIS SUPPLEMENTAL ACREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:  D. OTHER (Specify type of modification and authority)
A STATE OF THE STATE OF THE PROPERTY OF THE STATE OF THE
IMPORTANT: Contractor X is not, is required to sign this document and return copies to the issuing office.
DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)  Modification Control Number:  See SF30, block 14, continuation page.

EXCEPTION TO SF 30 APPROVED BY OIRM 11-84 002591

STANDARD FORM 30 (Rev. 10-83) Prescribed by GSA FAR (48 CFR) 53.243

(b)(4)

### **SECTION SF 30 BLOCK 14 CONTINUATION PAGE**

### The purpose of this modification is to:


- 1. Issue Change Order Modification P00260 for JLENS based on restructure letter JLENS-2012-031dated 20 September, 2011. Ceiling of contract will increase by a total of \$59,034,271.
- 2. This Change Order Modification will also incrementally fund this increase by \$16,145,226.39.

## SUMMARY OF CHANGES


1. SECTION A - SOLICITATION/CONTRACT FORM

The total cost of this contract was increased by \$59,034,271 from \$1,955,616,308.00 to \$2,014,650,579.00.

2. SECTION B - SUPPLIES OR SERVICES AND PRICES



The target cost and target fee set forth above and in the table below reflects the negotiated Section B values prior to any adjustments made resulting from estimated cost overruns and share ratio impacts to the fee. Any differences between the Estimated Cost values provided below and the Target Cost values provided above and shown on the table below are as a result of estimated cost overruns. Any differences between the Estimated Fee values provided below and the Target Fee values provided above and shown on the table below are a result of reductions based on current share ratio impacts to the Target Fee and do not include any allocation for yet to be earned incentives as set forth in Section H-19. As of the date of this modification, the estimated cost and estimated for are as follows:



Pursuant to FAR 16.405-1, the target cost and target fee will be finally determined and adjusted after contract performance.

The table below provides a summary of the target cost, target fee, and total:

Total Estimated Cost plus Fee is \$1,776,902,132.

CLIN	MOD	TARGET COST	FCCM	TARGET FEE	TOTAL
17AA	Pre-P00251	2			\$1,594,280,516.00
17 <b>AA</b>	P00251				\$1,594,280,516.00
17AA	P00254				\$1,595,005,395.00
17AA	P00258				\$1,595,005,395.00
17AA	P00259		:-		\$1,595,383,694.00
17AA	P00260				\$1,654,417,965.00

**CLIN 0030** 

The total cost of this line item has increased by \$16,000,000.00 from \$124,795,358.00 to \$140,795,358.00.

SUBCLIN 003008 is added as follows:

ITEM NO 003008 SUPPLIES/SERVICES

QUANTITY

UNIT

**UNIT PRICE** 

**AMOUNT** 

GFEBS Funding for SubCLIN 0017AA

**CPIF** 

FOB: Destination

**ACRN MX** 

CIN: GFEBS001024670000001

\$16,000,000.00

## B-17. INCENTIVE FEE FOR SUBCLIN 0017AA/CLIN 0018 (SEE H-19):

In accordance with FAR 52.216-10, entitled "Incentive Fee", the total amount originally negotiated, adjusted in accordance with paragraph d. of this clause, for target cost and target fee for performance under SubCLIN 0017AA/CLIN 0018 are set forth below:

**Target Cost** 

\$1,518,857,479

^{*} As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017AA, identified, accounted for, analyzed, or reported separately from SubCLIN0017, including EVMS. All scope remains under SubCLIN 0017AA with associated incentive events and flat zones.

DASG60-98-C-0001 P00260 Page 4 of 20

	Target Fee	\$		(b)(4)	(30)
	Incentive Arrangement:	Maximum Fee:			(A)(A)
		Minimum Fee:			(P)A
	(Share Ratio: Governme	ent/Contractor)			
maximum fe	Underrun: the ee is attained.	amount by which the total	l allowable cost is less than the estimated cost until		(b)(4)
minimum fe	Overrun: br the age is attained.	amount by which the total	allowable cost exceeds the estimated cost until	(b)(4)	Ph
FA	R 52.216-10, INCENTIV	E, paragraph (e)(1), is state	ed as follows:		
(e)	Fee Payable.				
cost exceeds	wable cost is less than the	estimated cost or decrease event shall the fee be grea	target fee increased by for every dollar that by the for every dollar that the total allowable ter than Maximum fee) or less that		(P)(A) (P)(A) (P)(C)
			VE FEE, MINIMUM INCENTIVE FEE, SEMENT FOR SUBCLIN 0017AA/CLIN 0018:		
<u>su</u>	BCLIN 0017AA - (Two	SDD JLENS Systems)			
a.	Estimated cost:			(b)(	4) هري
b.	Estimated fee:				6)4
c.	Minimum incentive fee:				(b)X4
d.	Maximum incentive fee:		S		(b)(4
e.	Total estimated cost and	estimated fee:	\$1,776,902,132		


# 3. SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation

Summary for the Payment Office

As a result of this modification, the total funded amount for this document was increased by \$16,145,226.39 from \$1,949,073,997.63 to \$1,965,219,224.02.

SUBCLIN 0017AA:



MF: 21 1 2040 5L 5L68 P172419E555L 255Y 4M1J730000 S01021 4M1J730000/14MJLE/4M5 was increased by \$126,899.39 from \$270,780,923.00 to \$270,907,822.39

Estimated Cost, Estimated Fee, and Estimated total for the above increase of \$126,899.39 is distributed as follows and includes an increase in estimated cost of f cost and of facilities capital cost of money) and an increase in estimated fee of Estimated Cost Estimated Fee (b)(4) Total \$126,899.39

MY: 21 1 2040 5L 5L68 P172419E555L 2516 4M1MMICST3 S01021 4M1MMICST3/14MJMM/4M5 was increased by \$18,327.00 from \$0.00 to \$18,327.00

The contract ACRN MY has been added.

Estimated Cost, Estimated Fee, and Estimated total for the above increase of \$18,327 is distributed as follows and includes an increase in estimated cost of of cost and Second facilities capital cost of money) and (\$ an increase in estimated fee of

Estimated Cost **Estimated Fee** Total \$18,327

(h)(A)

### CLIN 0030:

### SUBCLIN 003008:

Funding on SUBCLIN 003008 is initiated as follows:

ACRN: MX

CIN: GFEBS001024670000001

Acctng Data: 02120122013204000001171722550030003242A.0000013.1.1


6100.9000021001

Increase: \$16,000,000.00

Total: \$16,000,000.00

Cost Code: A5XFJ

Estimated Cost, Estimated Fee, and Estimated total for the above increase of \$16,000,000 is distributed as follows and includes an increase in estimated cost of \$ of cost and of facilities capital



DASG60-98-C-0001

IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows:

SUBCLIN 0017AA:	-	THIS	CUMULATIVE
	PRIOR	MODIFICATION	TOTAL*
(1) Amount Required for Full Funding,			
Including Fee:			(b)(4) $(b)$
(2) Amount Allotted Under the LOF Clause			
for Payment of Costs:			(b)X4
(3) Amount Separately Obligated for			(1.)(4)
Payment of Fee:	\$		(b)(4)
(4) Total Amount Allotted and Obligated:	\$1,715,871,307.27	\$16,145,226.39	\$1,732,016,533.66
(5) Net Amount Required for Full Funding	\$ 1,996,553.73	\$ 42,889,044.61	\$ 44,885,598.34

^{*} These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17AH)

## 4. SECTION H - SPECIAL CONTRACT REQUIREMENTS is revised as follows:

Paragraph H-19, INCENTIVE FEE STRUCTURE AND PAYMENT FOR CLIN 0017, SYSTEM DEVELOPMENT AND DEMONSTRATION (SDD), subparagraph a., b., and c., are revised as follows:

#### a. General.

SubCLIN 0017AA, System Development and Demonstration (SDD), is a cost-plus-incentive-fee (CPIF) Line Item with cost and schedule incentives as described below. Paragraph H-19(b) applies only to the Cost Incentive and

Paragraph H-19(c) applies only to the Schedule Incentive. The target contract price amount of includes a target cost of cost and the schedule includes the schedule of cost and the schedule cost of facilities capital cost of money) and a target incentive fee of the schedule which is the schedule of target cost less facilities capital cost of money.	PACH
b. Cost Incentive.	
(1) The target fee payable under SubCLIN 0017AA is subsection of the estimated cost less facilities capital cost of money and amount equal to subsect the subsection of the estimated cost less facilities capital cost of money and subsection of the estimated cost less facilities capital cost of money and subsection of the estimated cost less facilities capital cost of money and subsection of the estimated cost less facilities capital cost of money and subsection of the estimated cost less facilities capital cost of money and subsection of the estimated cost less facilities capital cost of money and subsection of the estimated cost less facilities capital cost of money and subsection of the estimated cost less facilities capital cost of money and subsection of the estimated cost less facilities capital cost of money and subsection of the estimated cost less facilities capital cost of money and subsection of the estimated cost less facilities capital cost of the estimated cost of the estimated cost less facilities capital cost of the estimated cost of the estimated	(b)(4)(b)(4)
(2) The maximum fee payable under SubCLIN 0017AA is substituted cost less facilities capital cost of money and the substitute of the estimated cost less facilities capital cost of money and the substitute of th	(b)(4)
(3) The minimum fee payable under SubCLIN 0017AA is the estimated cost less facilities capital cost of money an amount equal to the substantial and amount equal to the substantial and the substantial and the substantial substantial and the substantial substa	(5X4)
(4) Fee will be adjusted for actual cost that is less than or more than the estimated cost stated above using a share ratio of Government / Contractor for actual costs less than the estimated cost, and a ratio of Government / Contractor for actual costs greater than the estimated cost range applied according to Paragraph H-19(c)(1).	(BX4)
(5) Nothing stated in this clause shall take precedence over the clause 52.216-10 - Incentive Fee contained in this contract.	-27
c. Schedule and Performance Incentive.	
(1) A maximum "flat zone" will be established at the target cost value of with the conduct of milestones below. The "flat zone" over which the contractor will earn target fee is for eligible costs from once the program milestones set forth below are conducted. (Note: As of the effective date of Modification P00260, only acknowledged as earned.)	(b)(d) (b)(d)
(a) Leach Value he SDD System Functional Review NLT 2nd Quarter, Fiscal Raytheon completed the requirement for this live of little and a state of little a	(b)(4 (b)(4
Final determination of ince conclusion of the contract. Reference letter,	(B)(P)
(b) Orbit Critical Design review NLT 2nd Quarter, Fiscal Year  t that Raytheon	(b)(4)
completed the requirement for this flat zone a determination of incentive fee payment utiliz sion of the	(b)(H
contract. Reference letter, dated 12 January 2	(P)(P)
(c) Developmental  Test 1 (DT-1) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance  Criteria for ILENS SDD Contract Section H-19(c) dated 08/10/12 (It is hereby acknowledged by the government	61Lin

that Raytheon completed the requirement for this flat zone and earned a "Flat Zone" schedule incentive of

"Flat Zone" amount will be made at the conclusion of the contract.)	(6)લ્યુ
(d) control of the maximum benefit of the "flat zone", earned by the conduct of the Electromagnetic Environmental Effects (E3) Testing in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12.	611
(e) of the maximum benefit of the "flat zone", earned by the conduct of the Integrated Fire Control Event in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned a "Flat Zone" schedule incentive of	P)(n)
or of the available Final determination of incentive fee payment utilizing the	6)(4
"Flat Zone" amount will be made at the conclusion of the contract.) *NOTE: The potential has been decreased from \$	(b)(d)
(f) (b)(3)(A)  (f) (i)&Title 10  Sec 130 (a)(b)  Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. *Note: The potential has been	(b) (4.
increased from 5 to 5 due to movement of the incentive for 5 (b)(3)(A) (i)&Title 10 Sec	(P)\A
(g)	(b)K4,
(h) of the maximum benefit of the "flat zone", earned by the conduct of the Early User Test (previously defined as Limited User Test) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. *	1984;
(i) of the maximum benefit of the "flat zone", earned by the conduct of the Final Functional Configuration Audit (FCA) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. *	(P)(A)
(3) For Earned Value and cost reporting purposes, the estimated cost value of \$1,518,857,479 will be used.	
d. Changes issued under FAR 52.243-2, Changes - Cost Reimbursement	
In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the performance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLIN 0017 are added and exercised, the incentive fee for cost and schedule/performance applicable to	

5. The following is an update to Modification P00259 showing a summary of funding by ACRN through Modification P00260:

the Option will be incorporated in accordance with the incentive fee structure of this provision.

ACRN FUNDING

AA	440,100.00
AB	2,298,235.00
AC	17,832,987.00
AD	0.00
AE	7,500,000.00
AF	3,300,000.00
AG	17,192,400.00
AH	700,000.00
AJ	200,000.00
AK	85,000.00
AL	45,000.00
AM	17,045,000.00
AN	5,800.00
AP	20,779,000.00
AQ	105,000.00
AR	35,000.00
AS	0.00
AT	6,984,678.52
AU	7,970,000.00
AV	0.00
AW	100,000.00
AX	3,396,000.00
AY	550,000.00
AZ	19,412,000.00
ВА	24,527,878.00
ВВ	146,000.00

ВС	72,000.00
BD	85,000.00
BE	100,000.00
BF	100,000.00
BG	1,975,321.00
ВН	38,018,908.00
ВЈ	7,896,673.34
BK	260,000.00
BL	0.00
ВМ	125,000.00
BN	103,000.00
BP	10,199,288.50
BU	350,000.00
BV	9,000.00
BW	84,896,852.00
вх	1,146,000.00
BY	3,880,000.00
BZ	190,000.00
KL	118,250.00
KM	192,793,000.00
KN	0.00
KQ	92,811.00
KR	0.00
KS	0.00
KT	386,377,998.00
KU	2,203,183.00
KV	65,000.00

KW	20,000.00
KX	60,000.00
KY	25,000.00
KZ	25,000.00
LA	13,508.00
LB	12,500.00
LC	200,000.00
LD	7,943,648.00
LE	1,173,850.00
LF	10,000.00
LG	62,000.00
LH	400,000.00
LJ	7,476.00
LK	\$281,575,897.00
LL	\$173,798.00
LM	\$1,410,376.00
LN	\$630,061.00
LP	\$83,200.00
LQ	\$235,566.00
LR	\$125,000.00
LS	\$6,069,616.00
LT	\$530,377.00
LU	\$9,100,000.00
LV	\$1,957,265.00
LW	\$255,567.00
LX	\$68,000.00
LY	\$264,807,424.52

LZ	\$1,751,384.00
MA	\$2,982,442.00
MB	\$375,000.00
MC	\$2,283,481.00
MD	\$8,573.00
ME	\$0.00
MF	\$270,907,822.39
MG	\$6,262,095.00
МН	\$213,390.00
МЈ	\$858,495.00
MK	\$56,076.00
ML	\$116,044.00
MM	\$1,618,600.00
MN	\$2,573,000.00
MP	\$250,000.00
MQ	\$691,421.00
MR	\$0.00
MS	\$700,000.00
MT	\$16,289,524.00
MU	\$7,864,499.00
MV	\$39,921,199.75
MW	\$10,000,000.00
MX	\$140,795,358.00
MY	\$18,327.00

^{6.} The following is an update to Modification P00259 showing a summary of funding by CLIN by ACRN through Modification P00260:

CLIN	ACRN	FUNDING AMT	CLIN TOTAL
CLIN 0001	AA	440,100.00	
CLIN 0001	AD	0.00	
			440,100.00
CLIN 0003	AB	2,298,235.00	
CLIN 0003	AC	17,832,987.00	
CLIN 0003	AD	0.00	
CLIN 0003	AE	7,500,000.00	
CLIN 0003	AF	3,300,000.00	
CLIN 0003	AG	17,192,400.00	
CLIN 0003	AH	700,000.00	
CLIN 0003	AM	17,045,000.00	
CLIN 0003	AN	5,800.00	
CLIN 0003	AP	20,779,000.00	
CLIN 0003	AS	0.00	
CLIN 0003	AT	6,984,678.52	
CLIN 0003	AW	100,000.00	
CLIN 0003	AY	550,000.00	
			94,288,100.52
CLIN 0005	BA	24,527,878.00	
CLIN 0005	BB	146,000.00	
CLIN 0005	BC	72,000.00	
CLIN 0005	BD	85,000.00	
CLIN 0005	BE	100,000.00	


	100,000.00	BF	CLIN 0005
	1,975,321.00	BG	CLIN 0005
	38,018,908.00	ВН	CLIN 0005
	0.00	BL	CLIN 0005
	0.00	BZ	CLIN 0005
65,025,107.00			
	10,199,288.50	ВР	CLIN 0007AA
10,199,288.50			
	==		
	45,106.00	AQ	CLIN 0009AA
	0.00	AV	CLIN 0009AA
	256,545.00	BK	CLIN 0009AA
	125,000.00	BM	CLIN 0009AA
	21,315.00	BN	CLIN 0009AA
447,966.00	<del></del> -		
	**************************************		
	200,000.00	AJ	CLIN 0009AB
	85,000.00	AK	CLIN 0009AB
	45,000.00	AL	CLIN 0009AB
	59,894.00	AQ	CLIN 0009AB
	35,000.00	AR	CLIN 0009AB
	3,455.00	BK	CLIN 0009AB
	81,685.00	BN	CLIN 0009AB
	350,000.00	BU	CLIN 0009AB
	9,000.00	BV	CLIN 0009AB

			869,034.00
CLIN 0013	AU	7,970,000.00	
CLIN 0013	AX	3,396,000.00	
CLIN 0013	AY	0.00	
CLIN 0013	AZ	19,412,000.00	
CLIN 0013	ВЈ	7,896,673.34	
			38,674,673.34
CLIN 0017	BW	0.00	
CLIN 0017	KM	0.00	
CLIN 0017	PTAI	0.00	0.00
CLIN 0017AA	BY	3,880,000.00	
CLIN 0017AA	BX	1,146,000.00	
CLIN 0017AA	BW	84,896,852.00	
CLIN 0017AA	BZ	0.00	
CLIN 0017AA	KM	192,793,000.00	
CLIN 0017AA	KN	0.00	
CLIN 0017AA	KQ	66,151.00	
CLIN 0017AA	KS	0.00	
CLIN 0017AA	KT	386,204,200.00	
CLIN 0017AA	KU	2,203,183.00	
CLIN 0017AA	KY	0.00	
CLIN 0017AA	LC	200,000.00	
CLIN 0017AA	LD	7,943,648.00	
CLIN 0017AA	LE	0.00	

CLIN 0017AA	LH	400,000.00	
CLIN 0017AA	LJ	7,476.00	
CLIN 0017AA	LK	281,575,897.00	
CLIN 0017AA	LQ	235,566.00	
CLIN 0017AA	LS	6,069,616.00	
CLIN 0017AA	LT	530,377.00	
CLIN 0017AA	LU	\$9,100,000.00	
CLIN 0017AA	LV	\$1,957,265.00	
CLIN 0017AA	LW	\$255,567.00	
CLIN 0017AA	LX	\$68,000.00	
CLIN 0017AA	LY	\$264,807,424.52	
CLIN 0017AA	MB	\$375,000.00	
CLIN 0017AA	MC	\$2,283,481.00	
CLIN 0017AA	MD	\$8,573.00	
CLIN 0017AA	ME	\$0.00	
CLIN 0017AA	MF	\$270,907,822.39	
CLIN 0017AA	MH	\$213,390.00	
CLIN 0017AA	MJ	\$858,495.00	
CLIN 0017AA	MK	\$56,076.00	
CLIN 0017AA	ML	\$116,044.00	
CLIN 0017AA	MM	\$1,618,600.00	
CLIN 0017AA	MN	\$2,573,000.00	
CLIN 0017AA	MP	\$250,000.00	
CLIN 0017AA	MQ	\$691,421.00	
CLIN 0017AA	MR	\$0.00	

CLIN 0017AA	MS	\$700,000.00	
CLIN 0017AA	MT	\$16,289,524.00	
CLIN 0017AA	MV	\$39,921,199.75	
CLIN 0017AA	MW	\$10,000,000.00	
CLIN 0017AA	MX	\$140,795,358.00	
CLIN 0017AA	MY	\$18,327.00	
		:	1,732,016,533.66
CLIN 0017AB	KL	118,250.00	
			118,250.00
CLIN 0017AC	BZ	190,000.00	
		-	190,000.00
CLIN 0017AD	KN	0.00	
CLIN 0017AD	KS	0.00	
		-	0.00
CLIN 0017AE	LL	173,798.00	
			173,798.00
CLIN 0017AH	KT	173,798.00	
			173,798.00
		=	

CLIN 0020AA	KN	0.00	
CLIN 0020AA	KQ	26,660.00	
			26,660.00
CLIN 0021AA	KW	0.00	0.00
			0.00
CLIN 0021AB	KV	0.00	
CLIN 0021AB	LB	0.00	
CLIN 0021AB	KX	0.00	
CLIN 0021AB	KY	0.00	
			0.00
CLIN 0021AC	KZ	0.00	
CLIN 0021AC	LA	0.00	
			0.00
CLIN 0022	KW	0.00	
			0.00
CLIN 0023	KX	60,000.00	
CLIN 0023	KY	25,000.00	
CLIN 0023	KV	65,000.00	
CLIN 0023	LB	12,500.00	
CLIN 0023	LF	10,000.00	
CLIN 0023	LR	\$125,000.00	



297,500.00			
	-		
	13,508.00	LA	CLIN 0024
	62,000.00	LG	CLIN 0024
	25,000.00	KZ	CLIN 0024
	20,000.00	KW	CLIN 0024
**************************************	83,200.00	LP	CLIN 0024
203,708.00	<u></u>		
	1,173,850.00	LE	CLIN 0025
	1,080,404.00	LM	CLIN 0025
	0.00	MA	CLIN 0025
2,254,254.00			
	630,061.00	LN	CLIN 0026
630,061.00	enemant.		
	1,751,384.00	LZ	CLIN 0027
1,751,384.00			
	329,972.00	LM	CLIN 0028
	2,982,442.00	MA	CLIN 0028
	6,262,095.00	MG	CLIN 0028
	\$7,864,499	MU	CLIN 0028
17,439,008.00			

CLIN 003001*	MX	\$52,974,283.00	
CLIN003002*	MX	\$719,132.00	
CLIN 000303*	MX	\$5,747.00	
CLIN 000304*	MX	\$16,000,000.00	4-11-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-
CLIN 000305*	MX	\$16,000,000.00	
CLIN 003006*	MX	\$38,000,000.00	
CLIN 003007*	MX	\$1,096,196.00	,
CLIN 003008*	MX	\$16,000,000.00	
			140,795,358.00

^{*} CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. For pruposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017AA and should not be counted twice with regards to the total contract funding obligated.

(End of Summary of Changes)

AMENDMENT OF SOLICIT	TATION/MODI	FICATION OF CONTRAC	Т	1.CONTRACT	ID CODE	PAGEOF	PAGES
AMENDMENT OF SOCIETY		TICATION OF CONTINAC		v		1 1	15
2. AMENDMENT/MODIFICATION NO. POODUS	3. EFFECTIVE DATE 13-Nov-2012	4. REQUISITION/PURCHASE REQ. NO.			5. PROJECT	NO (Ifapplicat	ole)
S. ISSUED BY CODE	W9113M	7. ADMINISTERED BY (Ifother than item 6	)	CO	DE \$220	5A	
USASMDC/ARSTRAT SMDC-RDC PO BOX 1900 HUNTSVILLE AL 35807-3801		DCMA RAYTHEON 50 APPLE HILL DRIVE MIS TEPR2 TEWKSBURY MA 01878	•		<u> </u>		
B. NAME AND ADDRESS OF CONTRACTOR RAYTHEON COMPANY	(No., Street, County,	State and Zip Code)	Γ	9A. AMENDM	ENT OF SO	LICIT AT 10	N NO.
350 LOWELL ST. ANDOVER MA 01810-4400				9B. DATED (SI	EE ITEM 11	1)	
			×	LOA MOD OF DASG60-98-C			1O.
200F 86746	Te . du . ee . doe		√x	10B. DATED ( 30-Jan-1998	SEE ITEM	13)	1
CODE 05716	FACILITY COL	APPLIES TO AMENDMENTS OF SO	٠	<del></del>			
The above numbered solicitation is amended as set for Offer must acknowledge receipt of this amendment pri (a) By completing Items 8 and 15, and returning or (c) By separate letter or telegram which includes a received A THE PLACE DESIGNATED FOR TREJECTION OF YOUR OFFER. If by virtue of this approvided each telegram or letter makes reference to the	or to the hour and date spec copies of the amendmen effects to the solicitation HE RECEIPT OF OFFERS mendment you desire to cha solicitation and this amend	ised in the solicitation or as amended by one of nt; (b) By acknowledging receipt of this amendr and amendment numbers. FAILURE OF YOUR PRIOR TO THE HOUR AND DATE SPECIFIE unge an offer already submitted, such change may	ent o ACK D M/ be m	n each copy of the of NOWLEDGMENT AY RESULT IN Ide by telegramor let	TO BE		
2. ACCOUNTING AND APPROPRIATION D See Schedule	A I A (It required)						
		TO MODIFICATIONS OF CONTRAC CT/ORDER NO. AS DESCRIBED IN I					
A. THIS CHANGE ORDER IS ISSUED PURSI CONTRACT ORDER NO. IN ITEM 10A.					IADE IN T	HE	
B. THE ABOVE NUMBERED CONTRACT/O office, appropriation date, etc.) SET FORT					s changes in	n paying	
C. THIS SUPPLEMENT AL AGREEMENT IS	SENTERED INTO PU	IRSUANT TO AUTHORITY OF:					
D. OTHER (Specify type of modification and BLATERAL; FAR 52.232-22	authority)						
. IMPORTANT: Contractor X is not,	is required to sign	n this document and return	co	pies to the issuing	office.		
4. DESCRIPTION OF AMENDMENT/MODIF where feasible.) Modification Control Number: See SF30, block 14, continuation page.	ICATION (Organized	by UCF section headings, including soli	citat	ion/contract subje	ect matter		(b)(i
					<b>.</b>		
acept as provided herein, all terms and conditions of the d	ocument referenced in Itoms recint)	I 6A. NAME AND TITLE OF CO	_			or print)	(KV)
		TEL					10.70
	ISC. DATE SIGNED				1	C. DATE SIC	1 . 1.
	11/13/12	(Signature of Confracting O	Tice			30013	
XCEPTION TO SF 30 PPROVED BY OIRM 11-84	:	30-105-04			NDARD FO cribed by GS	DRM 30 (Rev Sa	r. 10-83)

ST ANDARD FORM 30 (Rev. 10-83) Prescribed by GSA FAR (48 CFR) 53.243

#### SECTION SF 30 BLOCK 14 CONTINUATION PAGE

#### **SUMMARY OF CHANGES**

#### 1. SECTION B - SUPPLIES OR SERVICES AND PRICES

**CLIN 0030** 

The total cost of this line item has decreased by \$2,000,000.00 from \$140,795,358.00 to \$138,795,358.00.

* As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017AA, identified, accounted for, analyzed, or reported separately from SubCLIN0017, including EVMS. All scope remains under SubCLIN 0017AA with associated incentive events and flat zones.

## 2. SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation


Summary for the Payment Office

As a result of this modification, the total funded amount for this document was decreased by \$2,000,000.00 from \$1,965,219,224.02 to \$1,963,219,224.02.

### SUBCLIN 003008:

MX: 02120122013204000001171722550030003242A.0000013.1.1 6100.9000021001 A5XFJ (CIN GFEBS001024670000001) was decreased by \$2,000,000.00 from \$16,000,000.00 to \$14,000,000.00

Estimated Cost, Estimated Fee, and Estimated total for the above decrease of \$2,000,000 is distributed as follows and includes a decrease in estimated cost of cost and cost of facilities capital cost of money) and a decrease in estimated fee of



(P)(A)

PAG

6×4

IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS

# (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows:

SUE	BCLIN 0017AA:	-	THIS	CUMULATIVE	
		PRIOR	MODIFICATION	TOTAL*	
(1)	Amount Required for Full Funding,				
	Including Fee:		\$ 0	\$	(b)(H)
(2)	Amount Allotted Under the LOF Clause				
	for Payment of Costs:				(PX4)
(3)	Amount Separately Obligated for				
	Payment of Fee:			\$	6)(4
(4)	Total Amount Allotted and Obligated:	\$1,732,016,533.26	(\$2,000,000.00)	\$1,730,016,533.26	
(5)	Net Amount Required for Full Funding	\$ 44,885,598.34	\$ 2,000,000.00	\$ 46,885,598.34	

^{*} These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17AH)

3. The following is an update to Modification P00260 showing a summary of funding by ACRN through Modification P00261:

<u>ACRN</u>	<u>FUNDING</u>	
AA		440,100.00
AB		2,298,235.00
AC		17,832,987.00
AD		0.00
AE		7,500,000.00
AF		3,300,000.00
AG		17,192,400.00

AH	700,000.00
AJ	200,000.00
AK	85,000.00
AL	45,000.00
AM	17,045,000.00
AN	5,800.00
AP	20,779,000.00
AQ	105,000.00
AR	35,000.00
AS	0.00
AT	6,984,678.52
AU	7,970,000.00
AV	0.00
AW	100,000.00
AX	3,396,000.00
AY	550,000.00
AZ	19,412,000.00
BA	24,527,878.00
ВВ	146,000.00
BC	72,000.00
BD	85,000.00
BE	100,000.00
BF	100,000.00
BG	1,975,321.00
ВН	38,018,908.00
ВЈ	7,896,673.34
ВК	260,000.00

BL	0.00
BM	125,000.00
BN	103,000.00
ВР	10,199,288.50
BU	350,000.00
BV	9,000.00
BW	84,896,852.00
BX	1,146,000.00
BY	3,880,000.00
BZ	190,000.00
KL	118,250.00
KM	192,793,000.00
KN	0.00
KQ	92,811.00
KR	0.00
KS	0.00
KT	386,377,998.00
KU	2,203,183.00
KV	65,000.00
KW	20,000.00
KX	60,000.00
KY	25,000.00
KZ	25,000.00
LA	13,508.00
LB	12,500.00
LC	200,000.00
LD	7,943,648.00

LE	1,173,850.00
LF	10,000.00
LG	62,000.00
LH	400,000.00
LJ	7,476.00
LK	\$281,575,897.00
LL	\$173,798.00
LM	\$1,410,376.00
LN	\$630,061.00
LP	\$83,200.00
LQ	\$235,566.00
LR	\$125,000.00
LS	\$6,069,616.00
LT	\$530,377.00
LU	\$9,100,000.00
LV	\$1,957,265.00
LW	\$255,567.00
LX	\$68,000.00
LY	\$264,807,424.52
LZ	\$1,751,384.00
MA	\$2,982,442.00
MB	\$375,000.00
MC	\$2,283,481.00
MD	\$8,573.00
ME	\$0.00
MF	\$270,907,822.39
MG	\$6,262,095.00

MH	\$213,390.00
MJ	\$858,495.00
MK	\$56,076.00
ML	\$116,044.00
MM	\$1,618,600.00
MN	\$2,573,000.00
MP	\$250,000.00
MQ	\$691,421.00
MR	\$0.00
MS	\$700,000.00
MT	\$16,289,524.00
MU	\$7,864,499.00
MV	\$39,921,199.75
MW	\$10,000,000.00
MX	\$138,795,358.00
MY	\$18,327.00

4. The following is an update to Modification P00260 showing a summary of funding by CLIN by ACRN through Modification P00261:

<u>CLIN</u>	<u>ACRN</u>	FUNDING AMT	CLIN TOTAL
CLIN 0001	AA	440,100.00	
CLIN 0001	AD	0.00	
			440,100.00
		,	
CLIN 0003	AB	2,298,235.00	

CLIN 0003	AC	17,832,987.00	
CLIN 0003	AD	0.00	
CLIN 0003	AE	7,500,000.00	
CLIN 0003	AF	3,300,000.00	
CLIN 0003	AG	17,192,400.00	
CLIN 0003	AH	700,000.00	
CLIN 0003	AM	17,045,000.00	
CLIN 0003	AN	5,800.00	
CLIN 0003	AP	20,779,000.00	
CLIN 0003	AS	0.00	
CLIN 0003	AT	6,984,678.52	
CLIN 0003	AW	100,000.00	
CLIN 0003 CLIN 0003	AW AY	100,000.00 550,000.00	
			94,288,100.52
			94,288,100.52
			94,288,100.52
CLIN 0003	AY	550,000.00	94,288,100.52
CLIN 0003 CLIN 0005	AY BA	550,000.00 ———————————————————————————————	94,288,100.52
CLIN 0003  CLIN 0005  CLIN 0005	BA BB	550,000.00 ———————————————————————————————	94,288,100.52
CLIN 0003  CLIN 0005  CLIN 0005  CLIN 0005	BA BB BC	550,000.00	94,288,100.52
CLIN 0003  CLIN 0005  CLIN 0005  CLIN 0005	BA BB BC BD	550,000.00	94,288,100.52
CLIN 0003  CLIN 0005  CLIN 0005  CLIN 0005  CLIN 0005	BA BB BC BD BE	550,000.00	94,288,100.52
CLIN 0003  CLIN 0005  CLIN 0005  CLIN 0005  CLIN 0005  CLIN 0005	BA BB BC BD BE BF	550,000.00	94,288,100.52
CLIN 0003  CLIN 0005  CLIN 0005  CLIN 0005  CLIN 0005  CLIN 0005  CLIN 0005	BA BB BC BD BE BF BG	550,000.00	94,288,100.52
CLIN 0003  CLIN 0005  CLIN 0005  CLIN 0005  CLIN 0005  CLIN 0005  CLIN 0005  CLIN 0005	BA BB BC BD BE BF BG BH	550,000.00	94,288,100.52

CLIN 0007AA	BP	10,199,288.50	
		***************************************	10,199,288.50
GY D L 0000 L L	40	45 106 00	
CLIN 0009AA	AQ	45,106.00	
CLIN 0009AA	AV	0.00	
CLIN 0009AA	BK	256,545.00	
CLIN 0009AA	ВМ	125,000.00	
CLIN 0009AA	BN	21,315.00	
			447,966.00
CL D. 2000 A D	AT	200 000 00	
CLIN 0009AB	AJ	200,000.00	
CLIN 0009AB	AK	85,000.00	
CLIN 0009AB	AL	45,000.00	
CLIN 0009AB	AQ	59,894.00	
CLIN 0009AB	AR	35,000.00	
CLIN 0009AB	вк	3,455.00	
CLIN 0009AB	BN	81,685.00	
CLIN 0009AB	BU	350,000.00	
CLIN 0009AB	BV	9,000.00	
			869,034.00
CLIN 0013	AU	7,970,000.00	
CLIN 0013	AX	3,396,000.00	
CLIN 0013	AY	0.00	
CLIN 0013	AZ	19,412,000.00	
CLIN 0013	BJ	7,896,673.34	

		-	38,674,673.34
		•	
CLIN 0017	BW	0.00	
CLIN 0017	KM	0.00	
		-	0.00
		=	
CLIN 0017AA	BY	3,880,000.00	
CLIN 0017AA	BX	1,146,000.00	
CLIN 0017AA	BW	84,896,852.00	
CLIN 0017AA	BZ	0.00	
CLIN 0017AA	KM	192,793,000.00	
CLIN 0017AA	KN	0.00	
CLIN 0017AA	KQ	66,151.00	
CLIN 0017AA	KS	0.00	
CLIN 0017AA	KT	386,204,200.00	
CLIN 0017AA	KU	2,203,183.00	
CLIN 0017AA	KY	0.00	
CLIN 0017AA	LC	200,000.00	
CLIN 0017AA	LD	7,943,648.00	
CLIN 0017AA	LE	0.00	
CLIN 0017AA	LH	400,000.00	
CLIN 0017AA	LJ	7,476.00	
CLIN 0017AA	LK	281,575,897.00	
CLIN 0017AA	LQ	235,566.00	
CLIN 0017AA	LS	6,069,616.00	
CLIN 0017AA	LT	530,377.00	
CLIN 0017AA	LU	\$9,100,000.00	

CLIN 0017AA	LV	\$1,957,265.00
CLIN 0017AA	LW	\$255,567.00
CLIN 0017AA	LX	\$68,000.00
CLIN 0017AA	LY	\$264,807,424.52
CLIN 0017AA	MB	\$375,000.00
CLIN 0017AA	MC	\$2,283,481.00
CLIN 0017AA	MD	\$8,573.00
CLIN 0017AA	ME	\$0.00
CLIN 0017AA	MF	\$270,907,822.39
CLIN 0017AA	MH	\$213,390.00
CLIN 0017AA	MJ	\$858,495.00
CLIN 0017AA	MK	\$56,076.00
CLIN 0017AA	ML	\$116,044.00
CLIN 0017AA	MM	\$1,618,600.00
CLIN 0017AA	MN	\$2,573,000.00
CLIN 0017AA	MP	\$250,000.00
CLIN 0017AA	MQ	\$691,421.00
CLIN 0017AA	MR	\$0.00
CLIN 0017AA	MS	\$700,000.00
CLIN 0017AA	MT	\$16,289,524.00
CLIN 0017AA	MV	\$39,921,199.75
CLIN 0017AA	MW	\$10,000,000.00
CLIN 0017AA	MX	\$138,795,358.00
CLIN 0017AA	MY	\$18,327.00
		1,730,016,533.26

			***************************************
		-	
		togic common colo	
CLIN 0017AB	KL	118,250.00	
		<del></del>	118,250.00
GT D1 2015 1 G	n.a	100.000.00	
CLIN 0017AC	BZ	190,000.00	
			190,000.00
CLIN 0017AD	KN	0.00	
CLIN 0017AD	KS	0.00	
			0.00
CLIN 0017AE	LL	173,798.00	
			173,798.00
CLIN 0017AH	KT	173,798.00	
			173,798.00
CLIN 0020AA	KN	0.00	
CLIN 0020AA	KQ	26,660.00	
			26,660.00
CLIN 0021AA	KW	0.00	
OBIN WEIRA	AX 11		0.00
			0.00

CLIN 0021AB	KV	0.00	
CLIN 0021AB	LB	0.00	
CLIN 0021AB	KX	0.00	
CLIN 0021AB	KY	0.00	
			0.00
		•	
CLIN 0021AC	KZ	0.00	
CLIN 0021AC	LA	0.00	
		-	0.00
		•	
CLIN 0022	KW	0.00	
		-	0.00
		=	
CLIN 0023	KX	60,000.00	
CLIN 0023	KY	25,000.00	
CLIN 0023	KV	65,000.00	
CLIN 0023	LB	12,500.00	
CLIN 0023	LF	10,000.00	
CLIN 0023	LR	\$125,000.00	
		-	297,500.00
		a	
CLIN 0024	LA	13,508.00	
CLIN 0024	LG	62,000.00	
CLIN 0024	KZ	25,000.00	
CLIN 0024	KW	20,000.00	
CLIN 0024	LP	83,200.00	
		<b>20</b>	

			203,708.00
CLIN 0025	LE	1,173,850.00	
CLIN 0025	LM	1,080,404.00	
CLIN 0025	MA	0.00	
			2,254,254.00
CLIN 0026	LN	630,061.00	
			630,061.00
CLIN 0027	LZ	1,751,384.00	
			1,751,384.00
CLIN 0028	LM	329,972.00	
CLIN 0028	MA	2,982,442.00	
CLIN 0028	MG	6,262,095.00	***************************************
CLIN 0028	MU	\$7,864,499	
			17,439,008.00
CLIN 003001*	MX	\$52,974,283.00	
CLIN003002*	MX	\$719,132.00	
CLIN 000303*	MX	\$5,747.00	
CLIN 000304*	MX	\$16,000,000.00	
CLIN 000305*	MX	\$16,000,000.00	
CLIN 003006*	MX	\$38,000,000.00	
CLIN 003007*	MX	\$1,096,196.00	

DASG60-98-C-0001 P00261 Page 15 of 15

CLIN 003008*	MX	\$14,000,000.00	
			138,795,358.00

* CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. For pruposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017AA and should not be counted twice with regards to the total contract funding obligated.

(End of Summary of Changes)

AMENDMENT OF SOLICIT	FATION/MODII	FICATION OF CONTRACT	1.0	ONTRACT V	ID CODE	PAGE OF PAGE	S
AMENDMENT/MODIFICATION NO.	3. EFFECTIVE DATE 18-Dec-2012	4. REQUISITION/PURCHASE REQ. NO.			5. PROÆCT	NO.(Ifapplicable)	
USSUED BY CODE USASMDC/ARSTRAT SMOC-RDC PO BOX 1500 HUNTSVILLE AL 35807-3801	W9113M	7. ADMINISTERED BY (Ifother than item 6) DCMA RAYTHEON 50 APPLE HILL DRIVE MS T2FR2 TEWKSBURY MA 01878	)	cor	DE \$2208	5A	
. NAME AND ADDRESS OF CONTRACT OF RAYTHEON COMPANY 350 LOWELL ST. ANDOVER MA 01810-4400	R (No., Street, County,	State and Zip Code)			ENT OF SOI	LICITATION NO	
						T/ORDER NO.	
CODE 05716	FACILITY CO		X 30-Ja	ın-1998	SEE IT EM	13)	_
The above numbered solicitation is amended as set & O Ser must acknowledge receipt of this amendment p (a) By completing Items 8 and 15, and returning or (c) By separate letter or telegram which includes a RECELVED AT THE PLACE DESIGNATED FOR REJECTION OF YOUR OFFER. If by virtue of this	orth in Item 14. The hour and nior to the hour and date spe copies of the amendme reference to the solicitation THE RECEIPT OF OFFERS	cified in the solicitation or as amended by one of ent; (b) By acknowledging receipt of this amendr and amendment numbers. FAILURE OF YOUR PRIOR TO THE HOUR AND DATE SPECIFIE	is extended in the following sent on each conduction of the conduc	methods: opy of the of EDGMENT	TO BE	nded.	
provided each telegramor letter makes reference to the 2. ACCOUNTING AND APPROPRIATION I		duzent, and is received prior to the opening hour	and date spec	ifed.			-
		TO MODIFICATIONS OF CONTRACT		l.		***************************************	-
A. THIS CHANGE ORDER IS ISSUED PUR CONTRACT ORDER NO. IN ITEM 10 A	SUANT TO: (Specify a	CT/ORDER NO. AS DESCRIBED IN IT authority) THE CHANGES SET FORTH		14 ARE M	IADE IN TE	HE	
B. THE ABOVE NUMBERED CONTRACT. office, appropriation date, etc.) SET FOR					is changes in	paying	$\dashv$
C. THIS SUPPLEMENT AL AGREEMENT							
D. OTHER (Specify type of modification an	d authority)						4
. IMPORTANT: Contractor is not,	· · · · · · · · · · · · · · · · · · ·	gn this document and return		the issuing			_
4. DESCRIPTION OF AMENDMENT/MODIL where feasible.) Modification Control Number: See SF30, block 14, continuation page.	FICATION (Organized	t by OCF section headings, including solu	citation/cor	itract subje	ct matter		
xcept as provided herein, all terms and conditions of the	document referenced in them	9A or IOA as heretofine changed comming uncha	used and in §	ill firme and	e <b>f</b> ct.		
SA NAME AND TITLE OF SIGNER (Type of		16A	and the same of				$\neg$ (
		TEL:					<u> </u>
The contract of the contract o	15C. DATE SIGNE			5	160	8 DEL 2012	
EXCEPTION TO SF 30 APPROVED BY OIRM 11-84		(Signature of Contracting O	nicer)		NDARD FO	PRM 30 (Rev. 10-8	!

ST ANDARD FORM 30 (Rev. 10-83) Prescribed by GSA FAR (48 CFR) 53.243

SECTION SF 30 BLOCK 14 CONTINUATION PAGE

SUMMARY OF CHANGES

SECTION A - SOLICITATION/CONTRACT FORM

The following have been acided by full text: PURPOSE SECTION SF 30 BLOCK 14 CONTINUATION PAGE

## The purpose of this modification is to:

- 1. Correct administrative errors to Modification P00260.
- 2. Summary of Changes for Modification P00260 should have read as follows:
- 3. All corrections are shown in **bold** red.

#### SUMMARY OF CHANGES

1. SECTION A - SOLICITATION/CONTRACT FORM

Change Order Modification P00260 for JLENS based on restructure letter JLENS-2012-031 dated 27 September, 2012. Ceiling of contract will increase by a total of \$59,034,271.

The total cost of this contract was increased by \$59,034,271 from \$1,955,616,308.00 to \$2,014,650,579.00.

## 2. SECTION B - SUPPLIES OR SERVICES AND PRICES

# SUBCLIN 0017AA

The target cost has increased by from The target fee has increased by from

The total target cost plus fee of this line item has increased by \$59,034,271 from \$1,595,383,694 to \$1,654,417,965.

This includes an increase in target cost of consisting of a \$ increase in cost and a ncrease in facilities capital cost of money, and an increase in target fee

The target cost and target fee set forth above and in the table below reflects the negotiated Section B values prior to any adjustments made resulting from estimated cost overruns and share ratio impacts to the fee. Any differences between the Estimated Cost values provided below and the Target Cost values provided above and shown on the table below are as a result of estimated cost overruns. Any differences between the Estimated Fee

values provided below and the Target Fee values provided above and shown on the table below are a result of reductions based on current share ratio impacts to the Target Fee and do not include any allocation for yet to be earned incentives as set forth in Section H-19. As of the date of this modification, the estimated cost and estimated fee are as follows:

The Estimated Cost is a consisting of \$1 in cost and in facilities capital cost of money.

16)(4

The Estimated Fee is \$

6)4

(b)(4)

(4)(4)

Total Estimated Cost plus Fee is \$1,776,902,132.

Pursuant to FAR 16.405-1, the target cost and target fee will be finally determined and adjusted after contract performance.

The table below provides a summary of the target cost, target fee, and total:

CLIN	MOD	TARGET COST	FCCM	TARGET FEE	TOTAL
17AA	Pre-P00251				\$1,594,280,516.00
17AA	200251	<b>COLUMN</b>			1,594,280,516.00
17AA	P00254	September 1			1,595,005,395.00
17AA	F00258				\$1,595,005,395.00
17AA	P00259	SECTION AND ADDRESS.	SEATOR CO		\$1,595,383,694.00
17AA	P00260				\$1,654,417,965.00

**CLIN 0030** 

The total cost of his line item has increased by \$16,000,000.00 from \$124,795,358.00 to \$140,795,358.00.

SUBCLIN 003008 is added as follows:

ITEM NO 003008 SUPPLIES/SERVICES

QUANTITY

UNIT

UNIT PRICE

AMO INT

GFEBS Funding for SubCLIN 0017AA

**CPIF** 

FOB: Destination

ACRN MX

CIN: GFEBS001024670000001

\$16,000,000.00

DASG60-98-C-0901 P00262 Page 4 of 21

* As stated in Modification 200251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017AA, identified, accounted for, analyzed, or reported separately from SubCLIN0017, including EVMS. All scope remains under SubCLIN 0017AA with associated incentive events and flat zones.

## B-17. INCENTIVE FEE FOR SUBCLIN 0017AA/CLIN 0018 (SEE H-19):

adjusted in accordance with paragraph d. of this clause, for target cost and target fee for performance under SubCLIN 0017AA/CLIN 0018 are set forth below:

Target Cost	
Target Fon	(P)(A)
incentive A rangement: Maximum Fee:	(عرف
Minimum Fee:	(PXG)
(Snare Ratio: Government/Contractor)	(6)(4)
Underrun: or the amount by which the total allowable cost is less than the estimated cost until maximum fee is attained.	(b)(4)
Overrun: the amount by which the total allowable cost exceeds the estimated cost until minimum fee is attained.	(b)(4)
FAR 52.216-19, INCENTIVE, paragraph (e)(1), is stated as follows:	
(e) Fee Payable.	/b\/4\
(i) The (see gayable under this contract shall be the target fee increased by for every dollar that the total allowable cost is less than the estimated cost or decreased by for every dollar that the total allowable cost exceeds the estimated cost. In no event shall the fee be greater than percent (Maximum fee) or less than percent (Minimum fee) of the estimated cost.	(b)(4) (b)(4) (b)(4) (b)(4)
B-13 ESTIMATED COST, ESTIMATED INCENTIVE FEE, MINIMUM INCENTIVE FEE, MAXIMUM INCENTIVE FEE, AND INCENTIVE ARRANGEMENT FOR SUBCLIN 0017AA/CLIN 0018:	
SUBCLIN 0017A - (Two SDD JLENS Systems)	
a. Estimated cos:	(P)X4)
b. Estimated fee	(6)(4)
c. Minimum incentive fee:	(b)(4)
d. Maximum insentive fee:	5.4
002635	(b) (t)

e. Total estimated cost and estimated fee:

\$1,776,902,132

# 3. SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation

Summary for the Payment Office

As a result of this modification, the total funded amount for this document was increased by \$16,145,226.39 from \$1,949,073,997.63 to \$1,965,219,224.02.

# SUBCLIN 0017AA:

MF: 21.1 2040 5L 5L68 P172419E555L 255Y 4M1J730000 S01021 4M1J730000/14MJLE/4M5 was increased by \$126,899.39 from \$270,780,923.00 to \$270,907,822.39

and includes an in	stimated Fee, and Estimated to acrease in estimated cost of a d an increase in estimated fee	total for the above increase of \$ cost and	is distributed as follows facilities capital	(b)(4) (b)(4) (b)(4)	(P)(1)
Estimated Cost					(6)(
Estimated Fee				(b)(4)	,58-85
Total	\$126,899.39				(P)(P

MY: 21 1 2040 5L 5L68 P172419E555L 2516 4M1MMICST3 S01021 4M1MMICST3/14MJMM/4M5 was increased by \$18,327.00 from \$0.00 to \$18,327.00

The contract ACRN MY has been added.

includes an increase in estimated cost of an increase in estimated cost of an increase in estimated fee of	money) and (b)(4)
Estimated Estimated	(b)(4)
Cost	

Estimated Cost

Estimated Fee

Total \$18,327

(b)(c

(b)(4)

CLIN 0030:

SUBCLIN 003008:

Funding on SUBCLIN 003008 is initiated as follows:

ACRN: MX

CIN: GFEBS001024670000001

Acctng Data: 02120122013204000001171722550030003242A.0000013.1.1

6100.9000021001

Increase: \$16,000.000 00

Total: \$16,000,000.00

Cost Code: A5XFJ

Estimated Cost. Estimated Fee, and Estimated total for the above increase of \$16,000,000 is distributed as follows and includes an increase in estimated cost of \$16,000,000 is distributed as follows and increase in estimated fee of Estimated Cost

Estimated Fee

Total \$16,000,000

IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows:

SUBCLIN 0017AA:

THIS

CUMULATIV:

1343

(b)(4)

PRIOR

MODIFICATION

TOTAL*

(1) Amount Required for Full Funding,

Including Fee:

\$1,717,867,861

\$ 59,034,271

\$ 1,776,902,132

(2) Amount Allotted Under the LOF Clause

for Payment of Costs:

Carlos Alexandrica de la companya del companya de la companya del companya de la companya de la

(3) Amount Separately Obligated for

Payment of Fee:

THE REPORT OF THE PARTY.

(b)(4)

(4) Total Amount Allotted and Obligated:

\$1,715,871,307.27 \$16,145,226.39

\$1,732,016,533.65

(5) Net Amount Required for Full Funding

\$ 1,996,553.73 \$ 42,889,044.61 P 44, 845,594.34 \$ 44,885,598.2 \$ 46,885,698.34

* These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17AE)	
4. SECTION H - SPECIAL CONTRACT REQUIREMENTS is revised as follows:	
Paragraph H-19. INCENTIVE FEE STRUCTURE AND PAYMENT FOR CLIN 0017, SYSTEM DEVELOPMENT AND DEMONSTRATION (SDD), subparagraph a., b., and c., are revised as follows:	
a. General.	
SubCLIN 0017AA, System Development and Demonstration (SDD), is a cost-plus-incentive-fee (CPIF) Line Item with cost and schedule incentives as described below. Paragraph H-19(b) applies only to the Cost Incentive and Paragraph H-19(c) applies only to the Schedule Incentive. The target contract price amount of \$1,654,417,965 includes a target cost of hich includes of cost and cost of facilities capital cost of money) and a target incentive fee of \$3.65 which is cost of target cost less facilities capital cost of money.	(b)X4)
b. Cost Incentive.	x
(1) The target fee payable under SubCLIN 0017AA is of the estimated cost less facilities capital cost of money (Subsection and amount equal to	(P) (1)
(2) The maximum fee payable under SubCLIN 0017AA is substituted cost less facilities capital cost of money an amount equal to	6)(3
(3) The minimum fee payable under SubCLIN 0017AA is the estimated cost less facilities capital cost of money ( an amount equal to money)	6)(4)
(4) Fee will be adjusted for actual cost that is less than or more than the estimated cost stated above using a share ratio of Government. Contractor for actual costs less than the estimated cost, and a ratio of Government. Contractor for actual costs greater than the estimated cost range applied according to Paragraph H-19(c)(1).	6)(4)
(5) Nothing stated in this clause shall take precedence over the clause 52.216-10 - Incentive Fee contained in this contract.	
c. Schedule and Performance Incentive.	
(1) A maximum "flat zone" will be established at the target cost value of \$1,518,857,379 with the conduct of milestones below. The "flat zone" over which the contractor will earn target fee is for eligible costs from	by
once the program milestones set forth below are conducted. (Note: As of the effective date of Modification P00260, only of the maximum flat zone" has been acknowledged as earned.)	(b)
(a) f the maximum benefit of the "flat zone", earned by the conduct of the SDD System	(6)(1)

Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the

Functional Review NLT 2nd Quarter, Fiscal Year 2007. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive of

conclusion of the contract. Asterence letter, dated 5 March 2007 from	(p	D(0)
		0 <b>.</b> 10 . 000
(b) the maximum benefit of the "flat zone", earned by the conduct of SDD Croit Critical Design review VLT 2nd Clarer, Fiscal Year 2009. (It is hereby acknowledged by the government that Raytheon		(b)(4)
completed the requirement for inis flat zone and earned the "Flat Zone" schedule incentive of see payment utilizing the "Flat Zone" amount will be made at the conclusion of the	d	(b)(4)
contract. Reservace le	(	( a) ( d)
		-
Test 1 (DT-1) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for ILENS SDD Contract, Section H-19(c), dated 08/10/12. (It is hereby acknowledged by the government that Raytheen completes the requirement for this flat zone and earned a "Flat Zone" schedule incentive of		PXA
of the available Final determination of incentive fee payment willizing the "Flat Zone" amount will be made at the conclusion of the contract.)		(b)(4
(d) Softhe maximum benefit of the "flat zone", earned by the conduct of the Electromagnetic Environmental Effects (E3 - Testing in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for ILENS SDD Contract, Section H-19(c), dated 08/10/12.		(PXH)
(e) D* of the maximum benefit of the "flat zone", earned by the conduct of the Integrated Fire Control Event in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JUENS SDD Contract, Section H-19(c), dated 08/10/12. (It is hereby acknowledged by the government of the Park Park Park Park Park Park Park Park		(b)(4
that Raytheon completed the requirement for this flat zone and earned a "Flat Zone" schedule incentive of the available Final determination of incentive fee payment utilizing the		CPXCF.
"Flat Zone" amount will be made at the conclusion of the contract.) *NOTE: The notential has been decreased from to to be due to movement of the second incentive for the s	(b)(3)(A)	(P)(A)
	(i)&Title 10 Sec 130	(1.3/-1
(f earned by the conduct of the Functional Configuration Audit (FCA) #1 in accordance with the criteria set forth in Section J attachment entitled Flat Zone	(a)(b)	(6)(4
Performance Criteria for ILENS SDD Contract, Section H-19(c), dated 08/10/12. *Note: The potential has been increased from to the state of the state	(b)(3)(A) (i)&Title	PXA
(g) the maximum benefit of the "flat zone", earned by the conduct of Developmental Test 2 (DT-2) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12.*	10 Sec 130 (a)(b)	(b)(x
(h)of the maximum benefit of the "flat zone", earned by the conduct of the Early User Test (previously defined as Limited User Test) in accordance with the criteria set forth in Section J attachmem entitled Flat Zone Performance Criteria for ILENS SDD Contract, Section H-19(c), dated 08/10/12. *		(b) (c
(i) Specific maximum benefit of the "flat zone", earned by the conduct of the Final Functional Configuration Audit (FCA) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for TLENS SDD Contract, Section H-19(c), dated 08/10/12. *		65X4)
(3) For Earned Value and post reporting purposes, the estimated cost value of will be used.		

# d. Changes issued under FAR 52.243-2, Changes - Cost Reimbursement

In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the performance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLIN 0017 are added and exercised, the incentive fee for cost and schedule/performance applicable to the Option will be incorporated in accordance with the incentive fee structure of this provision.

5. The following is an update to Modification P00259 showing a summary of funding by ACRN through Modification P00260:

ACRN	FUNDING	
AA		440,100.00
AB		2,298,235.00
AC		17,832,987.00
AD		0.00
AE		7,500,000.00
AF		3,300,000.00
AG		17,192,400.00
AH		700,000.00
AJ		200,000.00
AK.	9	85,000.00
AL		45,000.00
AM		17,045,000.00
AN		5,800.00
AP		20,779,000.00
AQ		105,000.00
AR .		35,000.00
AS		0.00
AT		6,984,678.52

AU	7,970,000.00
AV	0.00
AW	100,000.00
AX	3,396,000.00
AY	550,000.00
AZ	19,412,000.00
BA	24,527,878.00
98	146,000.00
<b>B</b> C	72,000.00
BD	85;000.00
BE	100,000.00
BF	100,000.00
BG	1,975,321.00
ВН	38,018,908.00
Bī	7,896,673.34
ВК	260,000.00
BL	0.00
ВМ	125,000.00
BN	103,000.00
BP	10,199,288.50
BU	350,000.00
BV	9,000.00
BW	84,896,852.00
вх	1,146,000.00
BA	3,880,000.00
BZ	190,000.00
KL	118,250.00

KM	192,793,000.00
KN	0.00
KQ	92,811.00
KR	0.00
KS	0.00
KT	386,377,998.00
KU	2,203,183.00
KV	65,000.00
KW	20,000.00
KX	60,000.00
KY	25,000.00
KZ	25,000.09
LA	13,508.00
LB	12,500.00
LC	200,000.00
i.D	7,943,648.00
LE	1,173,850.00
UF	10,000.00
LG	62,000.00
LH	400,000.00
Ľ.J.	7,476.00
LK	\$281,575,897.00
LL	\$173,798.00
LM	\$1,410,376.00
LN	\$630,061.00
LP	\$83,200.00
LQ	\$235,566.00

LR	\$125,000.00
1.3	\$6,069,616.00
LT	\$530,377.00
LU	\$9,100,000.00
LV	\$1,957,265.00
LW	\$255,567.00
LX	\$68,000.00
LY	\$264,807,424.52
LZ	\$1,751,384.00
МА	\$2,982,442.00
МВ	\$375,000.00
MC	\$2,283,481.00
MD	\$8,573.00
ME	\$0.00
MF	\$270,907,822.39
MG	\$6,262,095.00
MH	\$213,390.00
MJ	\$858,495.00
MK	\$56,076.00
ML	\$116,044.00
MM	\$1,618,600.00
MN	\$2,573,000.00
MP	\$250,000.00
MQ	\$691,421.00
MR	\$0.00
MS	\$700,000.00
MT	\$16,289,524.00

MU	\$7,864,499.00
MV	\$39,921,199.75
MW	\$10,000,000.00
MX	\$140,795,358.00
MY	\$18,327.00

6. The following is an update to Modification P00259 showing a summary of funding by CLIN by ACRN through Modification P00260:

CLIN	ACRN	FUNDING AMT	CLIN TOTAL
CLIN 0001	AA	440,100.00	
CLIN 0001	AD	0.00	
			440,100.00
CLIN 0003	AB	2,298,235.00	
CLIN 0003	AC	17,832,987.00	
CLIN 0003	AD	0.00	
CLIN 0003	AE	7,500,000.00	
CLIN 0003	AF	3,300,000.00	
CLIN 0003	AG	17,192,400.00	
CLIN 0003	AH	700,000.00	
CLIN 0003	AM	17,045,000.00	
CLIN 0003	AN	5,800.00	
CLIN 0003	AP	20,779,000.00	
CLIN 0003	AS	0.00	
CLIN 0003	AT	6,984,678.52	

	100,000.00	V	S. W	CLIN 0003
	550,000.00		60	CLIN 0003
94,288,100.52	_			
	_			
	24,527,878.00		46	CLIN 0005
	146,000.00		ВЗ	CLIN 0005
	72,000.00		BC	CLIN 0005
	85,000.00	>	BD	CLIN 0005
	100,000.00		BE	CLIN 0005
	100,000.00		BF	CLIN 0005
	1,975,321.00	j	BG	CLIN 0005
	38,018,908.00	and the state of t	BH	CLIN 0005
	0.00	e 4	36	CLIN 0005
	0.00		BZ	CLIN 0005
65,025,107.00	_			
	_			
	10,199,288.50		BP	CLIN 0007AA
10,199,288.50	_			
	45,106.00	2	AQ	CLIN 0009AA
	0.00	7	AV	CLIN 0009AA
	256,545.00		BK	CLIN 0009AA
	125,000.00	ſ	BM	CLIN 0009AA
	21,315.00		BN	CLIN 0009AA
447,966.00	-			
447,966.00	21,315.00		BN	0009AA

CLIN 0009AB	AI	200,000.00	
CLIN 0009AB	AX	85,000.00	
CLIN 0009AB	AL	45,000.00	
CLIN 0009AB	AQ	59,894.00	
CLIN 0009AB	AR	35,000.00	
CLIN 0009AB	BK	3,455.00	
CLIN 0009AB	BN	81,685.00	
CLIN 0009AB	BU	350,000.00	
CLIN 0009AB	BV	9,000.00	
		_	869,034.00
		-	
CLIN 0013	AU	7,970,000.00	
CLIN 0013	AX	3,396,000.00	
CLIN 0013	AY	0.00	
CLIN 0013	AZ	19,412,000.00	
CLIN 0013	b.J	7,896,673.34	
		_	38,674,673.34
		-	
CLIN 0017	BW	0.00	
CLIN 0017	N.X.	0.00	
		_	0.00
		_	
CLIN 0017AA	BY	3,880,000.00	
CLIN 0017AA	BX	1,146,000.00	
CLIN 0017AA	BW	84,896,852.00	
CLIN 0017AA	BZ	0.00	

CLIN 001TAA	MX	192,793,000.00	
CLIN 0017/5A	KN.	0.00	
CLIN 0017AA	KQ	66,151.00	
CLIN 0017AA	KS	0.00	
CLIN 0017AA	KT	386,204,200.00	
CLIN 0017AA	KT	2,203,183.00	
CLIN 0017AA	KY	0.00	
CLIN 0017AA	LC	200,000.00	
CLIN 0017AA	LD	7,943,648.00	
CLIN 0017AA	Lt	0.00	
CLIN 0017AA	LH	400,000.00	
CLIN 0017AA	M	7,476.00	
CLIN 0017AA	2.3	281,575,897.00	
CLIN 0017.4.A	LQ	235,566.00	
CLIN 0017AA	LS	6,069,616.00	
CLIN 0017AA	LT	530,377.00	
CLIN 0017AA	LG	\$9,100,000.00	
CLIN 0017AA	EA	\$1,957,265.00	
CLIN 0017AA	LW	\$255,567.00	
CLIN 0017AA	UX	\$68,000.00	
CLIN 0017AA	EY	\$264,807,424.52	and the same of th
CLIN 0017AA	ма	\$375,000.00	
CLIN 0017AA	MC	\$2,283,481.00	
CLIN 0017AA	MD	\$8,573.00	
CLIN 0017AA	ME	\$0.00	
CLIN 0017AA	MF	\$270,907,822.39	

CLIN 0017 \ A	243	\$213,390.00	
CLIN 0017AA	X-J	\$858,495.00	
CLIN 0017AA	NK	\$56,076.00	
CLIN 0017AA	NE	\$116,044.00	
CLIN 0017AA	VM	\$1,618,600.00	
CLIN 0017.4.A	MN	\$2,573,000.00	
CLIN 0017AA	MB	\$250,000.00	
CLIN 0017AA	V1Q	\$691,421.00	
CLIN 0017AA	VR	\$0.00	
CLIN 0017AA	MS	\$700,000.00	
CLIN 0017AA	MT	\$16,289,524.00	
CLIN 0017AA	MV	\$39,921,199.75	
CLIN 0017AA	MW	\$10,000,000.00	
CLIN 0017AA	MX	\$140,795,358.00	
CLIN 0017AA	MY	\$18,327.00	
		1,732,010	5,533.66 ?
		-	-
CLIN 0017AB	Kl	118,250.00	
		118	3,250.00
CLIN 0017AC		190,000.00	
CONTROL PORTER			0,000.00

	0.00	3.4	CLIN 0017AD
	0.00	ζ5	CLIN 0017AD
0.00	_		
	173,798.00	CC ·	CLIN 0017AE
173,798.00			
	173,798.00	ET.	CLIN 0017AH
173,798.00	-		
	0.00	8N	CLIN 0020AA
	26,660.00	KQ	CLIN 0020AA
26,660.00	_		
	0.00	X/W	CLIN 002iAA
0.00	_		
	0.00	KV	CLIN 0021AB
	0.00	LB	CLIN 0021AB
	0.00	CC	CLIN 0021AB
	0.00	XY.	CLIN 0021AB
0.00			
	0.00	KZ	CLIN 002: AC
	0.00	LA	CLIN 0021AC
0.00	_		
	to a constant		

	0.00	$\mathbb{K}^{ V }$	CLIN 0022
0.00	-		
	60,000.00	KX	CLIN 0023
	25,000.00	KY	CLIN 0023
	65,000.00	K.V	CLIN 0023
	12,500.00	LB	CLIN 0023
	10,000.00	LF	CLIN 0023
	\$125,000.00	LR	CLIN 0023
297,500.00			
	13,508.00	LA	CLIN 0024
	62,000.00	LG	CLIN 0024
	25,000.00	KZ	CLIN 0024
	20,000.00	XW	CLIN 0024
	83,200.00	LP	CLIN 0024
203,708.00	_		
	1,173,850.00	LE	CLIN 0025
	1,080,404.00	1_201	CLIN 0025
	0.00	MA	CLIN 0025
2,254,254.00	_		
	630,061.00	ĹŇ	CLIN 0026
630,061.00	-		

		-	
CLIN 0027	6.5	1,751,384.00	
		_	1,751,384.00
CLIN 0028	UM	329,972.00	
CLIN 0028	VA	2,982,442.00	
CLIN 0028	.∀ G	6,262,095.00	
CLIN 0028	M	\$7,864,499	
			17,439,008.00
CLIN 003001*	MX	\$52,974,283.00	
CLIN003002*	34X	\$719,132.00	
CLIN 000393**	MX	\$5,747.00	
CLIN 0003C4*	MX	\$16,000,000.00	
CLIN 000305*	MX	\$16,000,000.00	-
CLIN 003006*	MX	\$38,000,000.00	
CLIN 003007*	MX	\$1,096,196.00	
CLIN 003008*	MX	\$16,000,000.00	
		_	140,795,358.00
		_	

^{*} CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. For pruposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017AA and should not be counted twice with regards to the total contract funding obligated.

(End of Summary of Changes)

DASG60-98-C-0001 P00262 Page 21 of 21

AMENDMENT OF SOLICIT	TATION/MODIF	FICATION OF CONTRACT	,	1. CONTRACT V	ID CODE	1 .	F PAGES
2. AMENDMENT/MODIFICATION NO	3. EFFECTIVE DATE	4. REQUISITION/PURCHASE REQ. NO		V	5. PROJECT	1 VO.(Ifapplio	able)
P00263	14-Feb-2013	0010303589			2		22.01
6 ISSUED BY CODE  USASMDC/ARSTRAT SMDC-RDC PO BOX 1500 HUNTSVILLE AL 35807-3801	W9113M	7 ADMINISTERED BY (Ifother han item 6) DCMA RAYTHEON 50 APPLE HILL DRIVE M/S TZFR2 TEWKSBURY MA 01876		COI	S2205	δA	
8. NAME AND ADDRESS OF CONTRACT OR RAYTHEON COMPANY 350 LOWELL ST ANDOVER MA 01810-4400	(No., Street, County,	State and Zip Code)	9B	A. MOD. OF A. MOD. OF ASG60-98-C B. DATED (	CONTRAC	) T/ORDER	
CODE 05716	FACILITY COL	DE	X 30	-Jan-1998			
11	. THIS ITEM ONLY A	APPLIES TO AMENDMENTS OF SOLI	CITATI	IONS			
(a) By completing Items 8 and 15, and returning or (c) By separate letter or telegram which includes a RECEIVED ATTHE PLACE DESIGNATED FOR REJECTION OF YOUR OFFER. If by virtue of this provided each telegramor letter makes reference to the 12. ACCOUNTING AND APPROPRIATION I	reference to the solicitation THE RECEIPT OF OFFERS amendment you desire to cha e solicitation and this amend	PRIOR TO THE HOUR AND DATE SPECIFIED inge an offer already submitted, such change may be	ACKNOV D MAY R be made by	VLEDGMENT ESULT IN y telegramor le	TO BE		
See Schedule	ATA (II required)						
	DIFIES THE CONTRACTURE TO: (Specify a	TO MODIFICATIONS OF CONTRACT: CT/ORDER NO. AS DESCRIBED IN IT! uthority) THE CHANGES SET FORTH	EM 14.		IADE IN TH	НЕ	
B. THE ABOVE NUMBERED CONTRACT/ office, appropriation date, etc.) SET FOR C. THIS SUPPLEMENTAL AGREEMENT I	TH IN ITEM 14, PUR	SUANT TO THE AUTHORITY OF FA			as changes in	paying	
D. OTHER (Specify type of modification and Unilateral FAR 52.232-22 Incremental Fundi							
E. IMPORTANT: Contractor X is not,	is required to sig	n this document and return	copies	to the issuing	g office.		
4. DESCRIPTION OF AMENDMENT/MODIF where feasible.) Modification Control Number: The purpose of this modification is to increme for SLIN 0017AA in section G is incorrect an incorrect and should be disregarded.	entally fund CLIN 0017/	(b)(6)	) unt of \$	21,000,000.6	00. ACRNKI	M	
except as provided herein, all terms and conditions of the conditi	r print)	16A. NAME AND TITLE OF CO	NTRAC		CER (Type o		(b)(b)
5B. CONTRACTOR/OFFEROR	15C. DATE SIGNEI				<b>Q</b>	DATE S ( <b>b</b> Feb-201:	( <b>6</b> )(3) (3)(6)
(Signature of person authorized to sign)	I	respensiture of Contracting Of	ficer)		<del>-</del>		(-)

EXCEPTION TO SF 30 APPROVED BY OIRM 11-84 30-105-04 002653

STANDARD FORM 30 (Rev. 10-83) Prescribed by GSA FAR (48 CFR) 53.243

## SECTION SF 30 BLOCK 14 CONTINUATION PAGE

#### SUMMARY OF CHANGES

SECTION A - SOLICITATION/CONTRACT FORM

The following have been added by full text: PURPOSE

**CLIN 0030** 

* As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017AA, identified, accounted for, invoiced, analyzed, or reported separately from SubCLIN 0017, including EVMS. All scope remains under SubCLIN 0017AA with associated incentive events and flat zones.

The following have been deleted:

**PURPOSE** 

**PURPOSE** 

**PURPOSE** 

**PURPOSE** 

SECTION B - SUPPLIES OR SERVICES AND PRICES

SUBCLIN 003009 is added as follows:

\$0.00

ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT \$0.00

GFEBS Funding for SubCLIN 0017AA

**CPIF** 

FOB: Destination

PURCHASE REQUEST NUMBER: 0010303589

TARGET COST \$0.00

TARGET FEE \$0.00

TOTAL TGT COST + FEE

MINIMUM FEE \$0.00

MAXIMUM FEE \$0.00

SHARE RATIO ABOVE TARGET

SHARE RATIO BELOW TARGET

ACRN MZ \$21,000,000.00

CIN: GFEBS001030358900001

#### SECTION E - INSPECTION AND ACCEPTANCE

The following Acceptance/Inspection Schedule was added for SUBCLIN 003009:

INSPECT AT INSPECT BY ACCEPT AT ACCEPT BY N/A N/A Government

#### SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation

Summary for the Payment Office

As a result of this modification, the total funded amount for this document was increased by \$21,000,000.00 from \$1,922,617,489.68 to \$1,943,617,489.68.

## SUBCLIN 0017AA:

KM: 21 7 2040 5L 5L68 P17419E555L 255Y 4M7J730000 S01021 4M7J730000/74MJLE/4M was increased by \$192,793,000.00 from \$0.00 to \$192,793,000.00

The contract ACRN KP was changed to KM.

The Cost Code `has been added.

# SUBCLIN 003009:

Funding on SUBCLIN 003009 is initiated as follows:

ACRN: MZ

CIN: GFEBS001030358900001

Acctng Data: 02120132014204000001171722550030003242A.0009263.1.1

6100.9000021001

Increase: \$21,000,000.00

Total: \$21,000,000.00

Cost Code: A5XFJ

(End of Summary of Changes)

#### MOD00263 SECTION SF 30 BLOCK 14 CONTINUATION PAGE

## **SUMMARY OF CHANGES**

## 1. SECTION B - SUPPLIES OR SERVICES AND PRICES

**CLIN 0030** 

The total cost of this line item has increased by \$21,000,000.00 from \$138,795,358.00 to \$159,795,358.00.*

* As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017AA, identified, accounted for, invoiced, analyzed, or reported separately from SubCLIN 0017, including EVMS. All scope remains under SubCLIN 0017AA with associated incentive events and flat zones.

SUBCLIN 003009 is added as follows:

ITEM NO SUPPLIES/SERVICES C

QUANTITY UNIT

**UNIT PRICE** 

**AMOUNT** 

GFEBS Funding for SubCLIN 0017AA

**CPIF** 

003009

FOB: Destination

PURCHASE REQUEST NUMBER: 0010303589

ACRN MZ

\$21,000,000.00

CIN: GFEBS001030358900001

# 2. SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation

Summary for the Payment Office

As a result of this modification, the total funded amount for this document was increased by \$21,000,000.00 from \$1,963,219,224.00 to \$1,984,219,224.00.

# SUBCLIN 003009:

Funding on SUBCLIN 003009 is initiated as follows:

ACRN: MZ

CIN: GFEBS001030358900001

Acctng Data: 02120132014204000001171722550030003242A.0009263.1.1 6100.9000021001

Increase: \$21,000,000.00

Total: \$21,000,000.00

Cost Code: A5XFJ

Target Cost, Target Fee, and total for the above increase of \$21,000,000 is distributed as follows and includes increase in target cost of cost and increase in target fee of the cost of cost and cost of cos	
Target Cost Target Fee Total	(b)(4) (b)(4) (b)(2

IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows:

SUE	3CLIN 0017AA :	PRIOR	THIS MODIFICATION	CUMULATIVE <u>TOTAL*</u>
(1)	Amount Required for Full Funding,			
	Including Fee:	\$1,776,902,132	\$ 0	\$ 1,776,902,132
(2)	Amount Allotted Under the LOF Clause			
	for Payment of Costs:			(b)(4
(3)	Amount Separately Obligated for			(b)(4)
	Payment of Fee:	\$		( CAY
(4)	Total Amount Allotted and Obligated:	\$1,732,016,533.66	\$21,000,000	\$1,753,016,533.66
(5)	Net Amount Required for Full Funding	\$ 46,885,598.34	(\$21,000,000)	\$ 25,885,598.34

^{*} These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17AH)

3. The following is an update to Modification P00255 showing a summary of funding by ACRN through Modification P00263:

<u>ACRN</u>	<u>FUNDING</u>	
AA		440,100.00
AB		2,298,235.00
AC		17,832,987.00
AD		0.00
AE		7,500,000.00
AF		3,300,000.00
AG		17,192,400.00
AH		700,000.00
AJ		200,000.00
AK		85,000.00
AL		45,000.00
AM		17,045,000.00
AN		5,800.00

A D	20 770 000 00
AP	20,779,000.00
AQ	105,000.00
AR	35,000.00 0.00
A\$ AT	6,984,678.52
AU	
AV	7,970,000.00 0.00
AW	100,000.00
AX	3,396,000.00
AY	550,000.00
AZ	19,412,000.00
- <del>-</del>	
BA	24,527,878.00 146,000.00
BB	72,000.00
BC	
BD	85,000.00
BE	100,000.00 100,000.00
BF	*
BG	1,975,321.00
BH	38,018,908.00
BJ	7,896,673.34
BK	260,000.00 0.00
BL	
BM	125,000.00
BN	103,000.00 10,199,288.50
BP	
BU	350,000.00
BV	9,000.00
BW	84,896,852.00
BX	1,146,000.00 3,880,000.00
BY B7	· ·
BZ KL	190,000.00 118,250.00
KM KM	·
	192,793,000.00
KN KQ	92,811.00
KQ KR	0.00
KS	0.00
KT KU	386,377,998.00 2,203,183.00
KV	65,000.00
	20,000.00
KW KX	60,000.00
	·
KY V7	25,000.00
KZ	25,000.00
LA	13,508.00
LB	12,500.00
LC	200,000.00
LD	7,943,648.00
LE	1,173,850.00
LF	10,000.00

I.C.	62,000,00
LG	62,000.00
LH LJ	400,000.00
<del></del>	7,476.00 \$281,575,897.00
LK LL	\$173,798.00
LM	\$1,410,376.00
	\$630,061.00
LN LP	\$83,200.00
LP LQ	\$235,566.00
LQ LR	\$125,000.00
LS	•
LT	\$6,069,616.00
	\$530,377.00
LU	\$9,100,000.00
LV	\$1,957,265.00
LW	\$255,567.00
LX	\$68,000.00
LY	\$264,807,424.52
LZ	\$1,751,384.00
MA	\$2,982,442.00
MB	\$375,000.00
MC	\$2,283,481.00
MD	\$8,573.00
ME	\$0.00
MF	\$270,514,880.00
MG	\$6,262,095.00
MH	\$213,390.00
MJ	\$858,495.00
MK	\$56,076.00
ML	\$116,044.00
MM	\$1,618,600.00
MN	\$2,573,000.00
MP	\$250,000.00
MQ	\$691,421.00
MR	\$0.00
MS	\$700,000.00
MT	\$16,289,524.00
MU	\$7,864,499.00
MV	\$39,921,199.75
MW	\$10,000,000.00
MX	\$159,795,358.00

4. The following is an update to Modification P00255 showing a summary of funding by CLIN by ACRN through Modification P00256:

CLIN	<u>ACRN</u>	FUNDING AMT	CLIN TOTAL
CLIN 0001	AA	440,100.00 0.00	
CLIN 0001	AD	0.00	440,100.00

CLIN 0003	AB	2,298,235.00	
CLIN 0003	AC	17,832,987.00	
CLIN 0003	AD	0.00	
CLIN 0003	AE	7,500,000.00	
CLIN 0003	AF	3,300,000.00	
CLIN 0003	AG	17,192,400.00	
CLIN 0003	AH	700,000.00	
CLIN 0003	AM	17,045,000.00	
CLIN 0003	AN	5,800.00	
CLIN 0003	AP	20,779,000.00	
CLIN 0003	AS	0.00	
CLIN 0003	AT	6,984,678.52	
CLIN 0003	$\mathbf{A}\mathbf{W}$	100,000.00	
CLIN 0003	AY	550,000.00	
CEII 0005	7	330,000.00	94,288,100.52
		=	94,288,100.32
CLIN 0005	BA	24,527,878.00	
CLIN 0005	BB	146,000.00	
CLIN 0005	BC	72,000.00	
CLIN 0005	BD	85,000.00	
CLIN 0005	BE	100,000.00	
CLIN 0005	BF	100,000.00	
CLIN 0005	BG	1,975,321.00	
CLIN 0005	BH	38,018,908.00	
CLIN 0005	BL	0.00	
CLIN 0005	BZ	0.00	
		***	65,025,107.00
CLIN 0007AA	BP	10,199,288.50	
CEII (GOO/IAI	21	10,199,200.00	
		-	10,199,288.50
		=	10,199,200.30
CLIN 0009AA	AQ	45,106.00	
CLIN 0009AA	AV	0.00	
CLIN 0009AA	BK	256,545.00	
CLIN 0009AA	ВМ	125,000.00	
CLIN 0009AA	BN	21,315.00	
		,	447,966.00
		=	447,200.00
CLIN 0009AB	AJ	200,000.00	
CLIN 0009AB	AK	85,000.00	
CLIN 0009AB	AL	45,000.00	
CLIN 0009AB	AQ	59,894.00	
CLIN 0009AB	AR	35,000.00	
CLIN 0009AB	BK	3,455.00	
		J.4JJ.UU	
CI INI AAAA AD			
CLIN 0009AB	BN	81,685.00	
CLIN 0009AB	BN BU	81,685.00 350,000.00	
	BN	81,685.00	

			869,034.00
CLIN 0013	AU	7,970,000.00	
CLIN 0013	AX	3,396,000.00	
CLIN 0013	AY	0.00	
CLIN 0013	ΑZ	19,412,000.00	
CLIN 0013	BJ	7,896,673.34	
			38,674,673.34
CLIN 0017	BW	0.00	
CLIN 0017	KM	0.00	
			0.00
CLIN 0017AA	BY	3,880,000.00	
CLIN 0017AA	BX	1,146,000.00	
CLIN 0017AA	BW	84,896,852.00	
CLIN 0017AA	BZ	0.00	
CLIN 0017AA	KM	192,793,000.00	
CLIN 0017AA	KN	0.00	
CLIN 0017AA	KQ	66,151.00	
CLIN 0017AA	KS	0.00	
CLIN 0017AA	KT ·	386,204,200.00	
CLIN 0017AA	KU	2,203,183.00	
CLIN 0017AA	KY	0.00	
CLIN 0017AA	LC	200,000.00	
CLIN 0017AA	LD	7,943,648.00	
CLIN 0017AA	LE	0.00	
CLIN 0017AA	LH	400,000.00	
CLIN 0017AA	LJ	7,476.00	
CLIN 0017AA	LK	281,575,897.00	
CLIN 0017AA	LQ	235,566.00	
CLIN 0017AA	LS	6,069,616.00	
CLIN 0017AA	LT	530,377.00	
CLIN 0017AA	LU	\$9,100,000.00	
CLIN 0017AA	LV	\$1,957,265.00	
CLIN 0017AA	LW	\$255,567.00	
CLIN 0017AA	LX	\$68,000.00	
CLIN 0017AA	LY	\$264,807,424.52	
CLIN 0017AA	MB	\$375,000.00	
CLIN 0017AA	MC	\$2,283,481.00	
CLIN 0017AA	MD	\$8,573.00	
CLIN 0017AA	ME	\$0.00	
CLIN 0017AA	MF	\$270,514,880.00	
CLIN 0017AA	MH	\$213,390.00	
CLIN 0017AA	MJ	\$858,495.00	
CLIN 0017AA	MK	\$56,076.00	

CLIN 0017AA	ML	\$116,044.00	
CLIN 0017AA	MM	\$1,618,600.00	
CLIN 0017AA	MN	\$2,573,000.00	
CLIN 0017AA	MP	\$250,000.00	
CLIN 0017AA	MQ	\$691,421.00	
CLIN 0017AA	MR	\$0.00	
CLIN 0017AA	MS	\$700,000.00	
CLIN 0017AA	MT	\$16,289,524.00	
CLIN 0017AA	MV	\$39,921,199.75	
CLIN 0017AA	MW	\$10,000,000.00	
CLIN 0017AA	MX	\$140,795,358.00	
CLIN 0017AA	MY	\$18,327.00	
CLIN 0017AA	MZ	\$21,000,000.00	
		=	1,751,016,533.66
		=	
		=	
CLIN 0017AB	KL	118,250.00	
		=	118,250.00
CLINIONIZAC	D.7	100,000,00	
CLIN 0017AC	BZ	190,000.00	190,000.00
		=	190,000.00
CLIN 0017AD	KN	0.00	
CLIN 0017AD	KS	0.00 _	
		<u></u>	0.00
CLIN 0017AE	LL	173,798.00	152 500 00
			173,798.00
CLIN 0017AH	KT	173,798.00	
		_	173,798.00
		-	
CLIN 0020AA	KN	0.00	
CLIN 0020AA	KQ	26,660.00 _	26.660.00
			26,660.00
CI DI 0021 A A	*****	0.00	
CLIN 0021AA	KW	0.00 _	
			0.00
CLIN 0021AB	KV.	0.00	
CLIN 0021AB	KV LB	0.00 0.00	
CLIN 0021AB	KX	0.00	
CLIN 0021AB	KY	0.00 _	
			0.00

CLIN 0021AC	KZ	0.00	
CLIN 0021AC	LA	0.00	
		==	0.00
CL DI 0022	12317	0.00	
CLIN 0022	KW	0.00	0.00
		***************************************	0.00
CLIN 0023	КX	60,000.00	
CLIN 0023	KY	25,000.00	
CLIN 0023	KV	65,000.00	
CLIN 0023	LB	12,500.00	
CLIN 0023	LF	10,000.00	
CLIN 0023	LR	\$125,000.00	
			297,500.00
CLIN 0024	LA	13,508.00	
CLIN 0024	LG	62,000.00	
CLIN 0024	KZ	25,000.00	
CLIN 0024	KW	20,000.00	
CLIN 0024	LP	83,200.00	
			203,708.00
CLIN 0025	LE	1,173,850.00	
CLIN 0025	LM	1,080,404.00	
CLIN 0025	MA	0.00	
			2,254,254.00
CLIN 0026	LN	630,061.00	
			630,061.00
CLIN 0027	LZ	1,751,384.00	
			1,751,384.00
CLIN 0028	LM	329,972.00	
CLIN 0028	MA	2,982,442.00	
CLIN 0028	MG	6,262,095.00	
CLIN 0028	MU	\$7,864,499	
		· · · · · · · · · · · · · · · · · · ·	17,439,008.00
CLIN 003001*	MX	\$52,974,283.00	
CLIN003002*	MX	\$719,132.00	
CLIN 000303*	MX	\$5,747.00	
CLIN 000304*	MX	\$16,000,000.00	
CLIN 000305*	MX	\$16,000,000.00	

			159,795,358.00
CLIN 003009*	MX	\$21,000,000.00	
CLIN 003008*	MX	\$14,000,000.00	
CLIN 003007*	MX	\$1,096,196.00	The second secon
CLIN 003006*	MX	\$38,000,000.00	

^{*} CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. For purposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017AA and should not be counted twice with regards to the total contract funding obligated.

(End of Summary of Changes)

Page Intentionally Left Blank
Not a Contract Document

AMENDMENT OF SOLIC	CITATION/MODI	FICATION OF CONTRA	CT	I.CONTRACT	ID CODE	PAGE OF PAGES	
AMENDMENT/MODIFICATION NO. P00264	3. EFFECTIVE DATE 21-Mar-2013	4. REQUISITION/PURCHASE REQ. NO. 0010303569			5. PROJECT!	1 10 NO (((fapplicable)	1
SSUED BY CODE SASMDC/ARSTRAT MDC-RDC 0 BOX 1500 UNTSVALE AL 35807-3801		7. ADMINISTERED BY (If other than item DCMA RAYTHEON 50 APPLE HILL DRIVE M/S T2FR2 TEVKSBURY MA 01878	n 6)	COI	DE S2205	<b>A</b>	
NAME AND ADDRESS OF CONTRACT	OR (No., Street, County,	State and Zip Code)		9A. AMENDM	ENT OF SOL	ICITATION NO.	-
350 LOWELL ST. ANDOVER MA 01810-4400				9B. DATED (S	EE ITEM II	)	7
			X	10A. MOD. OF DASG80-98-C	CONTRACT	T/ORDER NO.	
			١,	10B. DATED (	SEE ITEM	13)	
DE 05718				30-Jan-1998			$\dashv$
The above numbered solicitation is arrended as se		APPLIES TO AMENDMENTS OF S	OLICI	is extended.	is not exten		4
(a) By completing items 8 and 15, and returning or (c) By separate latter or telegram which include RECEIVED AT THE PLACE DESIGNATED FOR REJECTION OF YOUR OFFER. If by virtue of it provided each telegram or letter makes reference to	os a reference to the solicitation OR THE RECEIPT OF OFFERS his amendment you desire to ch a the solicitation and this amen	and amendment numbers. FAILURE OF YOU PRIOR TO THE HOUR AND DATE SPECE ange an oral already submitted, such change in	JR ACK FIED M. my be m	NOWLEDGMENT AY RESULTIN ade by telegramor let	TO BE		
ACCOUNTING AND APPROPRIATION	N DATA (If required)						
		TO MODIFICATIONS OF CONTRA ACT/ORDER NO. AS DESCRIBED IN					
A. THIS CHANGE ORDER IS ISSUED PU CONTRACT ORDER NO. IN ITEM I		authority) THE CHANGES SET FOR	TH IN	ITEM 14 ARE M	ADE IN TH	IE	
THE ABOVE NUMBERED CONTRAC office, appropriation date, etc.) SET F     THIS SUPPLEMENTAL AGREEMEN	ORTH IN ITEM 14, PUF	SUANT TO THE AUTHORITY OF	FAR 4	CHANGES (such ( 3.103(B).	as changes in	paying	-
D. OT HER (Specify type of modification							$\dashv$
MPORTANT: Contractor is not.	, X is required to si	gn this document and return	03	pies to the issuing	z office.		-
DESCRIPTION OF AMENDMENT MO			=				$\dashv$
where feasible.) Modification Control Number: see Continuation Page							6
					_		
ept as provided herein, all terms and conditions of	ine document referenced in Item	19A or 10A, as hereto fore changed, remains un	cumaco		e≅ct. CER (Type o	r print)	١,
				0.11		- F100-1	(D) (d)
	ISC. DATE SIGNE	D 16B			160	. DATE SIGNED	46
(Signature of person authorized to sign)	3/21/201	p.	Office	r)		1 MAR 2013	(p)
CEPTION TO SF 30 PROVED BY OIRM 11-84		30-105-04		Pres	NDARD FO cribed by GS (48 CFR) 5:		3)

SECTION SF 30 BLOCK 14 CONTINUATION PAGE

The following items are applicable to this modification:

SECTION SF 30 BLOCK 14 CONTINUATION PAGE

SUMMARY OF CHANGES

SECTION A - SOLICITATION/CONTRACT FORM

The following have been added by full text: PURPOSE

The purpose of this modification is:


1. Settlement of P00260 Change Order Modification per the USD, AT&L Nunn-McCurdy directed restructure of JLENS contract DASG60-98-C-0001 submitted in letter JLENS-2012-031.

The target cost, target fee, and total contract value will not be adjusted from Change Order modification P00260 and subsequent modifications that make corrections or add incremental funding through modification P00263.

- 2. It is understood that P00260 Change Order amount of \$59,034,271 shall not change from \$59,034,271.00.
- 3. Attach GFE list dated 01/24/2013 in section J of the contract.
- 4. Attach Contractor Furnished Property (CFP) list dated 01/24/2013 which includes Cooperative

Engagement Capability (CEC) Hardware, and Revised additional test spares in section J of the contract. Note: Engineering units are acceptable for delivery so long as all components are form, fit and function equivalent.


- 5. Attach revised DD250 Plan dated 02-11-2013 in section J of the contract.
- 6. Attach revised Functional Configuration Audit (FCA) Plan dated 02/14/2013 in section J of the contract.
- 7. Attach revised Master Test Plan dated 02/04/2013 to section J of the contract.




## 10. Aerostat Accident Recoup Direction

The Aerostat Accident shall be considered settled within this restructure settlement with no further intent by the Government to take further action in this matter. In consideration for this accident Raytheon shall provide (2) JLENS compliant Tethers in the amount of \$2,316,819.00, as well as the Governments cost avoidance and other consideration. Agreement by Raytheon to this settlement relinquishes all claims for equitable adjustment by Raytheon, and the Government denies the increase to the Contract Budget Baseline (CBB) as requested by Raytheon. In consideration of the foregoing, the Government hereby releases Raytheon from any and all liability under the contract for further claims or liability attributable to the Aerostat Accident.

- 11. Upon execution of this contract modification, Raytheon will commence rebaselining the work to go including the FY'13 restructure as part of the SDD (CLIN 0017AA). Raytheon will incorporate the changes for the restructured baseline in accordance with its documented process guidelines and procedures.
- 12. Flat Spot Opportunity Incentive Criteria
- c. Schedule and Performance Incentive.
- (1) A maximum serious "flat zone" will be established at the target cost value of with the conduct of milestones below. The "flat zone" over which the contractor will earn target fee is for eligible costs from to (b)(4) (b)(4) once the program milestones set forth below are conducted. (Note: As of the effective date of Modification P00260, only flat zone" has (b)(4) (b)(4) been acknowledged as earned.)
- (a) of the maximum benefit of the "flat zone", earned by the conduct of the SDD System Functional Review NLT 2nd Quarter, Fiscal Year 2007. (It is hereby acknowledged by the government that Raytheon completed the requirement for this





In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the performance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLIN 0017 are added and exercised, the incentive fee for cost and schedule/performance applicable to the Option will be incorporated in accordance with the incentive fee structure of this provision.

SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS

The following have been modified:

SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS

The following have been modified:

## 5. SECTION J – LIST OF ATTACHMENTS:

Section J is changed as shown below:

TITLE	DATE	# OF PAGES
Contract Security Classification Specification (DD Form 254), Revision 11 (Added per Modification P00187) (DD Form 254 mailed via US Postal Service)	14 May 09	11
Contract Security Classification Specification (DD Form 254), Revision 13 (Added per Modification P00235)	14 Apr 11	13
JLENS Software Source Code Specifically Negotiated License, 04 Sep License Number JLENS-SWLA-01 (Added per Modification P00166)	08 8	
CLIN 0017:  JLENS System Development and Demonstration (SDD) Program Statement of Work (Revised by Incorporating CSDR Plans dated 20 Febr 2007 in Appendix C per Modification P00136)	30 Nov 06 - Revised 20 Feb 07	37
JLENS System Development and Demonstration (SDD) Program Statement of Work (Added per Modification P00187)	Revised 06 Apr 09	38
JLENS System Development and Demonstration (SDD) Program Statement of Work, Revision 2 (Added per Modification P00207)	Revised 09 Mar 10	36
JLENS System Development and Demonstration (SDD) Program Statement of Work, Revision 3 (Added per Modification P00239)	Revised 01 Sep 11	36
JLENS System Development and Demonstration (SDD) Program Statement of Work (Added per Modification P00240)	Revised 26 Sep 11	36

(b)(3)(A)(i)&Title 10 Sec 130 (a)(b)

Contract Data Requirements List (DD Form 1423) Exhibit A with Distribution List & Data Item Nos. B001 through B062 (Replace Data Item Nos. B026 and B027, only Per Modification P00136) (Replace Data Item Nos. B048 and B049, only Per Modification P00143 & to add statement in Section A of Modification P00143) (Replace Data Item No. B033 only, per Modification P00161)

01 Dec 06 63

Revised 05 Apr 07

Revised 24 Oct 07

Revised 11 Jul 08 1

Contract Data Requirements List (DD Form 1423) Exhibit A, Data Item Nos. B001 and B014 (Added per Modification P00187)	Revised 07 May 09	2
Contract Data Requirements List (DD Form 1423) Exhibit A, Data Item Nos. B002 through B062 (less B014) (Added per Modification P00187)	Revised 20 Mar 09	60
Contract Data Requirements List (DD Form 1423) Exhibit A, Data Item Nos. B001 and B014 (Added per Modification P00239)	Revised 30 Aug 11	2
Contract Data Requirements List (DD Form 1423) Exhibit A, Data Item Nos. B004 (Added per Modification P00257)	Revised 31 Jul 12	1
*Added statement below to address weekends/Holidays:	24 October 07	

(In Mod P00143)

*Per a mutual agreement between Raytheon and JLENS Product Office all Contract Data Requirements List (CDRL's) (DD Form 1423) are due on the next business day after the required due date if the due date falls on Saturday, Sunday or a Government Holiday. In addition, for any CDRL with a requirement to resubmit within 10 days or less after receipt of comments, where Raytheon receives the comments on a Friday, the timeframe for resubmittal will begin on the next business day. Statement added in Mod P00143 on 24 Oct. 2007.

28 Nov 06	2
15 Oct 07	6
Revised 22 Oct 07	
09 Mar 09	12
23 Feb 10	11
	15 Oct 07 Revised 22 Oct 07 09 Mar 09

**Per the DCMA and Raytheon is authorized rent free use on a non-interference use of the equipment listed below for utilization on JLENS Fire Control Radar Prime Contract DASG60-98-C-0001 for the period from 19 April 2007 through 30 September 2011.



Hereby added in Mod P00148 for tracking purposes:

Originated in Basic Contract:

Government Furnished Equipment - Spiral 1

(Spiral 1 Equipment Transferred to Government

Contract DASG60-00-C-0091, DD Form 1149 (attached)

(b)(6)

20 Jun 03

1 List

34 pages

(Revised 21 Nov 07)*

34 pages

Ship to address:

(b)(4)

*NOTE: Items 1-1060 transferred to Contract DASG60-00-C-0091 per revised GFE list dated 21 Nov 07. Items 1061 – 1116 GFE items retained on Contract DASG60-98-C-0001 for Spiral 2 per GFE list dated 25 Mar 07.

JLENS Performance Specification, MIS-PRF-55628, Revision A	27 Jun 08	136
(Added by reference per Modification P00168)		
Annex A to the JLENS Performance Specification, MIS-PRF-55628, Revision A (Added by reference per Modification P00168)	27 Jun 08	10
JLENS SDD DD250 Plan (Added per Modification P00207)	11 Dec 09	5
Engineering Change Proposal (ECP) MI-N3893, Revision 2, CDRL B039-005b	15 Nov 10	15
Engineering Change Proposal (ECP) MI-N3894, CDRL B039-006	18 Aug 10	16
Engineering Change Proposal (ECP) MI-N3895, CDRL B039-007	28 Sep 10	50
Engineering Change Proposal (ECP) JL1359 (Added per Modification P00240)	20 Jun 11	7
Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c)	01 Nov 11	4
(Added per Modification P00242)		
Revised Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c) (Added per Modification P00257)	02 Aug 12	7
Test Spares List (Added per Modification P00247)	Undated	8

# SubCLIN 0017AA

The following added by reference per Modification P000264

Government Furnished Equipment list (GFE)	24 Jan 13	1
Contractor Furnished Property list (CFP) 24 Jan 13 (Includes Cooperative Engagement Capability (CEC Hardware)		
` SDD DD250 Plan	11 Feb 13	4
Functional Configuration Audit (FCA) Plan FY13 Master Test Plan, H492257 Rev b	14 Feb 13 04 Feb 13	28 62
`FY13 Final Test Spares List	04 Mar 13	6
CLINs 0023 and 00024  JLENS Simulation Support  SOW dated 28 January 2008  For JDEP, Nimble Fire and  Simulation Support Tasks  (Added per Mod P00160)	28 January 2008	2 pages
<u>CLIN 0025</u>		
JLENS Integrated Fire Control Demonstration Program Statement of Work, Revision 3 (Added per Modification P00165)	14 Jan 08	3
JLENS Integrated Fire Control Demonstration Program Program and Technical Clarification Description, incorporated herein by reference (Added per Modification P00165)	25 Jul 08	17
JLENS Integrated Fire Control Demonstration Program Statement of Work, Revision 5 (Added per Modification P00211)	14 Sep 09	3
JLENS Integrated Fire Control Demonstration Program Program and Technical Clarification Description, incorporated herein by reference (Added per Modification P00211)	30 Mar 10	26
Contract Data Requirements List (DD Form 1423) Exhibit B, Data Items Nos. B001 through B004, with Data Item Descriptions (Added per Modification P00165)	16 Oct 07	19
Contract Data Requirements List (DD Form 1423), CLIN 0028, Exhibit B, Data Item Nos. B001 through B006 (Added per Modification P00211)	16 Jun 10	6

# CLIN 0027

JLENS System Integration Lab (SIL)

Equipment List
(Added per Modification P00196)

Revision to System Integration Lab (SIL)


Equipment List
(Added per Modification P00217)

Undated 6


02 Aug 10
6

(End of Summary of Changes)


(h)(h) (h)(h) (b) (3) (A) (i)& Title 10 Sec 130 (a) **(b)** Jares List FY 13 Final (b) (3) (A) (i)& Title 10 Sec 130 (a) (b)



(b)(3)(A)(i)&Title 10 Sec 130 (a)(b)



(b)(3)(A)(i)&Title 10 Sec 130 (a)(b)



(b)(3)(A)(i)&Title 10 Sec 130 (a)(b)


FY 13 Final .

(b)(3)(A)(i)&Title 10 Sec 130 (a)(b)


(b)(3)(A)(i)&Title 10 Sec 130 (a)(b)


(b)(3)(A)(i)&Title 10 Sec 130 (a)(b)

_	FLAT SPOT INCENTIVE CRITERIA FOR (	S SDD CONTRACT, SECTION H-19(C)
>		
2		




(b)(3)(A) (b)(4)








 $(b)(3)(A)(i)\&Title\ 10\ Sec\ 130\ (a)(b)$ 





(b)(3)(A) (i)&Title 10 Sec 130 (a)


(b)(3)(A) (i)&Title 10 Sec 130 (a)(b)


(b)(3)(A) (i)&Title 10 Sec 130 (a)

00"2693


(b)(4)


**(b)** 





(b)(3)(A) (i)&Title 10 Sec 130 (a) (b)









(b)(3)(A) (i)&Title 10 Sec 130

(b)(4)







## **Raytheon**


CAGE Code 05716 Doc H492257 Rev -4 February 2013

(b)(3)(A) (i)&Title 10 Sec 130 (a)(b) (b)(3)(A) (i)&Title 10 Sec 130 (a) (b) (b)(3)(A) (i)&Title 10 Sec 130 (a) (b) (b)(4)

> Page 12 of 62 002702

## Raytheon

CAGE Code 05716 Doc H492257 Rev-4 February 2013




(b)(3) (A) (i)&Title 10 Sec 130 (a) (b)



(b)(3)(A) (i)&Title 10 Sec 130 (a)(b)

(b)(3)(A) (i)&Title 10 Sec 130 (a)(b)

(b)(4)




(DG)

رحال) (عادرط)


(pyp)


(b)(b) (b)(b)



(b)(3)(A)(i)&Title 10 Sec 130 (a)(b)


1 1 3 (b)(b) (b)(b) (b)(3)(A) (i)&Title 10 Sec 130 (a) (b) (b) (b) b)(3)(A) i)&Title 10 Sec 30 (a)(b) (b)(4)






(b)(3)(A) (i)&Title 10 Sec 130 (a)(b) (b)(3)(A) (i)&Title 10 Sec 130 (a)(b) (b)(3)(A) (i)&Title 10 Sec 130 (a) (b) (b)(3)(A) (i)&Title 10 Sec 130 (a)(b) (b)(3)(A) (i)&Title 10 Sec · 130 (a) (b) (b)(3)(A) (i)&Title 10 Sec 130 (a)(b) (b)(4)002710

(b)(3)(A) (i)&Title 10 Sec 130 (a) (b) (b)(3)(A) (i)&Title 10 Sec 130 (a)(b) (b)(4)



(b)(3)(A) (i)&Title 10 Sec 130 (a) (b)



(b)(3)(A) (i)&Title (a)(b) (b)(3)(A) (i)&Title 10 Sec (b)(3)(A) (i)&Title (a)(b) (b)(3)(A) (i)&Title 10 Sec 130 (a) (b) 10 Sec 130 (a) (b) (b)(4)


10 Sec 130

130 (a)(b)

10 Sec 130


(b)(3)(A) (i)&Title









(b)(3)(A) (i)&Title 10 Sec 130 (a)(b) (b)(3)(A) (i)&Title 10 Sec 130 (a) (b)(3)(A) (i)&Title 10 Sec 130 (a)(b) (b)(3)(A) (i)&Title 10 Sec 130 (a)(b) (b)(3)(A) (i)&Title 10 Sec 130 (a) **(b)** (b)(4)002717













(b) (4)














(b)(3)(A) (i)&Title 10 Sec 130








(b)(7)(E) (b)(3)(A) (i)&Title 10 Sec 130 (a) (b) (b)(3)(A) (i)&Title 10 Sec 130 (a)(b) (b)(4)



10 Sec 130


(b)(3)(A) (i)&Title 10 Sec 130


(b)(3)(A) (i)&Title 10 Sec 130





(b)(3)(A) (i)&Title 10 Sec 130 (a)(b)


002732



















(b)(3)(A) (i)&Title 10 Sec 130 (a)(b) (b)(3)(A) (i)&Title 10 Sec 130 (a)(b) (b)(3)(A) (i)&Title 10 Sec 130 (a) (b) (b)(4)

















(b)(3) (A) (i)&Title 10 Sec 130 (a) (b)

(b)(3)(A) (i)&Title 10 Sec 130 (a)(b)








(b)(3) (A) (i)&Title 10 Sec 130 (a) (b) (b)(3) (A) (i)&Titl e 10 Sec 130 (a) (b) (b)(3) (A) (i)&Titl e 10 Sec 130 (a) (b)

002748



(b)(3)(A) (i)&Title 10 Sec (b)(3)(A) (i)&Title 10 Sec 130 (a)(b) (b)(3) (A) (i)&Title 10 Sec 130 (a) (b)

130 (a)(b)

